

NATIONAL ECZEMA SOCIETY

England & Wales · Charity number 1009671

Details

Other names	N E S - THE ECZEMA SOCIETY, Eczema UK
Status	Registered
Legal form	Charitable company
Company number	02685083
Registered	1992-03-10
Register	View on the Charity Commission register

Contact

Address	National Eczema Society 82 Tanner Street London SE1 3GN
---------	--

Phone	02072813553
-------	-------------

Email	info@eczema.org
-------	--

Website	www.eczema.org
---------	--

Activities

Objects: TO RELIEVE PEOPLE WITH ECZEMA, OTHER SKIN DISEASES AND RELATED CONDITIONS AND THE FAMILIES OF SUCH PEOPLE WHO ARE IN NEED EITHER INDIVIDUALLY OR COLLECTIVELY IN ANY MANNER WHICH IS DEEMED BY LAW TO BE CHARITABLE.

Activities: The National Eczema Society exists to support people affected by eczema and to work on their behalf. We run phone and email helplines, websites , publish a wide range of information booklets fact sheets and a quarterly magazine and put people in touch with local support groups. We also support medical research into eczema and provide information resources for healthcare professionals.

Classification

- **How:** Provides Services, Provides Advocacy/advice/information, Sponsors Or Undertakes Research
- **What:** Education/training, The Advancement Of Health Or Saving Of Lives
- **Who:** Children/young People, Elderly/old People, Other Charities Or Voluntary Bodies, Other Defined Groups

Geography

- Northern Ireland
- Scotland
- Throughout England And Wales

Finances

Period end	Income	Expenditure	Assets	Employees
2024-12-31	£529,182	£512,724	£677,689	5
2023-12-31	£497,252	£477,562	-	-
2022-12-31	£342,821	£413,759	-	-
2021-12-31	£535,712	£384,529	£721,691	4
2020-12-31	£551,160	£363,518	£536,369	4

Trustees

Name	Role	Appointed
Dr Angelika Razzaque		2026-01-08
Dr Celia Moss		2019-12-04
Hannah Beth Kunzlik		2022-03-16
Hedwig Laurien Vollers		2022-03-16
Luke William Patten Holmes		2026-01-08
Neil Mathur		2026-01-08
STEPHEN CROMMELIN PUGH		2017-02-25
Sumlit James Chiu-Man Pitayanukul		2020-03-18

Accounts

Company Registered Number: 02685083
Charity Registered Number (England & Wales): 1009671

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

UNAUDITED

TRUSTEES' REPORT AND FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2024

SATURDAY



AEBZ4V4P

A22

27/09/2025

#88

COMPANIES HOUSE

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

CONTENTS

	Page
Reference and Administrative Details of the Charity, its Trustees and Advisers	1
Trustees' Report	2 - 11
Trustees' Responsibilities Statement	12
Independent Examiner's Report	13 - 14
Consolidated Statement of Financial Activities	15
Consolidated Balance Sheet	16 - 17
Charity Balance Sheet	18 - 19
Consolidated Statement of Cash Flows	20
Notes to the Financial Statements	21 - 45

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

**REFERENCE AND ADMINISTRATIVE DETAILS OF THE CHARITY, ITS TRUSTEES AND ADVISERS
FOR THE YEAR ENDED 31 DECEMBER 2024**

Trustees	Stephen Pugh, Chair Hannah Kunzlik Professor Celia Moss OBE James Pitayanukul, Treasurer Hedwig Vollers Suzanne Watson
Company registered number	02685083
Charity registered number	1009671
Registered office	82 Tanner Street London SE1 3GN United Kingdom
Chief executive officer & Company secretary	Andrew Proctor
Independent Examiner	MHA Chartered Accountants MHA House Charter Court Swansea Enterprise Park Swansea SA7 9FS
Principal Bankers	CAF Bank Ltd National Westminster Bank plc
Status and Governing Document	National Eczema Society is a charitable company, limited by guarantee. It was incorporated on 6 February 1992 and registered as a charity on 10 March 1992. It is governed by its Articles of Association.
Subsidiary Companies	Eczema Trading Limited

NATIONAL ECZEMA SOCIETY

(A Company Limited by Guarantee)

TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2024

The trustees present their annual report together with the financial statements of the Group and the Charity for the year 1 January 2024 to 31 December 2024. The trustees confirm that the Annual Report and financial statements of the company comply with the current statutory requirements, the requirements of the company's governing document and the provisions of the Statement of Recommended Practice (SORP), applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102). Since the Charity and the Group qualifies as small under section 383, the strategic report required of medium and large companies under The Companies Act 2006 (Strategic Report and Director's Report) Regulations 2013 is not required.

Purpose and Aims

National Eczema Society was established in 1975 to support people with eczema and their families and to work on their behalf. The charity is celebrating its 50th anniversary in 2025. We remain dedicated to these founding principles and today we continue to help people across the UK by providing evidence-based information and advice about eczema and its management. We deliver this in various ways through our website, webinars, instructional videos, social media communications and publications. We also provide a collective voice for people with eczema, fund and inform research, influence health policy to improve eczema care, and raise greater awareness and understanding of the condition among people affected by eczema and the wider public.

The prevalence of eczema has increased over recent decades, and around one in five children and one in ten adults are now impacted by this life-limiting condition in the UK. While the reasons for the increase are not fully understood, it does mean the charity's work is needed more than ever. There is no cure for eczema and, unless you have the condition, it can be hard to understand the daily challenge of living with relentless itching and inflamed, painful skin. Many healthcare professionals have limited dermatology training and timely access to specialist dermatology healthcare for people with eczema can often be difficult. National Eczema Society aims to provide the information and support needed for people to self-manage their eczema effectively, to become experts in their own care, learn from the experiences of others, and provide the reassurance of knowing they are not on their own.

Ensuring Our Work Delivers Our Charitable Aims

We review our activities each year and monitor the impact of our work to ensure we continue to fulfil our purpose of supporting people affected by eczema. Among other ways, we assess the Society's performance and achievements through the number of people we have helped with information and advice, the quality and consistency of the resources we provide, the eczema research we support, and the policy influencing we achieve.

We consider how planned activities will contribute to the aims and objectives we have set, and in doing this we have referred to the Charity Commission's general guidance on public benefit. We have had regard to the legislative and regulatory requirements for disclosing how our charitable objectives have provided such benefit, and complied with the duty set out in section 4 of the Charities Act 2011.

2024 Activity and Achievements - Delivering Public Benefit

All our charitable activities focus on supporting people affected by eczema and championing their needs, and further our charitable purposes for the public benefit. Here we present a summary of the Society's work over the year.

NATIONAL ECZEMA SOCIETY

(A Company Limited by Guarantee)

Strategic Review and Implementation

During the year we implemented a strategic review, with the purpose of enabling the charity to better serve the UK eczema community. We are a relatively small charity, serving a very large community of people affected by eczema – over eight million adults and children in the UK and their families. With limited funding, it is important the charity prioritises its resources to achieve the biggest impact we can for people with eczema. Our strategy is now focusing more on our work supporting eczema research, to develop better treatments and ultimately a cure, and influencing for better eczema care for all sufferers. These enable us to become a stronger collective voice for the eczema community, as we recognise too many people are struggling to achieve a good quality of life because of their eczema and need better care.

The change of focus brought about through the strategic review required some challenging choices, including withdrawing from providing personalised advice on managing eczema. This included taking the difficult decision to close the Society's eczema helpline service, in March 2024. We recognise this was disappointing for supporters and others who have used the Society's helpline in the past and have appreciated the advice we provided. We are committed to expanding other information resources, which are used by many people in our community. We were able to support around 1,000 callers a year to the helpline.

The strategic review proposed a number of new staff roles, and we recruited three new members of staff during the year, to lead on the Society's health content, research engagement, and communications and campaigning work. Under the new strategy, several existing staff roles were no longer required, and it is with regret these posts were made redundant in March 2024.

The Society's three core areas of charitable work continue to be:

- Providing eczema information and advice
- Supporting eczema research
- Advocacy and improving eczema care.

Providing Information and Advice for People Living with Eczema

The Society continues to provide a wide range of high quality, evidence-based information about eczema and its management for the UK eczema community. We produce a range of patient information booklets and factsheets about eczema management and treatment, available online and in print. We distribute printed copies at the events we organise and attend, and we provided over 17,500 copies of our printed publications to healthcare professionals during the year, for onward distribution to patients in hospital dermatology clinics and other healthcare settings across the UK. Our most popular booklets are Childhood Atopic Eczema and Itching and Scratching.

National Eczema Society factsheets and booklets are updated regularly on a rolling review cycle and checked by healthcare professionals to ensure the information is accurate and up-to-date. We updated and reprinted a number of publications over the year, including our Guide for Teenagers with Eczema and Eczema Guide for Healthcare Professionals.

Our eczema information is available on the Society's website, which received over two million visits during the year. Our webpages on facial eczema, seborrhoeic dermatitis, emollients, eye and ear eczema, hand eczema, topical steroid treatments, topical steroid withdrawal, pompholyx eczema and scalp eczema remain especially popular. Additionally, over 35,000 copies of our factsheets were downloaded during the year. We also promote health advice messages through our social media posts, e-newsletters, media engagement and other external communications.

In August, we launched a regular monthly email newsletter for supporters who have signed-up via our website to receive email communications from National Eczema Society. Over 10,000 people affected by

NATIONAL ECZEMA SOCIETY

(A Company Limited by Guarantee)

eczema now benefit from regular email updates on eczema news and developments, and about the work of the charity. We have received positive audience feedback on our e-newsletters and the mailing list continues to grow.

We launched the Exploring Eczema webinar series in September, presented by Dermatology Nurse Advisor Julie Van Onselen. We are planning eight webinars on different topics during 2024/2025 including, emollients, eczema triggers and managing baby and toddler eczema. Typically, between 100 and 200 people attend each of our webinars, with many more viewing the webinar recordings on our YouTube channel. We also continued our popular programme of webinars with St John's DermAcademy (part of Guy's and St Thomas' Hospital, London) to jointly deliver two events, one focusing on managing eczema itch and the other on facial eczema. Recordings of several past webinars are also available to view on the Society's social media pages or YouTube channel.

As noted above, the Society took the decision to close its eczema helpline service in March 2024, as part of a wider strategy change to focus more resources on supporting eczema research, campaigning for better eczema care, and broadening our information offer with new resources like webinars.

We continue to raise awareness of local volunteer-led patient support groups, by providing information and a presence for these groups on the Society's website. The West Surrey and North-East Hampshire Support Group held a number of fundraising events over the year and organised an information day in Guildford in February on the 'Combined Approach' to managing eczema. Dr Alpa Kanji talked about how habit reversal therapy combined with topical treatments can help people with eczema break the habitual eczema itch-scratch cycle. Dr Kanji is a dermatologist working at St John's Institute of Dermatology in London and she teaches habit reversal therapy. The event was livestreamed and recorded on Facebook, enabling many more people with eczema to access the talk.

NES Membership Scheme

National Eczema Society is a membership organisation and we are very grateful to our 2,000 members who support the Society through their annual membership fee and additional donations. Members receive our membership magazine Exchange, which features expert information and news about eczema. Members are also encouraged to attend the Society's Annual General Meeting and contribute their ideas on the running of the charity. As in previous years, support for our charity extends far beyond our membership and we remain grateful to all our donors, and to those members who continue to support us financially even though they no longer have any personal need of our help.

Income from the membership scheme has fallen as the number of members has gradually declined over the years. We took the difficult decision to move to producing two issues annually of Exchange magazine starting in 2024, replacing the previous quarterly publishing schedule, so that membership scheme costs are better aligned with membership income.

Supporting Eczema Research

National Eczema Society launched its first-ever eczema research call in December 2024, inviting research teams in UK universities to apply for funding from the charity. We want to improve the understanding and treatment of eczema and topical steroid withdrawal (TSW) and more research will help achieve this goal. The Society invited applications for innovation grants to fund new research ideas, as well as pump-priming grants to fund early-stage studies, enabling researchers to collect proof-of-concept data needed to take the research forward in larger studies. We also invited applications for PhD studentships, to support the next generation of world-leading eczema researchers. The applications were assessed in Spring 2025, and the awards announced early summer 2025. It is our intention to hold an eczema research call annually, subject to sufficient charity funds being available.

NATIONAL ECZEMA SOCIETY

(A Company Limited by Guarantee)

Building our internal research administration capability, the Society applied for and joined the Association of Medical Research Charities (AMRC) and has already benefitted from the AMRC's information and policy resources and training. This UK-based group represents and supports over 150 charities that fund medical research. National Eczema Society has also joined the Charities Research Involvement Group (CRIG), enhancing our ability to connect with patients, caregivers, other medical charities and healthcare professionals who share our passion for improving the lives of those affected by eczema.

During the year we established an 'Experts by Experience' (EXEC) patient group, to ensure the experiences and views of people living with eczema are fully considered in the Society's work. The 25-strong group includes both adults living with eczema and parents of children living with the condition. EXEC members provide feedback on eczema research initiatives, including projects funded by the Society, and a patient perspective on the charity's wider activities.

We continue to support patient involvement in shaping research. NES is approached regularly by researchers seeking patient views and to learn from patient experiences. It is so encouraging to see such a range of research underway and new treatments in the pipeline, following a long period when eczema was largely overlooked. The Society actively supports eczema research by participating in study steering groups, providing patient perspectives for research projects, promoting surveys, supporting patient recruitment for trials, and working with universities and companies that are assessing and developing new drug treatments. We do this to help ensure eczema research has the greatest chance of success in finding new treatments and ultimately a cure. Projects supported during the year include:

- A-STAR – UK-Irish Atopic Eczema Systemic Therapy Register
- BEACON Trial – Best systemic treatments for adults with atopic eczema over the long term
BEACONomics – study embedded within the BEACON Trial
- BIOMAP Innovative Medicines Initiative – Biomarkers in Atopic Dermatitis and Psoriasis
- END-ITCH Study – Eczema and Dermatitis, Implementing the Combined Approach
- Kids in Control Study – scratching awareness and behaviour change in children
- LEAD Study – pre-natal, pregnancy and post-natal eczema care and concerns of women of child bearing age
- Navigating Primary Care with Topical Steroid Withdrawal Study
- RAPID – Eczema Trials Programme
- SOCX Survey – looking at how skin colour affects the experience of people with eczema, acne and psoriasis
- SLEEP Study – Supporting children's sleep in those with eczema programme
- SMEDISS Study – exploring social media conversations about Janus-Kinase (JAK) Inhibitor medicines
- TLA4AE Study – temperature controlled laminar air flow device study
- TRANS-FOODS Study – aiming to prevent peanut allergy.

National Eczema Society provides a patient perspective for clinical guideline development, the assessment of new eczema treatments, and policy consultations. During the year, we continued to contribute patient insights and evidence for the assessment by the National Institute of Health and Care Excellence (NICE) of a new monoclonal antibody drug called lebrikizumab, used to treat moderate-to-severe eczema. This was approved by NICE in June 2024 and is the third biologic treatment for eczema after dupilumab and tralokinumab. As eczema affects people in different ways, it is very important we have a range of NHS treatment options to help ensure people can access a medicine that works effectively for them. We also provided patient evidence for the assessment by NICE of a new JAK Inhibitor topical treatment called delgocitinib for chronic hand eczema. The decision by NICE on whether delgocitinib will be approved for use by the NHS in England and Wales is expected mid-2025.

NATIONAL ECZEMA SOCIETY

(A Company Limited by Guarantee)

Advocacy and Improving Eczema Care

The charity undertakes a range of activities to raise awareness and understanding of eczema among the general public, influence for improved care, and to promote the information and advice the Society provides for people living with eczema and their families.

National Eczema Society scored a big win for the UK eczema community during the year. We were delighted when the MHRA, the UK medicines regulator, announced it was going to introduce clear strength labelling of topical steroids (TCS). This was in response to the Society's campaign launched a year earlier, calling on the MHRA to mandate clear strength labelling on topical steroid tubes, packaging and patient information leaflets. Prior to this, steroid creams and ointments used in the UK did not clearly show their strength on the tube or box.

Topical steroids are used by millions of adults and children in the UK to treat or prevent eczema flare-ups. It is important patients and their carers have the right information to use these medicines safely and effectively to manage eczema well. Topical steroids are effective treatments for eczema but, like many treatments, they can have side effects. People with eczema and carers are understandably concerned about overusing TCS. We believe clear potency labelling will help improve patient understanding and confidence in these widely-used medicines.

Our campaign had strong support from the eczema community. Some 95% of respondents in our online patient survey said they wanted to see clear strength labelling on all steroid creams and ointments. In a second patient survey we conducted, 98% of respondents knew steroid creams and ointments came in different strengths (potencies). However, almost half said they didn't know how many different strengths there were, and only 17% correctly answered '4'. Worryingly, 1 in 5 respondents in the survey underestimated the strength of their topical steroid and almost a quarter overestimated this. We recommended the MHRA use the words 'mild steroid', 'moderate steroid', 'strong steroid' or 'very strong steroid' on the labels, and we are delighted this has been adopted.

The MHRA announced the change in May 2024 and gave manufacturers 12 months to implement the new strength labelling, which is to appear on the packaging, tube and patient information leaflet for all topical steroid products. We are grateful to the eczema community for getting behind this initiative and to the professional dermatology bodies and other charities for supporting the campaign. We believe this is a significant step forward in supporting people to use these widely prescribed medicines safely and effectively.

Representing Patient Views

As a national patient organisation for the UK eczema community, the Society provides a collective voice to champion the needs of those affected by the condition. We seek to improve health outcomes for people with eczema by influencing health policy and participating in groups like the Dermatology Council for England and working with professional bodies like the British Association of Dermatologists (BAD), British Dermatological Nursing Group (BDNG), and Primary Care Dermatology Society (PCDS).

Patient interest and awareness of the side effects of topical steroid medication remains high, including concerns about topical steroid withdrawal (TSW), which feature widely on social media. Our website information on TSW is especially popular, attracting over 100,000 page views a year. TSW is complex and symptoms can be extremely painful and distressing. We are calling for more research into the causes, symptoms and treatments of TSW.

National Eczema Society worked with the British Association of Dermatologists and British Dermatological Nursing Group, to update our Joint Statement on TSW, first published 2021. We believe it is important for professional dermatological organisations and patient groups to work together to find better ways of diagnosing and supporting people with TSW. The updated Joint statement was published in February 2024. This builds on the earlier version, setting out what we know about TSW from the latest medical information available.

NATIONAL ECZEMA SOCIETY

(A Company Limited by Guarantee)

The British Association of Dermatologists has formed a Topical Steroid Withdrawal Working Party Group, in collaboration with National Eczema Society and other organisations, with the aim of producing expert consensus guidance on to support people with concerns about TSW. This includes producing a Patient Information Leaflet and any revisions to the TSW Joint Statement. The work is ongoing.

The UK medicines regulator, the MHRA updated its guidance on topical steroid safety during the year and National Eczema Society was pleased to contribute to this review.

National Eczema Society is working with corporate partner Aspire Pharma on a joint campaign to raise awareness and highlight the impact of menopause on eczema. There is limited research on the impact on women's skin during menopause. To learn more, we asked women living in the UK who are perimenopausal, menopausal or have been through the menopause to share their experiences in an online survey. We plan to announce the survey results next year.

During National Eczema Week in September, we highlighted the impact of eczema on people's mental health and emotional well-being, under the theme #LetsStartTheConversation. Our campaign encouraged open dialogue about eczema with friends, family, colleagues and healthcare professionals, and we created conversational resources to help our community to break the silence and open up about how eczema makes you feel. People often face particular challenges managing eczema at work, and we promoted our information resources to support with this. Many thanks to everyone in our community who shared their stories with us, raising awareness about living with eczema and how it affects mental health.

Media and Social Media Engagement

The Society provided information for a number of eczema stories in the media over the year. This included media comment for stories about eczema treatments on BBC Breakfast, synthetic skin research by Reuters, miracle eczema cures in The Telegraph, psychodermatology in the Sunday Times, and the new treatment for moderate-to-severe eczema called lebrikizumab in a range of media outlets. We contributed to a powerful story by the BBC in November about the huge impact eczema can have on people's lives, which featured the experiences of Chloe North, who has also been featured in the Society's Exchange magazine. The charity was featured in several professional publications including Pharmaceutical Journal, covering the MHRA announcement about new strength labelling for topical steroids. The Society was approached several times for media comment about topical steroid withdrawal (TSW) and we were mentioned in a feature on this by ITV This Morning, and in a BBC online story about TSW that included comment by National Eczema Society Trustee Professor Celia Moss.

We continued to expand our social media reach and activity during the year, reflecting how people increasingly seek and share information about eczema. The Society continues to grow its followers on Facebook, Instagram, X/Twitter and LinkedIn, with a combined social media following of over 45,000.

Growing Income and Building Financial Sustainability

We continue to commit resources to income generation, to achieve our charitable objectives and build future financial sustainability.

We would like to thank the many people who, as in previous years, by joining or renewing their membership, supporting our appeals and fundraising in a variety of often innovative ways, have enabled us to continue our work. The efforts and contribution of supporters and volunteers is invaluable to the Society. In particular, we are immensely grateful to our thoughtful and generous supporters who choose to leave a gift to National Eczema Society in their Will. We are grateful also to the charitable trusts and companies that have supported us during the year, and to all the healthcare professionals who have provided us with so much time, advice and support especially members of the Medical Advisory Board.

NATIONAL ECZEMA SOCIETY

(A Company Limited by Guarantee)

We continue to develop partnerships with companies that share our values and are willing to support our work and engage in joint education and awareness-raising activity. During the year we worked with AbbVie, Almirall, Aspire Pharma, Bioderma, Dermal Laboratories, Lilly, LEO Pharma and Sanofi.

There were many fundraising highlights during the year. Income from challenge events, including the London Marathon and Great North Run, was strong again in 2024 and we thank all our supporters for raising funds and awareness of eczema by participating in events like these. The Great South Run 2024 was cancelled at late notice due to bad weather, and we appreciated the support of our runners in this event and the funds they raised for the charity despite the disappointment of the event cancellation.

The Society's West Surrey and North-East Hampshire Support Group undertook various local fundraising activities around Guildford and presented a cheque for £2,000 at the Society's Annual General Meeting in September. Our members and donors generously supported our summer and Christmas fundraising appeals once again and we are grateful to everyone who supported the Society in different ways with their donations.

Organisational Development

During the year, we implemented our plans for the Society's office move. The lease on the charity's current offices at 11 Murray Street, London NW1 9RE expires in March 2025. We started our phased move into shared workspace offices at 82 Tanner Street, London, SE1 3GN, United Kingdom in December, to be completed by end February 2025.

2025 Plans and Development Priorities

Looking ahead, we aim to ensure National Eczema Society continues to achieve the greatest impact we can for the UK eczema community including our members. The charity's core work will continue, as we expand our support for eczema research and advocacy work in line with our strategy. We are celebrating the Society's 50 anniversary in 2025 and will be highlighting this milestone in our charity magazine Exchange and in other communications. During the year we will also continue scoping work to refresh the charity's brand and visual identity.

Priorities for 2025 include:

Providing Information and Advice

- Continue providing high-quality information and advice about eczema, disseminated through the Society's website, printed publications, Exchange magazine, e-newsletters, and webinars including the popular new Exploring Eczema webinar series.
- Scope Patient Information Forum 'Tick' quality accreditation.
- Grow our social media activity and followings, including LinkedIn and YouTube channel.

Supporting Eczema Research

- Deliver the planned eczema and TSW research call, establishing an expert panel to assess grant applications and recommend research awards.
- Grow our EXEC patient panel of people who are willing to share their experiences of living with eczema with researchers.
- Scope and provide leadership for an Eczema Priority Setting Partnership exercise in association with James Lind Alliance and other stakeholders.
- Consolidate our role as a 'hub' for patient and public involvement in eczema research, promoting research engagement opportunities and disseminating research findings.

NATIONAL ECZEMA SOCIETY

(A Company Limited by Guarantee)

Advocacy and Improving Eczema Care

- Increase public awareness and understanding of the challenges of living with eczema, highlighting the impact on people's physical and mental health and quality of life.
- Lead the annual national flagship awareness event, National Eczema Week in September.
- Raise awareness of the Society's successful campaign for clearer strength labelling of topical steroids.
- Continue to support initiatives to promote greater understanding, diagnosis and treatment of topical steroid withdrawal.
- Contribute patient perspectives to clinical guideline development and the assessment of new treatments and policy consultations, working with regulatory bodies including the MHRA, NICE and the SMC.

Financial Results

The Society planned for a modest budget surplus in 2024, following the annual £19,698 operating surplus achieved in 2023.

Income for the year was £529,182, with expenditure at £512,724, generating an annual surplus of £6,922. At 31 December 2024, the Society had reserves of £677,689 (2023: £670,767).

Reserves Policy

The trustees aim to maintain adequate reserves to permit the ongoing operations of the charity. In arriving at their assessment of a suitable limit, trustees have considered the predictability of the Society's income and the nature of its expenditure, together with the degree to which these are committed. Legacies form an important part of the Society's income, and whilst legacies can often be substantial relative to overall income, they are unpredictable, and historical trends show there can be periods of years where this source of income is much lower than the long-term average. Expenditure, on the other hand, is more consistent and predictable.

Trustees last reviewed the Reserves Policy in 2022, and considered that holding unrestricted reserves equal to approximately six months unrestricted charitable expenditure would be sufficient to close or merge the charity, should this ever be necessary. Given the known volatility of legacy income, trustees subsequently determined that a reserves target of 12 months' future overheads expenditure would be more appropriate. However, additional spend on research in 2025 meant that this policy was not met at the end of 2024 and the trustees will be conducting a further review of reserves policy ahead of the next accounts.

To make unrestricted reserves more transparent, funds that are not readily available to spend are held in reserves designated for specific purposes. A key aim of the Society is to promote research into the causes and treatment of eczema. This being so, the trustees have designated a proportion of reserves to fund future research activity, in addition to any funds that donors have specifically restricted for this purpose. Funds that are not readily available to spend, notably those represented by fixed assets, are held in a reserve designated for this purpose. The pension reserve shows future deficit payments owed in relation to an historical defined benefit pension scheme (see note 20).

The balance held in unrestricted funds at 31 December 2024 is £659,989 (2023: £664,016). Unrestricted funds include funds tied up in tangible assets of £4,372 (2023: £12,903), the pension reserve of (£9,896) (2023: (£4,567)), and designated Research funds of £110,000 (2023: £110,000). The remaining general funds of £555,513 (2023: £545,680) fall below the charity's reserves policy target of 12 months future overheads expenditure, budgeted at £752,600 for the 2025 financial year.

NATIONAL ECZEMA SOCIETY

(A Company Limited by Guarantee)

Risk Management

The trustees have taken steps to identify and address major risks facing the Society, including maintaining a risk register. The principal uncertainty in respect to the Society's future is the ability to maintain sufficient income to deliver the charity's operations, and ensure the Society has adequate resources to comply with regulatory changes affecting the voluntary sector. Greater focus and investment are being directed to fundraising activities, to ensure the Society generates sufficient income each year to fund planned activities. This includes building sustainable sources of non-legacy income.

The principal risk of financial sustainability for the charity is closely monitored by the trustees on a regular basis, including reviewing management accounts at quarterly Board meetings. Attention also continues to focus on non-financial risks including reputation, health and safety, security, confidentiality and data protection, which are supported by appropriate policies and procedures as well as management updates as needed.

The Trustees and Organisation

The Society is a charitable company. Although called trustees, we are the directors of the company for the purposes of company law. The trustees who served during the year and up to the date of this report are given on page 1.

The Society's governance processes are set out in its Articles of Association. The Board of Trustees administers the Society, which meets routinely four times a year and additionally as circumstances demand. A chief executive is appointed by the trustees to manage the day-to-day operations of the Society within a framework agreed by the B There must be a minimum of three trustees but there is no maximum number, and trustees must be elected by the members of the Society at its Annual General Meeting (AGM). Trustees may be co-opted onto the Board during the year and must then stand for election by the members at the next AGM. At least a third of trustees are required to retire from office each year but may, if they wish, offer themselves for re-election at the next AGM. Trustees are recruited through the Society's membership, local support groups, other eczema community networks and open advertising. In seeking trustees, the Society has regard of the need to ensure that the Trustee Board has an appropriate range of professional skills and experience, reflects our commitment to diversity, and are trustees are drawn from different areas of the UK.

Although not constitutionally binding, the Society wishes to work towards aligning with the Charity Governance Code, which recommends trustees serve fixed terms in office. The guidance recommends trustees serve an initial three-year term, with the possibility of being re-elected by members for a further three-year period. Trustees in particular roles (e.g. Chair, Treasurer) could serve a longer nine-year period, subject to formal review. One current trustee has served longer than nine years and provides specific professional skills to the Board. As yet, it has not been possible to find a replacement with comparable expertise.

New trustees are provided with an introduction pack, which includes the Society's governing documents, copies of the past year's accounts, and a briefing on their duties and responsibilities and of the Society's governance processes. Prior to joining the Board, new trustees will usually attend at least one Board meeting in an observer capacity, which gives them the opportunity to meet the trustees and chief executive.

Trustees receive no remuneration and no trustee has a beneficial interest in any of the group companies.

The Society has a Medical Advisory Board (MAB), comprised of healthcare professionals who act in an advisory and ambassadorial capacity for the charity. Members volunteer their time and are all experienced healthcare professionals who work in the field of dermatology, and who have a particular professional interest in eczema management and research. The MAB is chaired by National Eczema Society trustee, Professor Celia Moss.

NATIONAL ECZEMA SOCIETY

(A Company Limited by Guarantee)

The trustees set the remuneration of the chief executive and approve the remuneration of other Society staff. Remuneration levels are based on research of similar roles in the sector and benchmark salary data.

The Trustees Report has been prepared in accordance with the provisions applicable to entities subject to the small companies regime.

Approved by order of the members of the board of Trustees and signed on their behalf by:



Stephen Pugh
Chair

September 23, 2025
Date.....

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

STATEMENT OF TRUSTEES' RESPONSIBILITIES
FOR THE YEAR ENDED 31 DECEMBER 2024

The Trustees (who are also the directors of the Charity for the purposes of company law) are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the Trustees to prepare financial statements for each financial . Under company law, the Trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the Group and the Charity and of their incoming resources and application of resources, including their income and expenditure, for that period. In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles of the Charities SORP (FRS 102);
- make judgements and accounting estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards (FRS 102) have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Group will continue in business.

The Trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the Group and the Charity's transactions and disclose with reasonable accuracy at any time the financial position of the Group and the Charity and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the Group and the Charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Approved by order of the members of the Board of Trustees and signed on its behalf by:



.....
Stephen Pugh
Chair

Date: September 23, 2025

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

INDEPENDENT EXAMINER'S REPORT
FOR THE YEAR ENDED 31 DECEMBER 2024

Independent Examiner's Report to the Trustees of National Eczema Society ('the Group')

I report to the Charity Trustees on my examination of the consolidated accounts of the Group, set out on pages 14 to 45, comprising the National Eczema Society ('the parent Charity') and its subsidiary undertakings for the year ended 31 December 2024.

Responsibilities and Basis of Report

As the Trustees of the parent Charity (and its directors for the purposes of company law) you are responsible for the preparation of the consolidated accounts of the Group in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the consolidated accounts are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of the Group's accounts as carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

Independent Examiner's Statement

Since the Group's gross income exceeded £250,000 your examiner must be a member of a body listed in section 145 of the 2011 Act. I confirm that I am qualified to undertake the examination because I am a member of the Institute of Chartered Accountants in England and Wales, which is one of the listed bodies.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe in any material respect:

1. accounting records were not kept in respect of the parent Charity and its subsidiaries as required by section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a 'true and fair' view which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102).

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

INDEPENDENT EXAMINER'S REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

Signed:



Dated: 23 September 2025

Rachel Doyle ACA DChA

MHA
Chartered Accountants
MHA House
Charter Court
Swansea Enterprise Park
Swansea
SA7 9FS

MHA is the trading name of MHA Audit Services LLP, a limited liability partnership in England and Wales (registered number OC455542).

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

CONSOLIDATED STATEMENT OF FINANCIAL ACTIVITIES (INCORPORATING INCOME AND EXPENDITURE ACCOUNT)
FOR THE YEAR ENDED 31 DECEMBER 2024

	Note	Unrestricted funds 2024 £	Restricted funds 2024 £	Total funds 2024 £	Total funds 2023 £
Income from:					
Donations and legacies	4	512,330	-	512,330	481,158
Other trading activities:	5				
Income from fundraising		91	-	91	5,732
Income from trading activities		2,462	-	2,462	2,965
Investments	6	14,299	-	14,299	7,397
Total income		529,182	-	529,182	497,252
Expenditure on:					
Raising funds		101,913	-	101,913	71,317
Charitable activities	8	410,811	-	410,811	406,245
Total expenditure		512,724	-	512,724	477,562
Net income		16,458	-	16,458	19,690
Transfers between funds	21	(10,949)	10,949	-	-
Net movement in funds before other recognised gains		5,509	10,949	16,458	19,690
Other recognised gains/(losses):					
Gains/(losses) on pension scheme		(9,536)	-	(9,536)	8
Net movement in funds		(4,027)	10,949	6,922	19,698
Reconciliation of funds:					
Total funds brought forward		664,016	6,751	670,767	651,069
Net movement in funds		(4,027)	10,949	6,922	19,698
Total funds carried forward		659,989	17,700	677,689	670,767

The Consolidated Statement of Financial Activities includes all gains and losses recognised in the year. All income and expenditure derive from continuing activities.

The notes on pages 21 to 45 form part of these financial statements.

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)
REGISTERED NUMBER: 02685083

CONSOLIDATED BALANCE SHEET
AS AT 31 DECEMBER 2024

	Note	2024 £	2024 £	2023 £	2023 £
Fixed assets					
Intangible assets	14		2,255		1,462
Tangible assets	15		2,117		10,733
			<u>4,372</u>		<u>12,195</u>
Current assets					
Debtors: Amounts falling due within one year	17	116,944		88,906	
Investments	18	253,616		-	
Cash at bank and in hand		428,458		728,799	
		<u>799,018</u>		<u>817,705</u>	
Current liabilities					
Creditors: Amounts falling due within one year	19	(118,750)		(158,773)	
Net current assets			<u>680,268</u>		<u>658,932</u>
Total assets less current liabilities			<u>684,640</u>		<u>671,127</u>
Creditors: Amounts falling due after more than one year	20		(6,951)		(360)
Total net assets			<u><u>677,689</u></u>		<u><u>670,767</u></u>
Group funds					
Restricted funds	21		17,700		6,751
Unrestricted funds	21		659,989		664,016
Total funds			<u><u>677,689</u></u>		<u><u>670,767</u></u>

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)
REGISTERED NUMBER: 02685083

CONSOLIDATED BALANCE SHEET (CONTINUED)
AS AT 31 DECEMBER 2024

The Charity was entitled to exemption from audit under section 477 of the Companies Act 2006.

The members have not required the company to obtain an audit for the year in question in accordance with section 476 of Companies Act 2006.

The Trustees acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to entities subject to the small companies regime.

The financial statements were approved and authorised for issue by the Trustees and signed on their behalf by:



.....
Stephen Pugh

Chair

Date: September 23, 2025

The notes on pages 21 to 45 form part of these financial statements.

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)
REGISTERED NUMBER: 02685083

CHARITY BALANCE SHEET
AS AT 31 DECEMBER 2024

	Note	2024 £	2024 £	2023 £	2023 £
Fixed assets					
Intangible assets	14		2,255		1,462
Tangible assets	15		2,117		10,733
Investments	16		100		100
			<u>4,472</u>		<u>12,295</u>
Current assets					
Debtors: Amounts falling due within one year	17	116,944		154,841	
Investments	18	253,616		-	
Cash at bank and in hand		336,093		581,497	
		<u>706,653</u>		<u>736,338</u>	
Current liabilities					
Creditors: Amounts falling due within one year	19	(124,480)		(115,791)	
Net current assets			<u>582,173</u>		<u>620,547</u>
Total assets less current liabilities			<u>586,645</u>		<u>632,842</u>
Creditors: Amounts falling due after more than one year	20		(6,951)		(360)
Total net assets			<u><u>579,694</u></u>		<u><u>632,482</u></u>
Charity funds					
Restricted funds	21		-		6,751
Unrestricted funds	21		579,694		625,731
Total funds			<u><u>579,694</u></u>		<u><u>632,482</u></u>

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)
REGISTERED NUMBER: 02685083

CHARITY BALANCE SHEET (CONTINUED)
AS AT 31 DECEMBER 2024

The Charity's net movement in funds for the year was £(52,788) (2023 - £(48,111)).

The Charity was entitled to exemption from audit under section 477 of the Companies Act 2006.

The members have not required the company to obtain an audit for the year in question in accordance with section 476 of Companies Act 2006.

The Trustees acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to entities subject to the small companies regime.

The financial statements were approved and authorised for issue by the Trustees and signed on their behalf by:



.....
Stephen Pugh

Chair

Date: September 23, 2025

The notes on pages 21 to 45 form part of these financial statements.

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

CONSOLIDATED STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED 31 DECEMBER 2024

	Note	2024 £	2023 £
Cash flows from operating activities			
Net cash used in operating activities	22	(308,540)	38,315
Cash flows from investing activities			
Investment income		14,299	7,397
Purchase of intangible assets		(2,000)	(2,021)
Purchase of tangible fixed assets		(4,100)	(2,000)
Net cash provided by investing activities		8,199	3,376
Change in cash and cash equivalents in the year		(300,341)	41,691
Cash and cash equivalents at the beginning of the year		728,799	687,108
Cash and cash equivalents at the end of the year	23	428,458	728,799

The notes on pages 21 to 45 form part of these financial statements

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

1. General information

National Eczema Society is a charitable company limited by guarantee and is registered with the Registrar of Companies (Company Registered Number: 02685083), the Charity Commission in England and Wales (Charity Registered Number: 1009671).

In the event of the Charity being wound up, the liability in respect of the guarantee is limited to £1 per Member of the Charity.

The address of the registered office is given in the Charity information on page 1 of these financial statements. The nature of the Charity's operations and principal activities are detailed in the Trustees' Report.

The significant accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all years presented unless otherwise stated.

2. Accounting policies

2.1 Basis of preparation of financial statements

The financial statements have been prepared in accordance with the Charities SORP (FRS 102) - Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

National Eczema Society meets the definition of a public benefit entity under FRS 102.

Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy.

The Consolidated Statement of Financial Activities (SOFA) and Consolidated Balance Sheet consolidate the financial statements of the Charity and its subsidiary undertaking. The results of the subsidiary are consolidated on a line by line basis.

The financial statements are prepared in sterling which is the functional and presentational currency of the Group and are rounded to the nearest pound.

2.2 Going concern

The Trustees have assessed the use of going concern and have considered possible events or conditions that might cast significant doubt on the ability of the Group to continue as a going concern. The Trustees have made this assessment for a period of at least one year from the date of the approval of these financial statements. The Trustees have concluded that there is a reasonable expectation that the Group has adequate resources to continue in operational existence for the foreseeable future, and that no material uncertainties exist. The Group therefore continues to adopt the going concern basis in preparing these financial statements.

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

2. Accounting policies (continued)

2.3 Income

All income is recognised once the Group has entitlement to the income, it is probable that the income will be received and the amount of income receivable can be measured reliably.

For donations and gift aid to be recognised the Group will have been notified of the amounts and the settlement date in writing. If there are conditions attached to the donation and this requires a level of performance before entitlement can be obtained then income is deferred until those conditions are fully met or the fulfilment of those conditions is within the control of the Group and it is probable that they will be fulfilled.

The recognition of income from legacies is dependent on establishing entitlement, the probability of receipt and the ability to estimate with sufficient accuracy the amount receivable. Evidence of entitlement to a legacy exists when the Group has sufficient evidence that a gift has been left to them (through knowledge of the existence of a valid will and the death of the benefactor) and the executor is satisfied that the property in question will not be required to satisfy claims in the estate. Receipt of a legacy must be recognised when it is probable that it will be received and the fair value of the amount receivable, which will generally be the expected cash amount to be distributed to the Group, can be reliably measured.

Subscription income is received in full and recognised evenly over the course of the subscription. The amount recognised in the Consolidated Statement of Financial Activities relates to the financial period in question.

Income from trading activities includes income earned from fundraising events and trading activities to raise funds for the Group. Income is received in exchange for supplying goods and services in order to raise funds and is recognised when entitlement has occurred.

Corporate membership income is received in full and recognised evenly over the course of the membership. The amount recognised in the Consolidated Statement of Financial Activities relates to the financial period in question.

2.4 Expenditure

All expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all costs related to the categories. Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Central staff costs are allocated on the basis of time spent, and depreciation charges allocated on the portion of the asset's use.

Expenditure on charitable activities is incurred on directly undertaking the activities which further the Group's objectives, as well as any associated support costs.

All expenditure is inclusive of irrecoverable VAT.

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

2. Accounting policies (continued)

2.5 Interest receivable

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the Group; this is normally upon notification of the interest paid or payable by the institution with whom the funds are deposited.

2.6 Taxation

The Charity is considered to pass the tests set out in Paragraph 1 Schedule 6 of the Finance Act 2010 and therefore it meets the definition of a charitable company for UK corporation tax purposes. Accordingly, the Charity is potentially exempt from taxation in respect of income or capital gains received within categories covered by Chapter 3 Part 11 of the Corporation Tax Act 2010 or Section 256 of the Taxation of Chargeable Gains Act 1992, to the extent that such income or gains are applied exclusively to charitable purposes.

2.7 Intangible assets and amortisation

Intangible assets costing £500 or more are capitalised and recognised when future economic benefits are probable and the cost or value of the asset can be measured reliably.

Intangible assets are initially recognised at cost. After recognition, under the cost model, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

Amortisation is provided on intangible assets at rates calculated to write off the cost of each asset on a straight-line basis over 3 years.

Assets under construction are not amortised until ready for use.

2.8 Tangible fixed assets and depreciation

Tangible fixed assets costing £500 or more are capitalised and recognised when future economic benefits are probable and the cost or value of the asset can be measured reliably.

Tangible fixed assets are initially recognised at cost. After recognition, under the cost model, tangible fixed assets are measured at cost less accumulated depreciation and any accumulated impairment losses. All costs incurred to bring a tangible fixed asset into its intended working condition should be included in the measurement of cost.

At each reporting date the Group assesses whether there is any indication of impairment. If such indication exists, the recoverable amount of the asset is determined to be the higher of its fair value less costs to sell and its value in use. An impairment loss is recognised where the carrying amount exceeds the recoverable amount.

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

2. Accounting policies (continued)

2.8 Tangible fixed assets and depreciation (continued)

Depreciation is charged so as to allocate the cost of tangible fixed assets less their residual value over their estimated useful lives, using the straight-line method.

Depreciation is provided on the following bases:

Leasehold improvements	- over 10 years
Furniture and fittings	- over 10 years
Office equipment	- over 10 years
Computer equipment	- over 3 years

2.9 Investments

The investment in the subsidiary company is valued at cost less provision for impairment.

2.10 Debtors

Trade and other debtors are recognised at the settlement amount after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

2.11 Cash at bank and in hand

Cash at bank and in hand includes cash and short-term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

2.12 Liabilities and provisions

Liabilities are recognised when there is an obligation at the Balance Sheet date as a result of a past event, it is probable that a transfer of economic benefit will be required in settlement, and the amount of the settlement can be estimated reliably.

Liabilities are recognised at the amount that the Group anticipates it will pay to settle the debt or the amount it has received as advanced payments for the goods or services it must provide.

Provisions are measured at the best estimate of the amounts required to settle the obligation. Where the effect of the time value of money is material, the provision is based on the present value of those amounts, discounted at the pre-tax discount rate that reflects the risks specific to the liability. The unwinding of the discount is recognised in the Consolidated Statement of Financial Activities as a finance cost.

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

2. Accounting policies (continued)

2.13 Financial instruments

The Group only holds basic Financial Instruments. The financial assets and financial liabilities of the Group are as follows:

Debtors – other debtors are basic financial instruments and are debt instruments measured at amortised cost as detailed in Note 17.

Cash at bank – is classified as a basic financial instrument and is measured at face value.

Liabilities – accruals are classified as financial instruments, and are measured at amortised cost as detailed in Notes 19 and 20.

2.14 Operating leases

Rentals paid under operating leases are charged to the Consolidated Statement of Financial Activities on a straight line basis over the lease term.

2.15 Pensions

Through its past participation, the Group has a liability to a pension scheme called the Series 3 Growth Plan, which closed in 2013. Since then, the Group has participated in a defined contribution pension scheme for employees, operated by workplace pension provider TPT.

The Group is part of the Series 3 Growth Plan which is a multi-employer pension Scheme which closed in 2013. The Scheme administrators have confirmed that it is not possible to separately identify the assets and liabilities of participating employers on a consistent and reasonable basis. The assets of the Scheme are co-mingled for investment purposes and benefits are paid from total Scheme assets. A deficit reduction plan has been agreed.

The Group accounts for its participation in this Plan as a defined contribution plan, as there is insufficient information available to account for this as a defined benefit plan, as the share of its assets and liabilities cannot be identified.

To avoid crystallizing an immediate payment of the apparent under-funding in the Series 3 Scheme, the Group is participating in the Series 3 Recovery Plan and the liability is included in Notes 19 and 20. The Group recognises its liability to make payments to fund the deficit relating to past service under an agreement to make those payments. It recognises the full liability for the present value of contributions payable that results from the agreement for funding the multi employer plan.

The Group also participates in a defined contribution pension scheme for its employees. The Group pays fixed contributions into a separate scheme. Once the defined contribution payments have been made, the Group has no further payment obligations in respect of this scheme. The contributions are recognised as an expense in the Consolidated Statement of Financial Activities as they fall due.

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

2. Accounting policies (continued)

2.16 Fund accounting

General funds are unrestricted funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the Group and which have not been designated for other purposes.

Designated funds comprise unrestricted funds that have been set aside by the Trustees for particular purposes. The aim and use of each designated fund is set out in the notes to the financial statements.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the Group for particular purposes. The costs of raising and administering such funds are charged against the specific fund. The aim and use of each restricted fund is set out in the notes to the financial statements.

Investment income, gains and losses are allocated to the appropriate fund.

3. Critical accounting estimates and areas of judgement

Estimates and judgements are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

Critical accounting estimates and assumptions:

The Group makes estimates and assumptions concerning the future. The resulting accounting estimates and assumptions will, by definition, seldom equal the related actual results. The estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are listed below.

- Allocation of support costs
- Legacy income recognition
- Depreciation rates for tangible fixed assets
- Useful economic lives of assets
- The discount rate used in valuing the year-end Pension Scheme deficit.

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

4. Income from donations and legacies

	Unrestricted funds 2024 £	Total funds 2024 £
Donations and similar income	175,519	175,519
Legacies	189,454	189,454
Subscriptions	126,734	126,734
Gift aid	20,623	20,623
Total 2024	512,330	512,330

	Unrestricted funds 2023 £	Total funds 2023 £
Donations and similar income	205,431	205,431
Legacies	110,610	110,610
Subscriptions	141,813	141,813
Gift aid	23,304	23,304
Total 2023	481,158	481,158

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

5. Income from other trading activities

Income from fundraising events

	Unrestricted funds 2024 £	Total funds 2024 £
Other activities	91	91

	Unrestricted funds 2023 £	Total funds 2023 £
Other corporate income	2,896	2,896
Other activities	2,836	2,836
Total 2023	5,732	5,732

Income from non charitable trading activities

	Unrestricted funds 2024 £	Total funds 2024 £
Trading subsidiary	2,462	2,462

	Unrestricted funds 2023 £	Total funds 2023 £
Trading subsidiary	2,965	2,965

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

6. Income from investments

	Unrestricted funds 2024 £	Total funds 2024 £
Bank interest receivable	14,299	14,299
	Unrestricted funds 2023 £	Total funds 2023 £
Bank interest receivable	7,397	7,397

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

7. Expenditure on raising funds

	2024 £	2023 £
Fundraising costs		
Direct costs	78,339	65,707
Support costs	23,572	5,604
	<u>101,911</u>	<u>71,311</u>

Analysis of support costs - fundraising costs

	2024 £	2023 £
Staff costs	6,368	1,912
Depreciation	1,212	382
Premises costs	2,451	728
Carriage and postage	264	116
HCP services and fees	149	33
Professional fees	1,377	349
Bought-in services	129	41
Website, database and computing	3,794	712
Other costs	6,757	835
Governance costs	1,071	496
	<u>23,572</u>	<u>5,604</u>

	2024 £	2023 £
Trading costs		
Trading subsidiary - Direct costs	<u>2</u>	<u>6</u>

In both the current and previous financial years all Expenditure on raising funds was from Unrestricted funds.

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

8. Analysis of expenditure on charitable activities - by fund

	Unrestricted funds 2024 £	Total 2024 £
Communications, awareness and campaigns	88,371	88,371
Health Information and Advice	219,290	219,290
Research	103,150	103,150
Total 2024	410,811	410,811

	Unrestricted funds 2023 £	Total 2023 £
Helpline	110,547	110,547
Membership services	181,415	181,415
Information services	114,283	114,283
Total 2023	406,245	406,245

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

9. Analysis of expenditure on charitable activities - by type

	Activities undertaken directly 2024 £	Support costs 2024 £	Total funds 2024 £
Communications, awareness and campaigns	12,523	75,848	88,371
Health Information and Advice	101,432	117,858	219,290
Research	79,577	23,573	103,150
Total 2024	193,532	217,279	410,811

	Activities undertaken directly 2023 £	Support costs 2023 £	Total funds 2023 £
Helpline	60,804	49,743	110,547
Membership services	102,860	78,555	181,415
Information services	73,335	40,948	114,283
Total 2023	236,999	169,246	406,245

During the year the charity restructured its activities and therefore the prior year is not directly comparable to the current year. If the current year was allocated on the same basis as previous years the total expenditure for each activity would be as follows:

Raising Funds £86,710

Helpline £108,713

Membership services £201,896

Information services £106,405

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

9. Analysis of expenditure on charitable activities - by type (continued)

Analysis of support costs

	Total funds 2024 £	Total funds 2023 £
Staff costs	57,314	55,947
Depreciation	10,910	11,165
Premises costs	22,064	21,302
Carriage and postage	2,373	3,399
Professional fees	12,390	13,130
Bought-in services	1,161	1,205
Website, database and computing	34,149	20,833
Insurance	231	1,750
Other costs	65,711	27,930
Governance costs	9,636	11,619
HCP services and fees	1,340	966
	217,279	169,246

10. Governance costs

	2024 £	2023 £
Independent Examiner's remuneration	2,535	2,000
Staff training	-	2,065
Insurance	7,626	5,789
Recruitment	-	-
Room hire & Conference expenses	202	1,498
Trustees expenses	-	-
Travel, hotels & subsistence	344	639
General office expenses	-	26
	10,707	12,017

Total Governance costs above comprise £1,071 (2023 - £398) of Expenditure on raising funds and £9,636 (2023 - £11,619) of Expenditure on charitable activities.

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

11. Auditors' and Independent examiner's remuneration

	2024 £	2023 £
Independent Examiner's remuneration - Examination of the financial statements	<u>5,520</u>	<u>5,250</u>

12. Staff costs

	Group 2024 £	Group 2023 £	Charity 2024 £	Charity 2023 £
Wages and salaries	238,434	212,525	238,434	212,525
Social security costs	23,212	19,710	23,212	19,710
Pension costs	7,849	10,327	7,849	10,327
	<u>269,495</u>	<u>242,562</u>	<u>269,495</u>	<u>242,562</u>

Included in Wages and salaries above are redundancy costs of £29,812 (2023: £NIL). Of this amount, £29,812 (2023: £NIL) relates to statutory redundancy.

The average number of persons employed by the Charity during the year was as follows:

	Group 2024 No.	Group 2023 No.
Direct charitable activities	3	3
Fundraising and communication	1	1
Support and governance	1	1
	<u>5</u>	<u>5</u>

The number of employees whose employee benefits (excluding employer pension costs) exceeded £60,000 was:

	Group 2024 No.	Group 2023 No.
In the band £60,001 - £70,000	-	1
In the band £70,001 - £80,000	1	-

The total amount of employee benefits, including employers national insurance and pension contributions, received by Key Management Personnel is £102,576 (2023 - £138,823). The Charity considers its Key Management Personnel comprise the Trustees and the Chief Executive Officer and deputy CEO.

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

13. Trustees' remuneration and expenses

During the year, no Trustees received any remuneration or other benefits (2023 - £NIL).

During the year ended 31 December 2024, expenses totalling £147 were reimbursed or paid directly to 1 trustee (2023 - £499 - 2 Trustees) in relation to travel and conference costs.

14. Intangible assets

Group and Charity

	Website £
Cost	
At 1 January 2024	23,009
Disposals	(20,988)
Revaluations	2,000
At 31 December 2024	<u>4,021</u>
Amortisation	
At 1 January 2024	21,547
Charge for the year	1,210
On disposals	(20,991)
At 31 December 2024	<u>1,766</u>
Net book value	
At 31 December 2024	<u><u>2,255</u></u>
At 31 December 2023	<u><u>1,462</u></u>

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

15. Tangible fixed assets

Group and Charity

	Leasehold improvements £	Furniture and fixtures £	Office equipment £	Computer equipment £	Total £
Cost or valuation					
At 1 January 2024	41,470	2,493	3,873	26,189	74,025
Additions	1,330	-	-	2,770	4,100
Disposals	-	-	(177)	(22,044)	(22,221)
Transfers between classes	-	-	-	(2,000)	(2,000)
At 31 December 2024	42,800	2,493	3,696	4,915	53,904
Depreciation					
At 1 January 2024	34,230	2,178	3,063	23,821	63,292
Charge for the year	8,570	315	540	1,288	10,713
On disposals	-	-	(177)	(22,041)	(22,218)
At 31 December 2024	42,800	2,493	3,426	3,068	51,787
Net book value					
At 31 December 2024	-	-	270	1,847	2,117
At 31 December 2023	7,240	315	810	2,368	10,733

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

16. Fixed asset investments

	Investment in subsidiary company £
Charity	
Cost or valuation	
At 1 January 2024	100
At 31 December 2024	<u>100</u>

Principal subsidiaries

The following was a subsidiary undertaking of the Charity:

Name	Company number	Registered office or principal place of business	Holding	Included in consolidation
Eczema Trading Limited	06895048	82 Tanner Street, London, SE1 3GN	100%	Yes

The financial results of the subsidiary for the year were:

Name	Income £	Expenditure £	Profit for the year £	Net assets £
Eczema Trading Limited	69,712	(5,002)	64,710	103,095

The results of Eczema Trading Limited are included in these consolidated accounts. Eczema Trading Limited did not meet the audit threshold and therefore did not require an audit for the year ended 31 December 2024. The reported surplus relates to intercompany management charges and minimal advertising and corporate membership revenue.

For the year ended 31 December 2024, Corporate memberships, the advertising revenue from our membership magazine, together with limited income from company supporters, is accounted for in Eczema Trading Limited.

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

17. Debtors

	Group 2024 £	Group 2023 £	Charity 2024 £	Charity 2023 £
Due within one year				
Trade debtors	-	20,762	-	2,762
Amounts owed by group undertakings	-	-	-	83,935
Other debtors	94,075	50,622	94,075	50,622
Prepayments and accrued income	22,869	17,522	22,869	17,522
	116,944	88,906	116,944	154,841

18. Current asset investments

	Group 2024 £	Group 2023 £	Charity 2024 £	Charity 2023 £
95 day savings accounts	253,616	-	253,616	-

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

19. Creditors: Amounts falling due within one year

	Group 2024 £	Group 2023 £	Charity 2024 £	Charity 2023 £
Trade creditors	2,881	5,127	2,881	5,127
Amounts owed to group undertakings	-	-	41,462	-
Other taxation and social security	12,326	15,401	12,326	15,401
Other creditors	3,998	4,395	3,998	4,395
Accruals and deferred income	99,545	133,850	63,813	90,868
	118,750	158,773	124,480	115,791
	Group 2024 £	Group 2023 £	Charity 2024 £	Charity 2023 £
Deferred income				
Deferred income at 1 January	115,512	78,080	72,530	50,447
Resources deferred during the year	97,525	164,308	15,000	77,409
Amounts released from previous periods	(133,616)	(126,876)	(45,916)	(55,326)
Deferred income at 31 December	79,421	115,512	41,614	72,530

Deferred income consists of membership income relating to future periods.

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

20. Creditors: Amounts falling due after more than one year

	Group	Group	Charity	Charity
	2024	2023	2024	2023
	£	£	£	£
Pension Scheme deficit	6,951	360	6,951	360

Through its past participation, the Group has a liability to a pension scheme called the Series 3 Growth Plan, which closed in 2013. Since then, the Group has participated in a defined contribution pension scheme for employees, operated by workplace pension provider TPT.

The Charity is participating in a recovery plan to eliminate its Series 3 scheme deficit over a ten year period. The Pensions Trust, the scheme administrator, has however advised that the amount of employer debt on the alternative of withdrawal from the Series 3 scheme has been estimated by actuaries to have been £200,161 as at 31 December 2016. As the Charity intends to continue participating in the recovery plan, no provision has been made for this potential withdrawal debt however, the Society accounted for the present value of all remaining contributions under the recovery plan in the 2017 accounts at their present value of £120,000, as advised by the scheme administrator. This liability has been adjusted annually to unwind the relevant discount applied.

In order to meet their share of the shortfall, the Charity has been asked to pay additional contributions to the scheme. A full actuarial valuation was carried out by the actuaries during the year and the funding shortfall calculated at that date gave rise to a remeasurement reduction of £9,896 in the deficit as at 31 December 2024. The deficit of the scheme is £9,896, (2023 - £4,556) at 31 December 2024. The payment by the Charity in the year was £4,324 (2023 - £4,324) with an interest payment of £129 (2023 - £311) and a revaluation gain of £Nil (2023 - £8).

In addition, the Charity elected to switch, with effect from 1 October 2013, from Series 3 to Series 4, a defined contribution scheme. The pension cost in the accounts represents amounts payable by the charity as ordinary employer contributions to the Series 4 defined contribution fund.

During the year employer contributions of £7,849 (2023 - £10,327), interest of £42 (2023 - £311), actuarial (gains)/losses of £Nil (2023 - £8) and remeasurements for amendments to the contribution schedule of £9,525 (2023 - £Nil) have been charged to the Consolidated Statement of Financial Activities, along with scheme costs of £5,091 (2023: £3,625). There were no accrued contributions at 31 December 2024 (2023 - £Nil) but there is a liability of £9,896 (2023 - £4,566) for future contributions under the Series 3 Recovery Plan. Of this £2,945 (2023 - £4,206) is reported in Creditors: Amounts falling due within one year as part of Other creditors and £6,951 (2023 - £360) is reported in Creditors: Amounts falling due after more than one year.

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

21. Statement of funds

Statement of funds - current year

	Balance at 1 January 2024 £	Income £	Expenditure £	Transfers in/(out) £	Gains/ (Losses) £	Balance at 31 December 2024 £
Unrestricted funds						
Designated funds						
Fixed asset fund	12,903	-	(10,910)	2,379	-	4,372
Pension reserve	(4,567)	-	(5,132)	9,339	(9,536)	(9,896)
Research fund	110,000	-	-	-	-	110,000
	<u>118,336</u>	<u>-</u>	<u>(16,042)</u>	<u>11,718</u>	<u>(9,536)</u>	<u>104,476</u>
General funds						
General funds	<u>545,680</u>	<u>529,182</u>	<u>(496,682)</u>	<u>(22,667)</u>	<u>-</u>	<u>555,513</u>
Total Unrestricted funds	<u>664,016</u>	<u>529,182</u>	<u>(512,724)</u>	<u>(10,949)</u>	<u>(9,536)</u>	<u>659,989</u>
Restricted funds						
Research	<u>6,751</u>	<u>-</u>	<u>-</u>	<u>10,949</u>	<u>-</u>	<u>17,700</u>
Total of funds	<u><u>670,767</u></u>	<u><u>529,182</u></u>	<u><u>(512,724)</u></u>	<u><u>-</u></u>	<u><u>(9,536)</u></u>	<u><u>677,689</u></u>

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

21. Statement of funds (continued)

Statement of funds - prior year

	Balance at 1 January 2023 £	Income £	Expenditure £	Transfers in/out £	Gains/ (Losses) £	Balance at 31 December 2023 £
Unrestricted funds						
Designated funds						
Fixed asset fund	19,721	-	(10,839)	4,021	-	12,903
Pension reserve	(8,587)	-	(5,579)	9,591	8	(4,567)
Research fund	110,000	-	-	-	-	110,000
	<u>121,134</u>	<u>-</u>	<u>(16,418)</u>	<u>13,612</u>	<u>8</u>	<u>118,336</u>
General funds						
General funds	<u>523,185</u>	<u>497,252</u>	<u>(461,145)</u>	<u>(13,612)</u>	<u>-</u>	<u>545,680</u>
Total Unrestricted funds	<u>644,319</u>	<u>497,252</u>	<u>(477,563)</u>	<u>-</u>	<u>8</u>	<u>664,016</u>
Restricted funds						
Research	<u>6,751</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>6,751</u>
Total of funds	<u><u>651,070</u></u>	<u><u>497,252</u></u>	<u><u>(477,563)</u></u>	<u><u>-</u></u>	<u><u>8</u></u>	<u><u>670,767</u></u>

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

21. Statement of funds (continued)

Designated funds

The Pension reserve has been established to show the future pension deficit payments in regards to a defined benefit pension scheme. This pension scheme is being treated as a defined contribution pension scheme as a reliable estimate cannot be made of the liability at the year end. The transfer of £9,339, was made to separate the deficit payments due as at 31 December 2024 from the Unrestricted general fund. Actuarial gains / (losses) are charged to this fund as they arise.

The Fixed asset fund has been established to reflect the funds tied up in Tangible and Intangible fixed assets and agrees back to the Net Book Value presented on the Consolidated Balance Sheet. Depreciation is charged to this fund as expenditure.

The Research fund has been established to designate funds for research into the causes and treatment of eczema, which is a key aim of the Society. The Society will provide grants to researchers on a periodic basis and it is necessary to designate sufficient reserves to fund the expected grant costs.

Unrestricted funds

General funds reflects funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the Charity and which have not been designated for other purposes.

Restricted funds

The Research fund exists to provide resources for research into the causes of eczema, with the aim of developing more effective treatments or a cure.

22. Reconciliation of net movement in funds to net cash flow from operating activities

	Group 2024 £	Group 2023 £
Net income for the period (as per Statement of Financial Activities)	16,458	19,690
Adjustments for:		
Depreciation charges	10,713	9,152
Amortisation charges	1,210	2,395
Dividends, interests and rents from investments	(14,299)	(7,397)
Loss on the sale of fixed assets	2,000	-
Increase in debtors	(281,654)	(53,516)
(Decrease)/increase in creditors	(33,432)	60,041
Actuarial Gains/ (loss) on pension	(9,536)	-
Net cash provided by/(used in) operating activities	(308,540)	30,365

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

23. Analysis of cash and cash equivalents

	Group 2024 £	Group 2023 £
Cash in hand	428,458	728,799
Total cash and cash equivalents	428,458	728,799

24. Analysis of changes in net debt

	At 1 January 2024 £	Cash flows £	At 31 December 2024 £
Cash at bank and in hand	728,799	(300,341)	428,458
95 day savings accounts	-	253,616	253,616
	728,799	(46,725)	682,074

25. Operating lease commitments

At 31 December 2024 the Group and the Charity had commitments to make future minimum lease payments under non-cancellable operating leases as follows:

	Group 2024 £	Group 2023 £	Charity 2024 £	Charity 2023 £
Not later than 1 year	30,600	21,000	30,600	21,000
Later than 1 year and not later than 5 years	-	4,333	-	4,333
	30,600	25,333	30,600	25,333

The following lease payments have been recognised as an expense in the Statement of Financial Activities:

	Group 2024 £	Group 2023 £	Charity 2024 £	Charity 2023 £
Operating lease rentals	21,000	21,000	21,000	21,000

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

26. Related party transactions

In the year ended 31 December 2024, unrestricted donations of £120 (2023 - £120) were made by the Trustees of the Charity.

27. Post balance sheet events

The charity has received a legacy from the Morton Estate. There are a number of assets that are in the process of being sold and therefore the expected legacy could not be accurately valued at the year end.

The charity also received a legacy from Enid Mary Shores Estate. The amount received could not be quantified at the year end.

Accounts

Company Registered Number: 02685083
Charity Registered Number (England & Wales): 1009671

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

UNAUDITED

TRUSTEES' REPORT AND FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2023

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

CONTENTS

	Page
Reference and Administrative Details of the Charity, its Trustees and Advisers	1
Trustees' Report	2 - 11
Statement of Trustees' Responsibilities	12
Independent Examiner's Report	13
Consolidated Statement of Financial Activities	14
Consolidated Balance Sheet	15 - 16
Charity Balance Sheet	17 - 18
Consolidated Statement of Cash Flows	19
Notes to the Financial Statements	20 - 44

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

**REFERENCE AND ADMINISTRATIVE DETAILS OF THE CHARITY, ITS TRUSTEES AND ADVISERS
 FOR THE YEAR ENDED 31 DECEMBER 2023**

Trustees	Stephen Pugh, Chair Hannah Kunzlik Professor Celia Moss OBE Bharat Pandya (resigned 31 December 2023) James Pitayanukul, Treasurer Hedwig Vollers Suzanne Watson
Company registered number	02685083
Charity registered number	1009671
Registered office	11 Murray Street London NW1 9RE
Chief executive officer & Company secretary	Andrew Proctor
Independent Examiner	MHA Chartered Accountants MHA House Charter Court Swansea Enterprise Park Swansea SA7 9FS
Principal Bankers	CAF Bank Ltd National Westminster Bank plc Barclays Bank plc
Status and Governing Document	National Eczema Society is a charitable company, limited by guarantee. It was incorporated on 6 February 1992 and registered as a charity on 10 March 1992. It is governed by its Articles of Association.
Subsidiary Companies	Eczema Trading Limited

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

TRUSTEES' REPORT
FOR THE YEAR ENDED 31 DECEMBER 2023

The trustees present their annual report together with the financial statements of the Group and the Charity for the year 1 January 2023 to 31 December 2023. The trustees confirm that the Annual Report and financial statements of the company comply with the current statutory requirements, the requirements of the company's governing document and the provisions of the Statement of Recommended Practice (SORP), applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102). Since the Charity and the Group qualifies as small under section 383, the strategic report required of medium and large companies under The Companies Act 2006 (Strategic Report and Director's Report) Regulations 2013 is not required.

Purpose and aims

National Eczema Society was established in 1975 to support people with eczema and their families and to work on their behalf. We remain dedicated to these founding principles and today we continue to help people across the UK by providing evidence-based information and advice about eczema and its management. We deliver this in various ways through our website, webinars, instructional videos, social media communications and publications. We also provide a collective voice for people with eczema, to inform research and influence health policy to improve eczema care, and raise greater awareness and understanding of the condition among people affected by eczema and the wider public.

The prevalence of eczema has increased over recent decades, and around one in five children and one in ten adults are now impacted by this life-challenging condition in the UK. While the reasons for the increase are not fully understood, it does mean the charity's work is needed more than ever. There is as yet no cure for eczema and, unless you have the condition, it can be hard to understand the daily challenge of living with relentless itching and inflamed, painful skin. Many healthcare professionals have limited dermatology training and timely access to specialist dermatology healthcare for people with eczema can often be difficult. National Eczema Society aims to provide the information and support needed for people to self-manage their eczema effectively, to become experts in their own care, learn from the experiences of others, and provide the reassurance of knowing they are not on their own.

Ensuring our work delivers our charitable aims

We review our activities each year and monitor the impact of our work to ensure we continue to fulfil our purpose of supporting people affected by eczema. Among other ways, we assess the Society's performance and achievements through the number of people we have helped with information and advice, and the quality and consistency of the resources we provide.

We consider how planned activities will contribute to the aims and objectives we have set, and in doing this we have referred to the Charity Commission's general guidance on public benefit. We have had regard to the legislative and regulatory requirements for disclosing how our charitable objectives have provided such benefit, and complied with the duty set out in section 4 of the Charities Act 2011.

2023 Activity and achievements - delivering public benefit

All our charitable activities focus on supporting people affected by eczema and championing their needs, and further our charitable purposes for the public benefit. Here we present a summary of the Society's work over the year.

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

TRUSTEES' REPORT
FOR THE YEAR ENDED 31 DECEMBER 2023

Delivering information and advice for people living with eczema

The Society continues to provide a wide range of high quality, evidence-based information and advice about eczema and its management for the UK eczema community.

We produce a wide range of patient information booklets and factsheets about eczema management and treatment, available online and in print. We distribute printed copies at events the charity organises and attends, and we provided over 17,500 copies of our printed publications to healthcare professionals during the year, for onward distribution to patients in hospital dermatology clinics and other healthcare settings.

National Eczema Society factsheets and booklets are updated regularly on a rolling review cycle and checked by healthcare professionals to ensure the information is accurate and up-to-date. We updated and reprinted a number of publications over the year, including our Itching and Scratching booklet, Living with Eczema (Adults) booklet, and Paste Bandages and Wet Wraps booklet.

All our eczema information is made available on the Society's website, which received over two million visits during the year. It is difficult to compare year-on-year activity because Google changed the way website activity is recorded with Google Analytics Version 4 in July 2023. Webpages on facial eczema, emollients, eye and ear eczema, hand eczema, topical steroid treatments, topical steroid withdrawal, pompholyx eczema and scalp eczema remain especially popular. We also promote health advice messages through our social media channels, media engagement and other external communications. We continued our programme of webinars, working in partnership with St John's DermAcademy (part of Guy's and St Thomas' Hospital, London) to jointly deliver two events, one focusing on new treatments for more severe eczema and the other exploring eczema and the mind-skin connection. Recordings of several past webinars are available to view on the Society's social media pages.

During this period / 2023, our eczema helpline provided personalised independent advice for people struggling to cope with eczema wherever they live in the UK. We received around 1,300 telephone, email and message enquiries a year from parents of children with eczema and adults living with the condition. We offered a dermatology nurse call-back service for people who had more complex enquiries, and around 40% of callers were helped by one of our experienced dermatology nurse advisers. Our Helpline was available free of charge to anyone affected by eczema in the UK who needs our support. Please note that the Society took the decision to stop offering a helpline service in March 2024, as part of a wider strategic change programme to increase our work supporting eczema research and campaigning for improved eczema care for the eight million adults and children affected by the condition in the UK.

We continue to raise awareness of local volunteer-led patient support groups, by providing information and a presence for these groups on the Society's website. The West Surrey and North-East Hampshire Support Group held a number of fundraising events over the year and organised an information day in Guildford in February on the 'Combined Approach' to managing eczema. Dr Alpa Kanji talked about how habit reversal therapy combined with topical treatments can help people with eczema break the habitual itch-scratch cycle. Dr Kanji is a dermatologist working at St John's Institute of Dermatology in London and she teaches habit reversal therapy. The event was livestreamed and recorded on Facebook, so many more people with eczema could access the talk.

Our planned work to develop an online forum to provide peer support for people affected by eczema was not taken forward again this year because of competing pressure on charity resources.

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

TRUSTEES' REPORT
FOR THE YEAR ENDED 31 DECEMBER 2023

NES membership scheme

National Eczema Society is a membership organisation and we are very grateful to our 2,000 members who support the Society through their annual membership fee and additional donations. Members receive our membership magazine Exchange, which features expert information and news about eczema. Members are also encouraged to attend the Society's Annual General Meeting and contribute their ideas on the running of the charity. As in previous years, support for our charity extends far beyond our membership and we remain grateful to all our donors, and to those members who continue to support us financially even though they no longer have any personal need of our help.

Income from the membership scheme has fallen as the number of members has gradually declined over the years. We took the difficult decision to move to producing two issues of Exchange magazine starting in 2024, replacing the previous quarterly publishing schedule, so that costs are better aligned with membership income.

Supporting eczema research

We continue to support patient involvement in shaping research. NES is approached regularly by researchers seeking patient views and to learn from patient experiences. It is so encouraging to see such a range of research underway and new treatments in the pipeline, following a long period when eczema was largely overlooked. The Society is actively supporting eczema research by participating in study steering groups, providing patient perspectives for research projects, promoting surveys, supporting patient recruitment for trials, and working with universities and companies that are assessing and developing new drug treatments. We do this to help ensure eczema research has the greatest chance of success in finding new treatments and ultimately a cure. Projects supported during the year include:

- A-STAR – UK-Irish Atopic Eczema Systemic Therapy Register
- BEACON trial – Best systemic treatments for adults with atopic eczema over the long term
BEACONomics - study embedded within the BEACON trial investigating how eczema treatments work
- BIOMAP Innovative Medicines Initiative – Biomarkers in Atopic Dermatitis and Psoriasis
- ECO trial – Eczema Care Online
- END-ITCH study - Eczema and Dermatitis, Implementing the Combined Approach
- Global Patient Initiative for Optimal Eczema Care
- Kids in Control study
- Navigating Primary Care with Topical Steroid Withdrawal
- RAPID Eczema Trials Programme
- SLEEP study - Supporting children's sleep in those with Eczema Programme
- TECH study - Teleconsultations for Eczema in Children
- TRANS-FOODS study - preventing peanut allergy

National Eczema Society staff and trustees contributed to several articles in academic journals over the year, including the following published in 2024:

Do people with eczema and their carers understand topical steroid potency? Results of two surveys; Celia Moss et al, Clinical and Experimental Dermatology, Volume 49, Issue 3, March 2024, Pages 267–270, <https://doi.org/10.1093/ced/llad372>

Linked to the above paper, Professor Celia Moss presented an abstract on this topic at the British Society for Paediatric Adolescent Dermatology session at the 103rd Annual Meeting of the British Association of Dermatologists in Liverpool in June.

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

TRUSTEES' REPORT
FOR THE YEAR ENDED 31 DECEMBER 2023

NES provides a patient perspective for clinical guideline development, the assessment of new eczema treatments, and policy consultations. During the year, we contributed to the assessment by the National Institute of Health and Care Excellence (NICE) of a new monoclonal antibody drug called Lebrikizumab. This is a new treatment for moderate to severe eczema. As eczema affects people in different ways, it is important that we have a range of NHS treatment options to help ensure people can access a treatment that works effectively for them.

Improving eczema care

The charity undertakes a range of activities to raise awareness and understanding of eczema among the general public, and to promote the information and advice the Society provides for people living with eczema and their families.

The Society launched a major campaign in May 2023, calling on the UK medicines regulator, the MHRA, to introduce clearer strength labelling of steroid creams and ointments. We are asking the MHRA to mandate clear potency labelling on topical steroid (TCS) tubes, packaging and patient information leaflets.

Topical steroids are used by millions of adults and children in the UK to treat or prevent eczema flare-ups. It is important patients and their carers have the right information to use these medicines safely and effectively to manage eczema well. Topical steroids are effective treatments for eczema but, like many treatments, they can have side effects. People with eczema and carers are understandably concerned about overusing TCS. We believe clear potency labelling will help improve patient understanding and confidence in these widely-used medicines.

This initiative has strong support from the eczema community. National Eczema Society conducted an online survey in January 2023, to find out more about people's knowledge and understanding of steroid potency. We received 943 responses, from both adults with eczema and parents of children with eczema, and many thanks to everyone in the eczema community who took part. Some 95% of respondents said they want to see clear strength labelling on all steroid creams and ointments.

This call for clearer labelling also has strong support from healthcare professionals and other charities, which endorsed this Society-led initiative. We are in dialogue with the MHRA about the campaign and are hopeful of a successful outcome.

In other work, the Society has contributed to MHRA reviews of topical steroid withdrawal reactions and welcome the MHRA guidance on this.

Representing patient views

As a national patient organisation for the eczema community, the Society plays a leading role in providing a collective voice to champion the needs of those affected by the condition. We seek to improve health outcomes for people with eczema by influencing health policy and participating in groups like the Dermatology Council for England and working with professional bodies like the British Association of Dermatologists (BAD) and Primary Care Dermatology Society (PCDS). As a member of the steering group, we contributed to the major NHS England Dermatology Outpatient Transformation Programme, which developed a range of new guidance to help dermatology healthcare providers meet the challenges of responding to service funding pressures.

Patient interest and awareness of the side effects of topical steroid medication, and concerns about topical steroid withdrawal (TSW), continues to grow. NES remains active in this area, building on our earlier work with the British Association of Dermatologists to develop a position statement on TSW, and our contribution to the MHRA review of topical steroid withdrawal reactions. Topical steroid withdrawal is complex and research into the causes, symptoms and treatments is limited. NES wants to see more research in this area, to support evidence-based diagnosis and treatment approaches.

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

TRUSTEES' REPORT
FOR THE YEAR ENDED 31 DECEMBER 2023

One of the challenges is that the symptoms people experience when stopping using topical steroids can appear similar to those of poorly controlled eczema. These symptoms can be very painful and distressing. The Society is emphasising the importance of using topical steroid treatments safely and effectively, and among other things is calling for clearer labelling of topical steroids to show their potency/strength.

National Eczema Week

Our goal for National Eczema Week 2023 was to raise awareness of the impact of eczema on patients' mental health. This is not widely recognised or understood outside the eczema community. We encouraged people to open up and start a conversation about living with eczema, sharing their experiences of the emotional, social and personal impacts of eczema.

We produced a powerful video for the campaign entitled 'More than just an itch', funded by corporate partner Sanofi. The short-form documentary-style video focussed on the experiences of five people with eczema, and how the condition has affected them. The videos received over 1,500 views, with 85 hours of watched content.

We also produced a series of podcasts to support the campaign, featuring both patients and healthcare professionals talking about the emotional impacts of eczema and approaches for supporting our mental health. The podcast has been downloaded and viewed over 700 times. All the videos and podcasts are available to view on the Society's YouTube channel.

We achieved national media profile for the campaign, with 32 items of coverage including two national media hits (The Independent online and Morning Live). Total potential audience reach with the campaign messaging was over 33 million.

Overall, on social media, the campaign videos received over 35,000 total views, with a 2.5% engagement rate on Facebook and 1.2% on Instagram. X/Twitter generated the highest engagement rate at 3.3%. Special thanks to our influencer partners Nicola Johnson and Katie Mackie for producing content to support the campaign, which generated positive engagement.

During National Eczema Week we held the 'Eczema and the Mind-Skin Connection' webinar, jointly with St. John's DermAcademy, which aligned closely with our campaign theme. Over 100 people attended the webinar.

Media and social media engagement

The Society provided press comment for a number of eczema stories in the media over the year. We contributed to stories about managing eczema in cold weather for BBC Morning Live and BBC Online, as well as coverage in the Mail of Sunday, The Times and i newspaper on topics ranging from waiting times for dermatology appointments to new treatments for eczema. Society supporter Ellen Vincent was featured in a major article in the Mail on Sunday about a forthcoming new treatment for more severe eczema called lebrikizumab. The Society was also featured in several professional publications including pharmacy publications. The Society was approached for media comment about topical steroid withdrawal during the year and we were mentioned in features on this topic produced by the BBC and ITV. Capacity constraints and competing priorities continue to impact on the proactive media work we are able to undertake.

We continued to grow our social media reach and activity during the year, reflecting how people increasingly seek and share information about eczema. The Society now has over 25,000 followers on Facebook, an increase of around 1,400 over the year. We also grew our following on X/Twitter to over 8,500, and almost 12,000 on Instagram by the end of 2023.

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

TRUSTEES' REPORT
FOR THE YEAR ENDED 31 DECEMBER 2023

Growing income and building financial sustainability

We continue to commit resources to income generation, to achieve our charitable objectives and build future financial sustainability. We are immensely grateful to our thoughtful and generous supporters who choose to leave a gift to National Eczema Society in their Will. Income from legacies was higher in 2023 and this significantly impacts our overall income.

We continue to develop partnerships with companies that share our values and are willing to support our work and engage in joint education and awareness-raising activity. During the year we worked with AbbVie, Almirall, Aspire Pharma, Bioderma, Dermal Laboratories, Lilly, LEO Pharma and Sanofi.

There were many fundraising highlights during the year. Income from challenge events, including the London Marathon and Great North Run, was strong in 2023 and we thank all our supporters for raising funds and awareness of eczema by participating in events like these. We continue to find it challenging securing grants from charitable trusts and foundations.

The Society's West Surrey and North-East Hampshire Support Group undertook various local fundraising activities around Guildford, and presented a cheque for £2,000 at the Annual General Meeting in September. The Society's members and donors generously supported our summer and Christmas fundraising appeals once again and we are grateful to everyone who supported the Society in different ways with their donations over what has been a challenging year with cost-of-living pressures.

Organisational development

During the year, we continued our work preparing for the Society's office move. The lease on the charity's current office expires in March 2025 and future provision needs to take into account the changing needs of the charity following the introduction of hybrid working arrangements.

Strategy work undertaken included refining the Society's vision, mission and values and scoping work to refresh the charity's brand and visual identity. We have also positioned our charitable work into three core areas:

- Provide information and advice
- Improve eczema care
- Support eczema research

2024 Plans and development priorities

Looking ahead, we aim to ensure National Eczema Society continues to achieve the greatest impact we can for members and the UK eczema community. The charity's core charitable work will continue, as well as taking forward strategically important activity including growing our support for eczema research and strengthening our work to improve eczema care. We plan to conduct a strategic review in 2023/24 that will potentially change the focus of some areas of National Eczema Society's work.

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

TRUSTEES' REPORT
FOR THE YEAR ENDED 31 DECEMBER 2023

Development priorities for 2024 include:

Providing information and advice

- Continue providing high-quality eczema information and advice, through the website, printed publications, webinars and other channels.
- Scope and develop resources to highlight the impact of eczema on people's mental health and emotional well-being.
- Introduce a regular monthly e-newsletter for NES stakeholders.
- Scope and plan an NES-moderated online forum and closed Facebook group.

Improving eczema care

- Increase public awareness and understanding of the challenges of living with eczema, highlighting the impact on people's physical, mental health and quality of life.
- Lead the annual national flagship awareness event, National Eczema Week in September.
- Lead a coalition campaigning for clearer potency labelling of topical steroids.
- Continue to call for more research into diagnosis and treatment of topical steroid withdrawal.
- Contribute patient perspectives to clinical guideline development and the assessment of new treatments and policy consultations, working with regulatory bodies including the MHRA, NICE and the SMC.

Supporting eczema research

- Scope options for developing an NES research grant programme, to fund studentships and innovation grants for eczema research.
- Recruit a panel of people with eczema to share their experiences of living with the condition with researchers.
- Continue to contribute patient insights for major eczema research projects and programmes.

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

TRUSTEES' REPORT
FOR THE YEAR ENDED 31 DECEMBER 2023

Financial Results

The Society planned to achieve a budget surplus in 2023, made possible largely by higher legacy income. This is in contrast to the loss recorded the previous year.

Income for the year was £497,252, with expenditure at £477,562, generating an annual surplus of £19,698. This compares with a deficit of £70,621 in the year ended 31 December 2022. At 31 December 2023, the Society had reserves of £670,767 (£651,070).

We would like to thank the many people who, as in previous years, by joining or renewing their membership, supporting our appeals and fundraising in a variety of often innovative ways, have enabled us to continue our work. The efforts and contribution of supporters and volunteers is invaluable to the Society. We are grateful also to those who remembered the Society in their Wills, the charitable trusts and companies that have supported us during the year, and to all the healthcare professionals who have provided us with so much time, advice and support especially members of the Medical Advisory Board.

Reserves Policy

The trustees aim to maintain adequate reserves to permit the ongoing operations of the charity. In arriving at their assessment of a suitable limit, trustees have considered the predictability of the Society's income and the nature of its expenditure, together with the degree to which these are committed. Legacies form an important part of the Society's income, and whilst legacies can often be substantial relative to overall income, they are unpredictable and historical trends show there can be periods of years where this source of income is much lower than the long-term average. Expenditure, on the other hand, is more consistent and predictable.

Trustees last reviewed the Reserves Policy in 2022, and consider that holding unrestricted reserves equal to approximately six months unrestricted charitable expenditure would be sufficient to close or merge the charity, should this ever be necessary. However, given the known volatility of legacy income, trustees have determined a reserves target of 12 months' future overheads expenditure is more appropriate to respond to fluctuations in income.

In order to make unrestricted reserves more transparent, funds that are not readily available to spend are held in reserves designated for specific purposes. A key aim of the Society is to promote research into the causes and treatment of eczema. This being so, the trustees have designated a proportion of reserves to fund future research activity, in addition to any funds that donors have specifically restricted for this purpose. Funds that are not readily available to spend, notably those represented by fixed assets, are held in a reserve designated for this purpose. The pension reserve shows future deficit payments owed in relation to an historical defined benefit pension scheme (see note 19).

The balance held in unrestricted funds at 31 December 2023 is £664,016 (2022: £644,319). Unrestricted funds include funds tied up in tangible assets of £12,903 (2022: £19,721), the pension reserve of (£4,567) (2022: (£8,587)) and designated Research funds of £110,000 (2022: £110,000). The remaining general funds of £545,680 (2022: £523,185) are materially in line with the charity's reserves policy target of 12 months future overheads expenditure, budgeted at £530,000 for the 2024 financial year.

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

TRUSTEES' REPORT
FOR THE YEAR ENDED 31 DECEMBER 2023

Risk Management

The trustees have taken steps to identify and address major risks facing the Society, including maintaining a risk register. The principal uncertainty in respect to the Society's future is the ability to maintain sufficient income to deliver the charity's operations, and ensure the Society has adequate resources to comply with regulatory changes affecting the voluntary sector. Greater focus and investment are being directed to fundraising activities, to ensure the Society generates sufficient income each year to fund planned activities. This includes building sustainable sources of non-legacy income.

The principal risk of financial sustainability for the charity is closely monitored by the trustees on a regular basis, including reviewing management accounts at quarterly Board meetings. Attention also continues to focus on non-financial risks including reputation, health and safety, security, confidentiality and data protection, which are supported by appropriate policies and procedures as well as management updates as needed.

The Trustees and Organisation

The Society is a charitable company. Although called trustees, we are the directors of the company for the purposes of company law. The trustees who served during the year and up to the date of this report are given on page 1.

The Society's governance processes are set out in its Articles of Association. The Board of Trustees administers the Society, which meets routinely four times a year and additionally as circumstances demand. A chief executive is appointed by the trustees to manage the day-to-day operations of the Society within a framework agreed by the Board.

There must be a minimum of three trustees but there is no maximum number, and trustees must be elected by the members of the Society at its Annual General Meeting (AGM). Trustees may be co-opted onto the Board during the year and must then stand for election by the members at the next AGM. At least a third of trustees are required to retire from office each year but may, if they wish, offer themselves for re-election at the AGM. Trustees are recruited through the Society's membership, local support groups, other eczema community networks and open advertising. In seeking trustees, the Society has regard of the need to ensure that the Trustee Board has an appropriate range of professional skills and experience, reflects our commitment to diversity, and also that trustees are drawn from different areas of the UK.

Although not constitutionally binding, the Society wishes to work towards aligning with the Charity Governance Code, which recommends trustees serve fixed terms in office. The guidance recommends trustees serve an initial three-year term, with the possibility of being re-elected by members for a further three-year period. Trustees in particular roles (e.g. Chair, Treasurer) could serve a longer nine-year period, subject to formal review. One current trustee has served longer than nine years and provides specific professional skills to the Board. As yet, it has not been possible to find a replacement with comparable expertise.

New trustees are provided with an introduction pack, which includes the Society's governing documents, copies of the past year's accounts, and a briefing on their duties and responsibilities and of the Society's governance processes. Prior to joining the Board, new trustees will usually attend at least one Board meeting in an observer capacity, which gives them the opportunity to meet the trustees and chief executive.

Trustees receive no remuneration and no trustee has a beneficial interest in any of the group companies.

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

TRUSTEES' REPORT
FOR THE YEAR ENDED 31 DECEMBER 2023

The Society has a Medical Advisory Board (MAB), comprised of healthcare professionals who act in an advisory and ambassadorial capacity for the charity. Members volunteer their time and are all experienced healthcare professionals who work in the field of dermatology, and who have a particular professional interest in eczema management and research. The MAB is chaired by National Eczema Society trustee, Professor Celia Moss OBE.

The trustees set the remuneration of the chief executive and approve the remuneration of other Society staff. Remuneration levels are based on research of similar roles in the sector and benchmark salary data.

The Trustees Report has been prepared in accordance with the provisions applicable to entities subject to the small companies regime.

This report was approved by the Board of Trustees on signed on their behalf by:

Signed by:

3E26469DDB4C4A6.....
Stephen Pugh
Chair

Date: September 25, 2024

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

STATEMENT OF TRUSTEES' RESPONSIBILITIES
FOR THE YEAR ENDED 31 DECEMBER 2023


The Trustees (who are also the directors of the Charity for the purposes of company law) are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the Trustees to prepare financial statements for each financial year. Under company law, the Trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the Group and the Charity and of their incoming resources and application of resources, including their income and expenditure, for that period. In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles of the Charities SORP (FRS 102);
- make judgements and accounting estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards (FRS 102) have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Group will continue in business.

The Trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the Group and the Charity's transactions and disclose with reasonable accuracy at any time the financial position of the Group and the Charity and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the Group and the Charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Approved by order of the Members of the Board of Trustees and signed on its behalf by:

Signed by:

.....
Stephen Pugh
Chair

Date: September 25, 2024

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

INDEPENDENT EXAMINER'S REPORT
FOR THE YEAR ENDED 31 DECEMBER 2023

Independent Examiner's Report to the Trustees of National Eczema Society ('the Group')

I report to the Charity Trustees on my examination of the consolidated accounts of the Group, set out on pages 14 to 45, comprising the National Eczema Society ('the parent Charity') and its subsidiary undertakings for the year ended 31 December 2023.

Responsibilities and Basis of Report

As the Trustees of the parent Charity (and its directors for the purposes of company law) you are responsible for the preparation of the consolidated accounts of the Group in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the consolidated accounts are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of the Group's accounts as carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

Independent Examiner's Statement

Since the Group's gross income exceeded £250,000 your examiner must be a member of a body listed in section 145 of the 2011 Act. I confirm that I am qualified to undertake the examination because I am a member of the Institute of Chartered Accountants in England and Wales, which is one of the listed bodies.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe in any material respect:

1. accounting records were not kept in respect of the parent Charity and its subsidiaries as required by section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a 'true and fair' view which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

Signed: 

Dated: September 25, 2024

Rachel Doyle ACA FCCA DChA

MHA
 Chartered Accountants
 MHA House
 Charter Court
 Swansea Enterprise Park
 Swansea
 SA7 9FS

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

**CONSOLIDATED STATEMENT OF FINANCIAL ACTIVITIES (INCORPORATING INCOME AND
EXPENDITURE ACCOUNT)
FOR THE YEAR ENDED 31 DECEMBER 2023**

	Note	Unrestricted funds 2023 £	Restricted funds 2023 £	Total funds 2023 £	Total funds 2022 £
Income from:					
Donations and legacies	4	481,158	-	481,158	327,075
Other trading activities:	5				
Income from fundraising		5,732	-	5,732	10,205
Income from trading activities		2,965	-	2,965	4,109
Investments	6	7,397	-	7,397	1,432
Total income		497,252	-	497,252	342,821
Expenditure on:					
Raising funds		71,317	-	71,317	64,906
Charitable activities	8	406,245	-	406,245	348,853
Total expenditure		477,562	-	477,562	413,759
Net movement in funds before other recognised gains		19,690	-	19,690	(70,938)
Other recognised gains/(losses):					
Gains/(losses) on pension scheme		8	-	8	317
Net movement in funds		19,698	-	19,698	(70,621)
Reconciliation of funds:					
Total funds brought forward		644,319	6,751	651,070	721,691
Net movement in funds		19,698	-	19,698	(70,621)
Total funds carried forward		664,017	6,751	670,768	651,070

The Consolidated Statement of Financial Activities includes all gains and losses recognised in the year. All income and expenditure derive from continuing activities.

The notes on pages 20 to 44 form part of these financial statements.

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)
REGISTERED NUMBER: 02685083

CONSOLIDATED BALANCE SHEET
AS AT 31 DECEMBER 2023

	Note	2023 £	2023 £	2022 £	2022 £
Fixed assets					
Intangible assets	14		1,462		1,836
Tangible assets	15		10,733		17,885
			12,195		19,721
Current assets					
Debtors: Amounts falling due within one year	17	88,906		65,445	
Cash at bank and in hand		728,799		687,108	
		817,705		752,553	
Creditors: Amounts falling due within one year	18	(158,773)		(116,940)	
Net current assets			658,932		635,613
Total assets less current liabilities			671,127		655,334
Creditors: Amounts falling due after more than one year	19		(360)		(4,264)
Total net assets			670,767		651,070
Group funds					
Restricted funds	20		6,751		6,751
Unrestricted funds	20		664,016		644,319
Total funds			670,767		651,070

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)
REGISTERED NUMBER: 02685083

CONSOLIDATED BALANCE SHEET (CONTINUED)
AS AT 31 DECEMBER 2023

The Charity was entitled to exemption from audit under section 477 of the Companies Act 2006.

The members have not required the company to obtain an audit for the year in question in accordance with section 476 of Companies Act 2006.

The Trustees acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to entities subject to the small companies regime.

The financial statements were approved and authorised for issue by the Trustees and signed on their behalf by:

Signed by:

.....
Stephen Pugh
Chair
Date: September 25, 2024

The notes on pages 20 to 44 form part of these financial statements.

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)
REGISTERED NUMBER: 02685083

CHARITY BALANCE SHEET
AS AT 31 DECEMBER 2023

	Note	2023 £	2023 £	2022 £	2022 £
Fixed assets					
Intangible assets	14		1,462		1,836
Tangible assets	15		10,733		17,885
Investments	16		100		100
			12,295		19,821
Current assets					
Debtors: Amounts falling due within one year	17	154,841		132,652	
Cash at bank and in hand		581,497		647,525	
		736,338		780,177	
Creditors: Amounts falling due within one year	18	(115,791)		(115,140)	
Net current assets			620,547		665,037
Total assets less current liabilities			632,842		684,858
Creditors: Amounts falling due after more than one year	19		(360)		(4,264)
Total net assets			632,482		680,594
Charity funds					
Restricted funds	20		6,751		6,751
Unrestricted funds	20		625,731		673,843
Total funds			632,482		680,594

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)
REGISTERED NUMBER: 02685083

CHARITY BALANCE SHEET (CONTINUED)
AS AT 31 DECEMBER 2023

The Charity's net movement in funds for the year was £(48,112) (2022 - £(69,728)).

The Charity was entitled to exemption from audit under section 477 of the Companies Act 2006.

The members have not required the company to obtain an audit for the year in question in accordance with section 476 of Companies Act 2006.

The Trustees acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to entities subject to the small companies regime.

The financial statements were approved and authorised for issue by the Trustees and signed on their behalf by:

Signed by:



.....
3E26469DD84C4A6...
Stephen Pugh

Chair

Date: September 25, 2024

The notes on pages 20 to 44 form part of these financial statements.

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

CONSOLIDATED STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED 31 DECEMBER 2023

	Note	2023 £	2022 £
Cash flows from operating activities			
Net cash used in operating activities	22	38,315	36,416
Cash flows from investing activities			
Investment income		7,397	1,432
Purchase of intangible assets		(2,021)	-
Purchase of tangible fixed assets		(2,000)	-
Net cash provided by investing activities		3,376	1,432
Change in cash and cash equivalents in the year		41,691	37,848
Cash and cash equivalents at the beginning of the year		687,108	649,260
Cash and cash equivalents at the end of the year	23	728,799	687,108

The notes on pages 20 to 44 form part of these financial statements

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023

1. General information

National Eczema Society is a charitable company limited by guarantee and is registered with the Registrar of Companies (Company Registered Number: 02685083), the Charity Commission in England and Wales (Charity Registered Number: 1009671).

In the event of the Charity being wound up, the liability in respect of the guarantee is limited to £1 per Member of the Charity.

The address of the registered office is given in the Charity information on page 1 of these financial statements. The nature of the Charity's operations and principal activities are detailed in the Trustees' Report.

The significant accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all years presented unless otherwise stated.

2. Accounting policies

2.1 Basis of preparation of financial statements

The financial statements have been prepared in accordance with the Charities SORP (FRS 102) - Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

National Eczema Society meets the definition of a public benefit entity under FRS 102.

Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy.

The Consolidated Statement of Financial Activities (SOFA) and Consolidated Balance Sheet consolidate the financial statements of the Charity and its subsidiary undertaking. The results of the subsidiary are consolidated on a line by line basis.

The financial statements are prepared in sterling which is the functional and presentational currency of the Group and are rounded to the nearest pound.

2.2 Going concern

The Trustees have assessed the use of going concern and have considered possible events or conditions that might cast significant doubt on the ability of the Group to continue as a going concern. The Trustees have made this assessment for a period of at least one year from the date of the approval of these financial statements. The Trustees have concluded that there is a reasonable expectation that the Group has adequate resources to continue in operational existence for the foreseeable future, and that no material uncertainties exist. The Group therefore continues to adopt the going concern basis in preparing these financial statements.

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023

2. Accounting policies (continued)

2.3 Income

All income is recognised once the Group has entitlement to the income, it is probable that the income will be received and the amount of income receivable can be measured reliably.

For donations and gift aid to be recognised the Group will have been notified of the amounts and the settlement date in writing. If there are conditions attached to the donation and this requires a level of performance before entitlement can be obtained then income is deferred until those conditions are fully met or the fulfilment of those conditions is within the control of the Group and it is probable that they will be fulfilled.

The recognition of income from legacies is dependent on establishing entitlement, the probability of receipt and the ability to estimate with sufficient accuracy the amount receivable. Evidence of entitlement to a legacy exists when the Group has sufficient evidence that a gift has been left to them (through knowledge of the existence of a valid will and the death of the benefactor) and the executor is satisfied that the property in question will not be required to satisfy claims in the estate. Receipt of a legacy must be recognised when it is probable that it will be received and the fair value of the amount receivable, which will generally be the expected cash amount to be distributed to the Group, can be reliably measured.

Subscription income is received in full and recognised evenly over the course of the subscription. The amount recognised in the Consolidated Statement of Financial Activities relates to the financial period in question.

Income from trading activities includes income earned from fundraising events and trading activities to raise funds for the Group. Income is received in exchange for supplying goods and services in order to raise funds and is recognised when entitlement has occurred.

Corporate membership income is received in full and recognised evenly over the course of the membership. The amount recognised in the Consolidated Statement of Financial Activities relates to the financial period in question.

2.4 Expenditure

All expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all costs related to the categories. Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Central staff costs are allocated on the basis of time spent, and depreciation charges allocated on the portion of the asset's use.

Expenditure on charitable activities is incurred on directly undertaking the activities which further the Group's objectives, as well as any associated support costs.

All expenditure is inclusive of irrecoverable VAT.

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023

2. Accounting policies (continued)

2.5 Interest receivable

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the Group; this is normally upon notification of the interest paid or payable by the institution with whom the funds are deposited.

2.6 Taxation

The Charity is considered to pass the tests set out in Paragraph 1 Schedule 6 of the Finance Act 2010 and therefore it meets the definition of a charitable company for UK corporation tax purposes. Accordingly, the Charity is potentially exempt from taxation in respect of income or capital gains received within categories covered by Chapter 3 Part 11 of the Corporation Tax Act 2010 or Section 256 of the Taxation of Chargeable Gains Act 1992, to the extent that such income or gains are applied exclusively to charitable purposes.

2.7 Intangible assets and amortisation

Intangible assets costing £500 or more are capitalised and recognised when future economic benefits are probable and the cost or value of the asset can be measured reliably.

Intangible assets are initially recognised at cost. After recognition, under the cost model, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

Amortisation is provided on intangible assets at rates calculated to write off the cost of each asset on a straight-line basis over 3 years.

Assets under construction are not amortised until ready for use.

2.8 Tangible fixed assets and depreciation

Tangible fixed assets costing £500 or more are capitalised and recognised when future economic benefits are probable and the cost or value of the asset can be measured reliably.

Tangible fixed assets are initially recognised at cost. After recognition, under the cost model, tangible fixed assets are measured at cost less accumulated depreciation and any accumulated impairment losses. All costs incurred to bring a tangible fixed asset into its intended working condition should be included in the measurement of cost.

At each reporting date the Group assesses whether there is any indication of impairment. If such indication exists, the recoverable amount of the asset is determined to be the higher of its fair value less costs to sell and its value in use. An impairment loss is recognised where the carrying amount exceeds the recoverable amount.

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023

2. Accounting policies (continued)

2.8 Tangible fixed assets and depreciation (continued)

Depreciation is charged so as to allocate the cost of tangible fixed assets less their residual value over their estimated useful lives, using the straight-line method.

Depreciation is provided on the following bases:

Leasehold improvements	- over 10 years
Furniture and fittings	- over 10 years
Office equipment	- over 10 years
Computer equipment	- over 3 years

2.9 Investments

The investment in the subsidiary company is valued at cost less provision for impairment.

2.10 Debtors

Trade and other debtors are recognised at the settlement amount after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

2.11 Cash at bank and in hand

Cash at bank and in hand includes cash and short-term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

2.12 Liabilities and provisions

Liabilities are recognised when there is an obligation at the Balance Sheet date as a result of a past event, it is probable that a transfer of economic benefit will be required in settlement, and the amount of the settlement can be estimated reliably.

Liabilities are recognised at the amount that the Group anticipates it will pay to settle the debt or the amount it has received as advanced payments for the goods or services it must provide.

Provisions are measured at the best estimate of the amounts required to settle the obligation. Where the effect of the time value of money is material, the provision is based on the present value of those amounts, discounted at the pre-tax discount rate that reflects the risks specific to the liability. The unwinding of the discount is recognised in the Consolidated Statement of Financial Activities as a finance cost.

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023

2. Accounting policies (continued)

2.13 Financial instruments

The Group only holds basic Financial Instruments. The financial assets and financial liabilities of the Group are as follows:

Debtors – other debtors are basic financial instruments and are debt instruments measured at amortised cost as detailed in Note 17.

Cash at bank – is classified as a basic financial instrument and is measured at face value.

Liabilities – accruals are classified as financial instruments, and are measured at amortised cost as detailed in Notes 18 and 19.

2.14 Operating leases

Rentals paid under operating leases are charged to the Consolidated Statement of Financial Activities on a straight line basis over the lease term.

2.15 Pensions

Through its past participation, the Group has a liability to a pension scheme called the Series 3 Growth Plan, which closed in 2013. Since then, the Group has participated in a defined contribution pension scheme for employees, operated by workplace pension provider TPT.

The Group is part of the Series 3 Growth Plan which is a multi-employer pension Scheme which closed in 2013. The Scheme administrators have confirmed that it is not possible to separately identify the assets and liabilities of participating employers on a consistent and reasonable basis. The assets of the Scheme are co-mingled for investment purposes and benefits are paid from total Scheme assets. A deficit reduction plan has been agreed.

The Group accounts for its participation in this Plan as a defined contribution plan, as there is insufficient information available to account for this as a defined benefit plan, as the share of its assets and liabilities cannot be identified.

To avoid crystallizing an immediate payment of the apparent under-funding in the Series 3 Scheme, the Group is participating in the Series 3 Recovery Plan and the liability is included in Notes 18 and 19. The Group recognises its liability to make payments to fund the deficit relating to past service under an agreement to make those payments. It recognises the full liability for the present value of contributions payable that results from the agreement for funding the multi employer plan.

The Group also participates in a defined contribution pension scheme for its employees. The Group pays fixed contributions into a separate scheme. Once the defined contribution payments have been made, the Group has no further payment obligations in respect of this scheme. The contributions are recognised as an expense in the Consolidated Statement of Financial Activities as they fall due.

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023

2. Accounting policies (continued)

2.16 Fund accounting

General funds are unrestricted funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the Group and which have not been designated for other purposes.

Designated funds comprise unrestricted funds that have been set aside by the Trustees for particular purposes. The aim and use of each designated fund is set out in the notes to the financial statements.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the Group for particular purposes. The costs of raising and administering such funds are charged against the specific fund. The aim and use of each restricted fund is set out in the notes to the financial statements.

Investment income, gains and losses are allocated to the appropriate fund.

3. Critical accounting estimates and areas of judgement

Estimates and judgements are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

Critical accounting estimates and assumptions:

The Group makes estimates and assumptions concerning the future. The resulting accounting estimates and assumptions will, by definition, seldom equal the related actual results. The estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are listed below.

- Allocation of support costs
- Legacy income recognition
- Depreciation rates for tangible fixed assets
- Useful economic lives of assets
- The discount rate used in valuing the year-end Pension Scheme deficit.

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023

4. Income from donations and legacies

	Unrestricted funds 2023 £	Restricted funds 2023 £	Total funds 2023 £
Donations and similar income	205,431	-	205,431
Legacies	110,610	-	110,610
Subscriptions	141,813	-	141,813
Gift aid	23,304	-	23,304
Total 2023	481,158	-	481,158

	Unrestricted funds 2022 £	Restricted funds 2022 £	Total funds 2022 £
Donations and similar income	132,853	5,013	137,866
Legacies	24,706	-	24,706
Subscriptions	143,952	-	143,952
Gift aid	20,551	-	20,551
Total 2022	322,062	5,013	327,075

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023

5. Income from other trading activities

Income from fundraising events

	Unrestricted funds 2023 £	Total funds 2023 £
Other corporate income	2,896	2,896
Other activities	2,836	2,836
Total 2023	5,732	5,732

	Unrestricted funds 2022 £	Total funds 2022 £
Other corporate income	6,265	6,265
Other activities	3,940	3,940
Total 2022	10,205	10,205

Income from non charitable trading activities

	Unrestricted funds 2023 £	Total funds 2023 £
Trading subsidiary	2,965	2,965

	Unrestricted funds 2022 £	Total funds 2022 £
Trading subsidiary	4,109	4,109

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023

6. Income from investments

	Unrestricted funds 2023 £	Total funds 2023 £
Bank interest receivable	7,397	7,397
	Unrestricted funds 2022 £	Total funds 2022 £
Bank interest receivable	1,432	1,432

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023

7. Expenditure on raising funds

	2023	2022
	£	£
Fundraising costs		
Direct costs	65,707	59,330
Support costs	5,604	5,574
	71,311	64,904

Analysis of support costs - fundraising costs

	2023	2022
	£	£
Staff costs	1,912	1,735
Depreciation	382	562
Premises costs	728	727
Carriage and postage	116	289
HCP services and fees	33	-
Professional fees	349	370
Bought-in services	41	33
Website, database and computing	712	583
Other costs	835	931
Governance costs	496	344
	5,604	5,574

	2023	2022
	£	£
Trading costs		
Trading subsidiary - Direct costs	6	2

In both the current and previous financial years all Expenditure on raising funds was from Unrestricted funds.

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023

8. Analysis of expenditure on charitable activities - by fund

	Unrestricted funds 2023 £	Total 2023 £
Helpline	110,547	110,547
Membership services	181,415	181,415
Information services	114,283	114,283
Total 2023	406,245	406,245
	Unrestricted funds 2022 £	Total 2022 £
Helpline	100,310	100,310
Membership services	174,303	174,303
Information services	74,240	74,240
Total 2022	348,853	348,853

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023

9. Analysis of expenditure on charitable activities - by type

	Activities undertaken directly 2023 £	Support costs 2023 £	Total funds 2023 £
Helpline	60,804	49,743	110,547
Membership services	102,860	78,555	181,415
Information services	73,335	40,948	114,283
Total 2023	236,999	169,246	406,245

	Activities undertaken directly 2022 £	Support costs 2022 £	Total funds 2022 £
Helpline	56,071	44,239	100,310
Membership services	96,182	78,121	174,303
Information services	33,519	40,721	74,240
Total 2022	185,772	163,081	348,853

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023

9. Analysis of expenditure on charitable activities - by type (continued)

Analysis of support costs

	Total funds 2023 £	Total funds 2022 £
Staff costs	55,947	50,750
Depreciation	11,165	16,435
Premises costs	21,302	21,266
Carriage and postage	3,399	8,468
Professional fees	13,130	10,838
Bought-in services	1,205	962
Website, database and computing	20,833	17,050
Insurance	1,750	-
Other costs	27,930	27,236
Governance costs	11,619	10,076
HCP services and fees	966	-
	169,246	163,081

10. Governance costs

	2023 £	2022 £
Independent Examiner's remuneration	2,000	2,000
Staff training	2,065	-
Insurance	5,789	6,681
Recruitment	-	1,150
Room hire & Conference expenses	1,498	50
Trustees expenses	-	198
Travel, hotels & subsistence	639	245
General office expenses	26	96
	12,017	10,420

Total Governance costs above comprise £398 (2022 - £344) of Expenditure on raising funds and £11,619 (2022 - £10,076) of Expenditure on charitable activities.

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023

11. Auditors' and Independent examiner's remuneration

	2023	2022
	£	£
Independent Examiner's remuneration - Examination of the financial statements	5,250	5,010
Independent Examiner's remuneration - prior year over-accrual	-	(3,010)
	=====	=====

12. Staff costs

	Group	Group	Charity	Charity
	2023	2022	2023	2022
	£	£	£	£
Wages and salaries	212,525	203,865	212,525	203,865
Social security costs	19,710	18,600	19,710	18,600
Pension costs	10,327	8,470	10,327	8,470
	=====	=====	=====	=====
	242,562	230,935	242,562	230,935

The average number of persons employed by the Charity during the year was as follows:

	Group	Group
	2023	2022
	No.	No.
Direct charitable activities	3	3
Fundraising and communication	1	1
Support and governance	1	1
	=====	=====
	5	5

The number of employees whose employee benefits (excluding employer pension costs) exceeded £60,000 was:

	Group	Group
	2023	2022
	No.	No.
In the band £60,001 - £70,000	1	1

The total amount of employee benefits, including employers national insurance and pension contributions, received by Key Management Personnel is £138,823 (2022 - £72,726). The Charity considers its Key Management Personnel comprise the Trustees and the Chief Executive Officer and deputy CEO.

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023

13. Trustees' remuneration and expenses

During the year, no Trustees received any remuneration or other benefits (2022 - £NIL).

During the year ended 31 December 2023, expenses totalling £499 were reimbursed or paid directly to 2 trustees (2022 - £198) in relation to travel and conference costs.

14. Intangible assets

Group and Charity

	Website £
Cost	
At 1 January 2023	20,988
Additions	2,021
At 31 December 2023	23,009
Amortisation	
At 1 January 2023	19,152
Charge for the year	2,395
At 31 December 2023	21,547
Net book value	
At 31 December 2023	1,462
At 31 December 2022	1,836

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023

15. Tangible fixed assets

Group and Charity

	Leasehold improvements £	Furniture and fixtures £	Office equipment £	Computer equipment £	Total £
Cost or valuation					
At 1 January 2023	41,470	2,493	3,873	24,189	72,025
Additions	-	-	-	2,000	2,000
At 31 December 2023	41,470	2,493	3,873	26,189	74,025
Depreciation					
At 1 January 2023	30,078	1,929	2,693	19,440	54,140
Charge for the year	4,152	249	370	4,381	9,152
At 31 December 2023	34,230	2,178	3,063	23,821	63,292
Net book value					
At 31 December 2023	7,240	315	810	2,368	10,733
At 31 December 2022	11,392	565	1,179	4,749	17,885

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023

16. Fixed asset investments

	Investment in subsidiary company £
Charity	
Cost or valuation	
At 1 January 2023	100
At 31 December 2023	<u>100</u>

Principal subsidiaries

The following was a subsidiary undertaking of the Charity:

Name	Company number	Registered office or principal place of business	Holding	Included in consolidation
Eczema Trading Limited	06895048	11 Murray Street, London, NW1 9RE	100%	Yes

The financial results of the subsidiary for the year were:

Name	Income £	Expenditure £	Profit for the year £	Net assets £
Eczema Trading Limited	67,816	(5,006)	62,810	33,385

The results of Eczema Trading Limited are included in these consolidated accounts. Eczema Trading Limited did not meet the audit threshold and therefore did not require an audit for the year ended 31 December 2023. The reported surplus relates to intercompany management charges and minimal advertising and corporate membership revenue.

For the year ended 31 December 2023, Corporate memberships, the advertising revenue from our membership magazine, together with limited income from company supporters, is accounted for in Eczema Trading Limited.

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023

17. Debtors

	Group 2023 £	Group 2022 £	Charity 2023 £	Charity 2022 £
Due within one year				
Trade debtors	20,762	26,160	2,762	-
Amounts owed by group undertakings	-	-	83,935	93,367
Other debtors	50,622	26,219	50,622	26,219
Prepayments and accrued income	17,522	13,066	17,522	13,066
	88,906	65,445	154,841	132,652

18. Creditors: Amounts falling due within one year

	Group 2023 £	Group 2022 £	Charity 2023 £	Charity 2022 £
Trade creditors	5,127	5,680	5,127	5,680
Other taxation and social security	15,401	12,616	15,401	12,616
Other creditors	4,395	6,995	4,395	6,995
Accruals and deferred income	133,850	91,649	90,868	89,849
	158,773	116,940	115,791	115,140

	Group 2023 £	Group 2022 £	Charity 2023 £	Charity 2022 £
Deferred income				
Deferred income at 1 January	79,880	75,422	78,080	73,622
Resources deferred during the year	181,318	78,080	99,318	78,080
Amounts released from previous periods	(150,585)	(73,622)	(77,235)	(73,622)
Deferred income at 31 December	110,613	79,880	100,163	78,080

Deferred income consists of membership income relating to future periods.

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023

19. Creditors: Amounts falling due after more than one year

	Group 2023 £	Group 2022 £	Charity 2023 £	Charity 2022 £
Pension Scheme deficit	360	4,264	360	4,264

Through its past participation, the Group has a liability to a pension scheme called the Series 3 Growth Plan, which closed in 2013. Since then, the Group has participated in a defined contribution pension scheme for employees, operated by workplace pension provider TPT.

The Charity is participating in a recovery plan to eliminate its Series 3 scheme deficit over a ten year period. The Pensions Trust, the scheme administrator, has however advised that the amount of employer debt on the alternative of withdrawal from the Series 3 scheme has been estimated by actuaries to have been £200,161 as at 31 December 2016. As the Charity intends to continue participating in the recovery plan, no provision has been made for this potential withdrawal debt however, the Society accounted for the present value of all remaining contributions under the recovery plan in the 2017 accounts at their present value of £120,000, as advised by the scheme administrator. This liability has been adjusted annually to unwind the relevant discount applied.

In order to meet their share of the shortfall, the Charity has been asked to pay additional contributions to the scheme until 2025. A full actuarial valuation was carried out by the actuaries at 30 September 2017 and the funding shortfall calculated at that date gave rise to a remeasurement reduction of £15,624 in the deficit as at 31 December 2018. The deficit of the scheme is £4,556, (2022 - £8,587) at 31 December 2023. The payment by the Charity in the year was £4,324, (2022 - £7,105) with an interest payment of £311 (2022 - £130) and a revaluation gain of £8 (2022 - £317).

In addition, the Charity elected to switch, with effect from 1 October 2013, from Series 3 to Series 4, a defined contribution scheme. The pension cost in the accounts represents amounts payable by the charity as ordinary employer contributions to the Series 4 defined contribution fund.

During the year employer contributions of £10,327 (2022 - £8,470), interest of £311 (2022 - £130), actuarial (gains)/losses of £8 (2022 - £317) and remeasurements for amendments to the contribution schedule of £Nil (2022 - £Nil) have been charged to the Consolidated Statement of Financial Activities, along with scheme costs of £3,625 (2021: £Nil). There were no accrued contributions at 31 December 2023 (2022 - £NIL) but there is a liability of £4,566 (2022 - £8,587) for future contributions under the Series 3 Recovery Plan. Of this £360 (2022 - £4,323) is reported in Creditors: Amounts falling due within one year as part of Other creditors and £360, (2022 - £4,264) is reported in Creditors: Amounts falling due after more than one year.

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023

20. Statement of funds

Statement of funds - current year

	Balance at 1 January 2023 £	Income £	Expenditure £	Transfers in/(out) £	Gains/ (Losses) £	Balance at 31 December 2023 £
Unrestricted funds						
Designated funds						
Fixed asset fund	19,721	-	(10,839)	4,021	-	12,903
Pension reserve	(8,587)	-	(5,579)	9,591	8	(4,567)
Research fund	110,000	-	-	-	-	110,000
	<u>121,134</u>	<u>-</u>	<u>(16,418)</u>	<u>13,612</u>	<u>8</u>	<u>118,336</u>
General funds						
General funds	<u>523,185</u>	<u>497,252</u>	<u>(461,145)</u>	<u>(13,612)</u>	<u>-</u>	<u>545,680</u>
Total Unrestricted funds	<u>644,319</u>	<u>497,252</u>	<u>(477,563)</u>	<u>-</u>	<u>8</u>	<u>664,016</u>
Restricted funds						
Restricted Funds - all funds	<u>6,751</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>6,751</u>
Total of funds	<u><u>651,070</u></u>	<u><u>497,252</u></u>	<u><u>(477,563)</u></u>	<u><u>-</u></u>	<u><u>8</u></u>	<u><u>670,767</u></u>

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023

20. Statement of funds (continued)

Statement of funds - prior year

	Balance at 1 January 2022 £	Income £	Expenditure £	Transfers in/out £	Gains/ (Losses) £	Balance at 31 December 2022 £
Unrestricted funds						
Designated funds						
Fixed asset fund	36,718	-	(16,997)	-	-	19,721
Pension reserve	(15,879)	-	(3,755)	10,730	317	(8,587)
Research fund	-	-	-	110,000	-	110,000
	<u>20,839</u>	<u>-</u>	<u>(20,752)</u>	<u>120,730</u>	<u>317</u>	<u>121,134</u>
General funds						
General funds	<u>699,114</u>	<u>337,808</u>	<u>(393,007)</u>	<u>(120,730)</u>	<u>-</u>	<u>523,185</u>
Total Unrestricted funds	<u>719,953</u>	<u>337,808</u>	<u>(413,759)</u>	<u>-</u>	<u>317</u>	<u>644,319</u>
Restricted funds						
Research	<u>1,738</u>	<u>5,013</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>6,751</u>
Total of funds	<u>721,691</u>	<u>342,821</u>	<u>(413,759)</u>	<u>-</u>	<u>317</u>	<u>651,070</u>

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023

20. Statement of funds (continued)

Designated funds

The Pension reserve has been established to show the future pension deficit payments in regards to a defined benefit pension scheme. This pension scheme is being treated as a defined contribution pension scheme as a reliable estimate cannot be made of the liability at the year end. The transfer of £9,591, was made to separate the deficit payments due as at 31 December 2023 from the Unrestricted general fund. Actuarial gains / (losses) are charged to this fund as they arise.

The Fixed asset fund has been established to reflect the funds tied up in Tangible and Intangible fixed assets and agrees back to the Net Book Value presented on the Consolidated Balance Sheet. Depreciation is charged to this fund as expenditure.

The Research fund has been established to designate funds for research into the causes and treatment of eczema, which is a key aim of the Society. The Society will provide grants to researchers on a periodic basis and it is necessary to designate sufficient reserves to fund the expected grant costs. The fund is expected to be utilised and grants awarded commencing in the financial year to 31 December 2024.

Unrestricted funds

General funds reflects funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the Charity and which have not been designated for other purposes.

Restricted funds

The Research fund exists to provide resources for research into the causes of eczema, with the aim of developing more effective treatments or a cure.

21. Analysis of net assets between funds

Analysis of net assets between funds - current year

	Unrestricted funds 2023 £	Restricted funds 2023 £	Total funds 2023 £
Tangible fixed assets	10,733	-	10,733
Intangible fixed assets	1,462	-	1,462
Current assets	810,954	6,751	817,705
Creditors due within one year	(158,773)	-	(158,773)
Creditors due in more than one year	(360)	-	(360)
Total	664,016	6,751	670,767

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023

21. Analysis of net assets between funds (continued)

Analysis of net assets between funds - prior year

	Unrestricted funds 2022 £	Restricted funds 2022 £	Total funds 2022 £
Tangible fixed assets	17,885	-	17,885
Intangible fixed assets	1,836	-	1,836
Current assets	745,802	6,751	752,553
Creditors due within one year	(116,940)	-	(116,940)
Creditors due in more than one year	(4,264)	-	(4,264)
Total	644,319	6,751	651,070

22. Reconciliation of net movement in funds to net cash flow from operating activities

	Group 2023 £	Group 2022 £
Net income/expenditure for the year (as per Statement of Financial Activities)	19,690	(70,938)
Adjustments for:		
Depreciation charges	9,152	10,001
Amortisation charges	2,395	6,996
Losses on investments	(7,397)	(1,432)
Decrease/(increase) in debtors	(53,516)	94,070
Increase/(decrease) in creditors	60,041	(2,598)
Actuarial Gains/ (loss) on pension	-	317
Net cash provided by operating activities	30,365	36,416

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023

23. Analysis of cash and cash equivalents

	Group 2023 £	Group 2022 £
Cash in hand	728,799	687,108
Total cash and cash equivalents	728,799	687,108

24. Analysis of changes in net debt

	At 1 January 2023 £	Cash flows £	At 31 December 2023 £
Cash at bank and in hand	687,108	41,691	728,799
	687,108	41,691	728,799

25. Operating lease commitments

At 31 December 2023 the Group and the Charity had commitments to make future minimum lease payments under non-cancellable operating leases as follows:

	Group 2023 £	Group 2022 £	Charity 2023 £	Charity 2022 £
Not later than 1 year	21,000	21,000	21,000	21,000
Later than 1 year and not later than 5 years	4,333	25,333	4,333	25,333
	25,333	46,333	25,333	46,333

The following lease payments have been recognised as an expense in the Statement of Financial Activities:

	Group 2023 £	Group 2022 £	Charity 2023 £	Charity 2022 £
Operating lease rentals	21,000	21,000	21,000	21,000

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023

26. Related party transactions

In the year ended 31 December 2023, unrestricted donations of £120 (2022 - £1,158) were made by the Trustees of the Charity.

Accounts

Company Registered Number: 02685083
Charity Registered Number (England & Wales): 1009671

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

UNAUDITED

TRUSTEES' REPORT AND FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2022



NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

CONTENTS

	Page
Reference and Administrative Details of the Charity, its Trustees and Advisers	1
Trustees' Report	2 - 10
Statement of Trustees' Responsibilities	11
Independent Examiner's Report	12 - 13
Consolidated Statement of Financial Activities	14
Consolidated Balance Sheet	15 - 16
Charity Balance Sheet	17 - 18
Consolidated Statement of Cash Flows	19
Notes to the Financial Statements	20 - 45

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

**REFERENCE AND ADMINISTRATIVE DETAILS OF THE CHARITY, ITS TRUSTEES AND ADVISERS
FOR THE YEAR ENDED 31 DECEMBER 2022**

Trustees	Edward Davies KC, Chair (resigned 19 May 2022) Ellen Vincent, Vice Chair (resigned 14 September 2022) Stephen Pugh, Treasurer (appointed to Chair 19 May 2022, resigned as Treasurer 19 May 2022) Catherine Escott (resigned 14 September 2022) Myrtle Johnston (resigned 14 September 2022) Hannah Kunzlik (appointed 16 March 2022) Dr Simon Lovegrove (appointed 16 March 2022, resigned 14 September 2022) Professor Celia Moss OBE Bharat Pandya (appointed 16 March 2022) James Pitayanukul (appointed to Treasurer 19 May 2022) Hedwig Vollers (appointed 16 March 2022) Suzanne Watson
Company registered number	02685083
Charity registered number	1009671
Registered office	11 Murray Street London NW1 9RE
Chief executive officer & Company secretary	Andrew Proctor
Independent Examiner	MHA Chartered Accountants Statutory Auditor 6th Floor 2 London Wall Place London EC2Y 5AU
Principal Bankers	CAF Bank Ltd National Westminster Bank plc Barclays Bank plc
Status and Governing Document	National Eczema Society is a charitable company, limited by guarantee. It was incorporated on 6 February 1992 and registered as a charity on 10 March 1992. It is governed by its Articles of Association.
Subsidiary Companies	Eczema Trading Limited

TRUSTEES' REPORT
FOR THE YEAR ENDED 31 DECEMBER 2022

The trustees present their annual report together with the financial statements of the Group and the Charity for the year 1 January 2022 to 31 December 2022. The trustees confirm that the Annual Report and financial statements of the company comply with the current statutory requirements, the requirements of the company's governing document and the provisions of the Statement of Recommended Practice (SORP), applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102). Since the Charity and the Group qualifies as small under section 383, the strategic report required of medium and large companies under The Companies Act 2006 (Strategic Report and Director's Report) Regulations 2013 is not required.

Purpose and aims

National Eczema Society was established in 1975 to support people with eczema and their families and to work on their behalf. We remain dedicated to these founding principles and today we continue to help people across the UK by providing evidence-based information and advice about eczema and its management. We deliver this in various ways through our website, webinars, instructional videos, social media communications, publications and nurse-supported Helpline. We also provide a collective voice for people with eczema, to inform research and influence health policy to improve eczema care, and raise greater awareness and understanding of the condition among people affected by eczema and the wider public.

The prevalence of eczema has increased over recent decades, and around one in five children and one in ten adults are now impacted by this life-challenging condition in the UK. While the reasons for the increase are not fully understood, it does mean the charity's work is needed more than ever. There is as yet no cure for eczema and, unless you have the condition, it can be hard to imagine the daily challenge of living with relentless itching and inflamed, painful skin. Many healthcare professionals have limited dermatology training and timely access to specialist dermatology healthcare for people with eczema can often be difficult. National Eczema Society aims to provide the information and support needed for people to self-manage their eczema effectively, to become experts in their own care, learn from the experiences of others, and provide the reassurance of knowing they are not on their own.

Ensuring our work delivers our charitable aims

We review our activities each year and monitor the impact of our work to ensure we continue to fulfil our purpose of supporting people affected by eczema. Among other ways, we assess the Society's performance and achievements through the number of people we have helped with information and advice, and the quality and consistency of the resources we provide.

We consider how planned activities will contribute to the aims and objectives we have set, and in doing this we have referred to the Charity Commission's general guidance on public benefit. We have had regard to the legislative and regulatory requirements for disclosing how our charitable objectives have provided such benefit, and complied with the duty set out in section 4 of the Charities Act 2011.

2022 Activity and achievements – delivering public benefit

All our charitable activities focus on supporting people affected by eczema and championing their needs, and further our charitable purposes for the public benefit. Here we present a summary of the Society's work over the year.

TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2022

Delivering information and advice for people living with eczema

The Society continues to provide a wide range of high quality, evidence-based information and advice about eczema and its management for people living with the condition and their families.

Our eczema Helpline provides personalised independent advice and reassurance needed by people struggling to cope with eczema wherever they live in the UK. We receive around 1,500 telephone, email and message enquiries a year from parents of children with eczema and adults living with the condition. These cover a wide range of questions about eczema symptoms and treatments, from the latest biologic drugs to eczema-friendly clothing. We offer a dermatology nurse call-back service for people who have more complex enquiries, and around 40% of callers are helped by one of our experienced dermatology nurse advisers. Our Helpline is available free of charge to anyone affected by eczema in the UK who needs our support.

Alongside our Helpline, the Society produces a wide range of patient information booklets and factsheets about eczema management and treatment, available online and in print. We distribute printed copies at events the charity organises and attends, and we provided over 14,000 copies of our printed publications to healthcare professionals during the year, for onward distribution to patients in hospital dermatology clinics and other healthcare settings.

National Eczema Society factsheets and booklets are updated regularly on a rolling review cycle and checked by healthcare professionals to ensure the information is accurate and up-to-date. We updated and reprinted a number of publications over the year, including our Contact Dermatitis booklet and Guide for Teenagers Living with Eczema.

We continue to raise awareness of local volunteer-led patient support groups, by providing information and a presence for these groups on the Society's website. With the lifting of Covid restrictions, the West Surrey and North-East Hampshire Support Group was able to return to local fundraising and awareness-raising. Dr George Moncrieff gave an excellent thought-provoking talk on the causes of eczema and latest thinking on eczema care at the Group's eczema information day in Guildford in March. It showed how much is still not known about eczema, but also how much progress has been made in management and treatment approaches over recent years. Group member Vicky Robinson received the Mayor's Award for Service to the Community in June, which recognises positive community working within the borough of Guildford. The award was richly deserved and reflects Vicky's fantastic work for the Society over many years, and that of the West Surrey and North-East Hampshire Group.

We publish all our eczema information on the Society's website, which received over two million visits during the year, with webpages on emollients, topical steroid treatments, eye and ear eczema, hand eczema, pompholyx eczema and scalp eczema especially popular. We also promote health advice messages through our social media channels, media engagement and other external communications. We continued our programme of webinars, working in partnership with St John's DermAcademy (part of Guy's and St Thomas' Hospital, London) to jointly deliver two events, one focusing on new treatments for eczema and the other about managing childhood eczema. Our own webinar in September on topical steroid treatments for eczema was well attended and thanks are due to Dr Paula Beattie for presenting this. Recordings of several past webinars are available to view on the Society's social media pages.

Our planned work to develop an online forum to provide peer support for people affected by eczema, and scoping a WhatsApp channel and an instant messaging on the Society's helpline, website for advice enquiries, were not taken forward because of competing pressure on charity resources.

TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2022

NES membership scheme

National Eczema Society is a membership organisation and we are very grateful to our 2,200 members who support the Society through their annual membership fee and additional donations. Members receive our membership magazine Exchange, which features expert information and news about eczema. Members are also encouraged to attend the Society's Annual General Meeting and contribute their ideas on the running of the charity. As in previous years, support for our charity extends far beyond our membership and we remain grateful to all our donors, and to those members who continue to support us financially even though they no longer have any personal need of our help.

Income from the membership scheme has fallen as the number of members has gradually declined over the years. We took the difficult decision to move to producing two issues of Exchange magazine in 2024, rather than the current quarterly schedule, so that costs are better aligned with membership income.

Representing patient views

As a national patient organisation for people with eczema, the Society plays a leading role in providing a collective voice to champion the needs of those affected by the condition. We seek to improve health outcomes for people with eczema by influencing health policy and participating in groups like the Dermatology Council for England and working with professional bodies like the British Association of Dermatologists (BAD) and Primary Care Dermatology Society (PCDS). As a member of the steering group, we contributed to the major NHS England Dermatology Outpatient Transformation Programme, which developed a range of new guidance to help dermatology healthcare providers meet the challenges of responding to service funding pressures and the disruption caused by Covid. This covered areas like teledermatology and waiting lists. We also continue to work to raise awareness of the need for better understanding and representation in dermatology for people with skin of colour.

Patient interest and awareness of the side effects of topical steroid medication, and concerns about topical steroid withdrawal (TSW), continues to grow. NES remains active in this area, building on our earlier work with the British Association of Dermatologists to develop a position statement on TSW, and our contribution to the Medicines and Healthcare products Regulatory Agency (MHRA) review of topical steroid withdrawal reactions. Topical steroid withdrawal is complex and research into the causes, symptoms and treatments is limited. NES wants to see more research in this area, to support evidence-based diagnosis and treatment approaches. One of the challenges is that the symptoms people experience when stopping using topical steroids can appear similar to those of poorly controlled eczema. These symptoms can be very painful and distressing. The Society is emphasising the importance of using topical steroid treatments safely and effectively, and among other things is calling for clearer labelling of topical steroids to show their potency/strength.

We continued to grow our organisational capacity to support patient involvement in shaping research. NES is approached regularly by researchers seeking patient views and to learn from patient experiences. It is so encouraging to see such a range of research underway and new treatments in the pipeline, following a long period when eczema was largely overlooked. The Society is actively supporting eczema research by participating in study steering groups, providing patient perspectives for research trials, and working with universities and companies that are assessing and developing new drug treatments. We do this to help ensure eczema research has the greatest chance of success in finding new treatments and ultimately a cure. Projects supported during the year include:

TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2022

- A-STAR - UK-Irish Atopic Eczema Systemic Therapy Register
- BEACON trial - Best systemic treatments for adults with atopic eczema over the long term
- BEACONomics - study embedded within the BEACON trial investigating how eczema treatments work
- BIOMAP Innovative Medicines Initiative - Biomarkers in Atopic Dermatitis and Psoriasis
- ECO trial - Eczema Care Online
- END-ITCH trial - Eczema and Dermatitis, Implementing The Combined Approach
- Global Patient Initiative for Optimal Eczema Care
- Navigating primary care with Topical Steroid Withdrawal
- RAPID Eczema Trials Programme
- SLEEP study - Supporting children's sleep in those with Eczema Programme
- TECH study - Teleconsultations for Eczema in Children
- TRANS-FOODS study - preventing peanut allergy

National Eczema Society staff and Trustees contributed to several articles in academic journals over the year, including:

Topical steroid withdrawal syndrome: time to bridge the gap; Chantal Cotter et al, British Journal of Dermatology, July 2022

Topical corticosteroid withdrawal: the patient community call for high quality research, clear definitions, and diagnostic criteria; et al. British Journal of Dermatology, Laura Howells et al, November 2022

The sound of silence: where are the voices of patients in eczema guideline development?; Korey Capozza et al; British Journal of Dermatology, December 2022

NES also provides a patient perspective for clinical guideline development, the assessment of new eczema treatments, and policy consultations. During the year, we contributed to the assessment by the National Institute of Health and Care Excellence (NICE) of a new monoclonal antibody drug called tralokinumab and two JAK-inhibitor treatments, upadacitinib and abrocitinib. These new treatments for moderate to severe eczema were all approved for use by the NHS. We also contributed to several drug assessments for the Scottish Medicines consortium (SMC) over the year. As eczema affects people in different ways, it is important that we have a range of treatment options to help ensure people can access a treatment that works effectively for them.

In other influencing activity, the Society continues to work with the Medicines and Healthcare products Regulatory Agency (MHRA) to support the Agency's communication programme to raise awareness of fire risks of emollients. Emollient packaging now comes with fire warning labels. Emollients are not flammable in themselves, or when they are on the skin. However, if bedding, clothing or dressings containing dried emollient residue catches fire (from a naked flame), they burn more quickly and intensely.

Awareness raising, communications and campaigning

The charity undertakes a range of activities to raise awareness and understanding of eczema among the general public, and to promote the information and advice the Society provides for people living with eczema and their families.

TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2022

Activity for National Eczema Week in September was limited due to capacity constraints and the period of national mourning following the death of Queen Elizabeth II earlier that month. We intend to return with a strong campaign for 2023. The Society provided press comment for a number of eczema stories in the media over the year. We achieved mentions on BBC Morning Live and BBC Online, as well as coverage in the Daily Mail, Daily Telegraph, The Times and i newspaper, on topics ranging from tests for babies to predict eczema risk, to new treatments and TSW. The Society was also featured in several professional publications including the Nursing Standard. Capacity constraints and competing priorities continue to impact on the proactive media work we are able to undertake.

We continued to grow our social media reach and activity during the year, reflecting how people increasingly seek and share information about eczema. The Society now has over 24,000 followers on Facebook, an increase of more than 1300 over the year. We also grew our following on Twitter to nearly 8,500, and 10,000 on Instagram by the end of 2022.

Growing income and building financial sustainability

In 2022, we invested more resources in income generation with the appointment of an experienced fundraiser, Sammi Skelding, as Deputy Chief Executive. This reflects our commitment to achieve our charitable objectives and build future financial sustainability. We are immensely grateful to our thoughtful and generous supporters who choose to leave a gift to National Eczema Society in their Will. Income from legacies was much lower in 2022 and this had a significant impact on our overall income, demonstrating the importance of prioritising legacy giving activity.

We continue to develop partnerships with companies that share our values and are willing to support our work and engage in joint education and awareness-raising activity. During the year AbbVie, Dermal, Eli Lilly, LEO Pharma and Sanofi were all corporate members. We are especially grateful to staff and partners at Swagelok Manchester for their continued generous support.

There were many fundraising highlights during the year. Income from challenge events, including the London Marathon, was much improved in 2022 following the disruption caused by Covid. NES organised several new fundraising events during the year, including the 'May Day March' and 'Cake Bake Donate', and thanks to everyone who took part and donated. Having scoped options, we took the decision not to proceed with developing a product endorsement scheme. We continue to find it challenging securing grants from charitable trusts and foundations.

The Society's West Surrey and North-East Hampshire Support Group undertook various local fundraising activities around Guildford, and presented a cheque for £2,000 at the Annual General Meeting in September. In addition, group members raised over £600 through taking part in the Guildford Rotary Annual Charity Sponsored Walk. The Society's members and donors generously supported our summer and Christmas fundraising appeals once again and we are grateful to everyone who supported the Society in different ways with their donations over what has been a challenging year with cost of living pressures.

Organisational development

During the year, we started the process of reviewing options and planning for the Society's future office requirements. The lease on the charity's current office expires in March 2025 and future provision needs to take into account changing needs following the introduction of hybrid working arrangements.

TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2022

Strategy work undertaken included refining the Society's vision, mission and values and scoping work to refresh the charity's brand and visual identity. We have also positioned our charitable work into three core areas:

- Provide information and advice
- Improve eczema care
- Support eczema research

Going forward, we want to give greater relative priority to awareness-raising, communications and campaigning, where we have the opportunity of helping greater numbers in the large eczema community.

2023 Plans and development priorities

Looking ahead, we aim to ensure National Eczema Society continues to achieve the greatest impact we can for members and others living with eczema. The charity's core charitable work will continue, as well as taking forward strategically important activity including building our digital capability, our fundraising, supporting research and strengthening our work to improve eczema care.

Development priorities for 2023 include:

Deliver information and advice

- Continue providing high-quality eczema information and advice, through the website, printed publications, Helpline, webinars and other channels.
- Scope and develop resources to highlight the impact of eczema on people's mental health and emotional well-being.
- Introduce a regular monthly e-newsletter for NES stakeholders.
- Scope and plan a NES-moderated online forum and closed Facebook group.

Improve eczema care

- Increase public awareness and understanding of the challenges of living with eczema, highlighting the impact on people's physical, mental health and quality of life.
- Lead the annual national flagship awareness event, National Eczema Week in September.
- Develop and lead a coalition to campaign for clearer potency labelling of topical steroids.
- Continue to engage with the topical steroid withdrawal community and call for more research into diagnosis and treatment.
- Contribute patient perspectives to clinical guideline development and the assessment of new treatments and policy consultations, working with regulatory bodies including the MHRA, NICE and the SMC.

Support eczema research

- Scope options for developing an NES research grant programme, to fund studentships and innovation grants for eczema research.
- Partner with the UK Dermatology Clinical Trials Network (UK DCTN) to offer a £10,000 award for eczema-related research, as part of the UK DCTN's joint research call for projects to improve dermatology care for people with skin of colour.
- Recruit a panel of people with eczema to share their experiences of living with the condition with researchers.

TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2022

- Continue to contribute patient insights for major eczema research projects and programmes.

We also have a number of initiatives planned to grow charity income and build organisational capability in 2023.

Financial Results

The Society planned for a deficit budget in 2022, although the reported figure is larger than anticipated. It is disappointing to experience this deficit in 2022 after achieving an operating surplus for several prior years and rebuilding reserves to a stronger position. The weaker 2022 result is largely down to lower than expected income from legacy gifts.

Income for the year was £342,821, with expenditure at £413,759 and an annual deficit of £70,621. This compares with a surplus of £185,322 in the year ended 31 December 2021. At 31 December 2022, the Society had reserves of £651,070 (£721,691).

We would like to thank the many people who, as in previous years, by joining or renewing their membership, supporting our appeals and fundraising in a variety of often innovative ways, have enabled us to continue our work. The efforts and contribution of supporters and volunteers is invaluable to the Society. We are grateful also to those who remembered the Society in their Wills, the charitable trusts and companies that have supported us during the year, and to all the healthcare professionals who have provided us with so much time, advice and support especially members of the Medical Advisory Board.

Reserves Policy

The trustees aim to maintain adequate reserves to permit the ongoing operations of the charity. In arriving at their assessment of a suitable limit, trustees have considered the predictability of the Society's income and the nature of its expenditure, together with the degree to which these are committed. Legacies form an important part of the Society's income, and whilst legacies can often be substantial relative to overall income, they are unpredictable and historical trends show there can be periods of years where this source of income is much lower than the long-term average. Expenditure on the other hand is more consistent and predictable.

Trustees last reviewed the Reserves Policy in 2022, and consider that holding unrestricted reserves equal to approximately six months unrestricted charitable expenditure would be sufficient to close or merge the charity, should this ever be necessary. However, given the known volatility of legacy income, trustees have determined a reserves target of 12 months' future overheads expenditure is more appropriate to respond to fluctuations in income.

In order to make unrestricted reserves more transparent, funds that are not readily available to spend are held in reserves designated for specific purposes. A key aim of the Society is to promote research into the causes and treatment of eczema. This being so, the trustees have designated a proportion of reserves to fund future research activity, in addition to any funds that donors have specifically restricted for this purpose. Funds that are not readily available to spend, notably those represented by fixed assets, are held in a reserve designated for this purpose. The pension reserve shows future deficit payments owed in relation to an historical defined benefit pension scheme (see note 19).

The balance held in unrestricted funds at 31 December 2022 is £644,319. Unrestricted funds include funds tied up in tangible assets of £19,721, the pension reserve of (£8,587) and designated Research funds of £110,000. The remaining general funds of £523,185 are materially in line with the charity's

TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2022

reserves policy target of 12 months future overheads expenditure, budgeted at £525,000 for the 2023 financial year.

Risk Management

The trustees have taken steps to identify and address major risks facing the Society, including maintaining a risk register. The principal uncertainty in respect to the Society's future is the ability to maintain sufficient income to deliver the charity's services, and ensure the Society has adequate resources to comply with regulatory changes affecting the voluntary sector. Greater focus and investment are being directed to fundraising activities, to ensure the Society generates sufficient income each year to fund planned activities. The financial outturn for the 2022 financial year emphasises the importance of building sustainable sources of non-legacy income.

The principal risk of financial sustainability for the charity is closely monitored by the trustees on a regular basis, including reviewing management accounts at quarterly Board meetings. Attention also continues to focus on non-financial risks including health and safety, reputation, security, confidentiality and data protection, which are supported by appropriate policies and procedures as well as management updates as needed.

Investment Policy

All surplus funds are currently placed on deposit.

The Trustees and Organisation

The Society is a charitable company. Although called trustees, we are the directors of the company for the purposes of company law. The trustees who served during the year and up to the date of this report are given on page 1.

The Society's governance processes are set out in its Articles of Association. The Board of Trustees administers the Society, which meets routinely four times a year and additionally as circumstances demand. A chief executive is appointed by the trustees to manage the day-to-day operations of the Society within a framework agreed by the Board.

There must be a minimum of three trustees but there is no maximum number, and trustees must be elected by the members of the Society at its Annual General Meeting (AGM). Trustees may be co-opted onto the Board during the year and must then stand for election by the members at the next AGM. At least a third of trustees are required to retire from office each year but may, if they wish, offer themselves for re-election at the AGM. Trustees are recruited through the Society's membership, local support groups, other eczema community networks and open advertising. In seeking trustees, the Society has regard of the need to ensure that the Trustee Board has an appropriate range of professional skills and experience, reflects our commitment to diversity, and also that trustees are drawn from different areas of the UK.

Although not constitutionally binding, the Society wishes to work towards aligning with the Charity Governance Code, which recommends trustees serve fixed terms in office. The guidance recommends trustees serve an initial three-year term, with the possibility of being re-elected by members for a further three-year period. Trustees in particular roles (e.g. Chair, Treasurer) could serve a longer nine-year period, subject to formal review. One current trustee has served longer than nine years and provides specific professional skills to the Board. As yet, it has not been possible to find a replacement with comparable expertise.

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2022

New trustees are provided with an introduction pack, which includes the Society's governing documents, copies of the past year's accounts, and a briefing on their duties and responsibilities and of the Society's governance processes. Prior to joining the Board, new trustees will usually attend at least one Board meeting in an observer capacity, which gives them the opportunity to meet the trustees and chief executive.

Trustees receive no remuneration and no trustee has a beneficial interest in any of the group companies.

The Society has a Medical Advisory Board (MAB), comprised of healthcare professionals who act in an advisory and ambassadorial capacity for the charity. Members volunteer their time and are all experienced healthcare professionals who work in the field of dermatology, and who have a particular professional interest in eczema management and research. The MAB is chaired by National Eczema Society Trustee, Professor Celia Moss OBE.

The trustees set the remuneration of the chief executive and approve the remuneration of other Society staff. Remuneration levels are based on research of similar roles in the sector and benchmark salary data.

Covid statement and response

National Eczema Society was able to maintain its core services and other charitable activities during the Coronavirus pandemic period, most of which are delivered remotely. This has required changes in the way the charity operates, with some staff now routinely working remotely for most of the time. We have invested in our IT and cloud computing capability to support remote working and now have an effective hybrid working model.

The Society benefits from a diverse range of income sources and is therefore more resilient to significant unexpected events like Covid. High inflation in 2022 and into 2023 presents challenges, in both managing costs and achieving income targets as supporters feel the financial pressures. Legacies are a significant element of the Society's overall income mix and we expect legacy income to be stronger again in 2023. Members, other individual donors and corporate partners continued their support during the pandemic. We expect some income sources to be stronger in 2023, including income from corporate supporters and challenge events and we have factored this into our budgeting. Hence, while remaining vigilant to the changeable external environment, the trustees do not have reason to be concerned over the continued financial sustainability of the charity from the longer-term economic impact of Covid. As referenced earlier, the trustees reviewed the NES Reserves Policy in 2022 to ensure reserves continue to meet current and known future requirements.

The Trustees Report has been prepared in accordance with the provisions applicable to entities subject to the small companies regime.

This report was approved by the Board of Trustees on *7th September 2023* and
signed on their behalf by:


.....
Stephen Pugh
Chair

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

STATEMENT OF TRUSTEES' RESPONSIBILITIES
FOR THE YEAR ENDED 31 DECEMBER 2022

The Trustees (who are also the directors of the Charity for the purposes of company law) are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the Trustees to prepare financial statements for each financial year. Under company law, the Trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the Group and the Charity and of their incoming resources and application of resources, including their income and expenditure, for that period. In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles of the Charities SORP (FRS 102);
- make judgements and accounting estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards (FRS 102) have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Group will continue in business.

The Trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the Group and the Charity's transactions and disclose with reasonable accuracy at any time the financial position of the Group and the Charity and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the Group and the Charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Approved by order of the Members of the Board of Trustees and signed on its behalf by:


.....
Stephen Pugh
Chair

Date: 7th September 2023

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

INDEPENDENT EXAMINER'S REPORT
FOR THE YEAR ENDED 31 DECEMBER 2022

Independent Examiner's Report to the Trustees of National Eczema Society ('the Group')

I report to the Charity Trustees on my examination of the consolidated accounts of the Group, set out on pages 14 to 45, comprising the National Eczema Society ('the parent Charity') and its subsidiary undertakings for the year ended 31 December 2022.

Responsibilities and Basis of Report

As the Trustees of the parent Charity (and its Directors for the purposes of company law) you are responsible for the preparation of the consolidated accounts of the Group in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the consolidated accounts are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of the Group's accounts as carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

Independent Examiner's Statement

Since the Group's gross income exceeded £250,000 your examiner must be a member of a body listed in section 145 of the 2011 Act. I confirm that I am qualified to undertake the examination because I am a member of the Institute of Chartered Accountants in England and Wales, which is one of the listed bodies.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe in any material respect:

1. accounting records were not kept in respect of the parent Charity and its subsidiaries as required by section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a 'true and fair' view which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

INDEPENDENT EXAMINER'S REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2022

Signed: 

Dated: 11/09/2023

Stuart McKay BSc FCA DChA

MHA
Chartered Accountants
London, United Kingdom

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

**CONSOLIDATED STATEMENT OF FINANCIAL ACTIVITIES (INCORPORATING INCOME AND EXPENDITURE ACCOUNT)
FOR THE YEAR ENDED 31 DECEMBER 2022**

	Note	Unrestricted funds 2022 £	Restricted funds 2022 £	Total funds 2022 £	Total funds 2021 £
Income from:					
Donations and legacies	4	322,062	5,013	327,075	528,134
Other trading activities:	5				
Income from fundraising		10,205	-	10,205	4,921
Income from trading activities		4,109	-	4,109	1,801
Investments	6	1,432	-	1,432	856
Total income		337,808	5,013	342,821	535,712
Expenditure on:					
Raising funds	7	64,906	-	64,906	32,804
Charitable activities	8	348,853	-	348,853	351,725
Total expenditure		413,759	-	413,759	384,529
Net movement in funds before other recognised gains		(75,951)	5,013	(70,938)	151,183
Other recognised gains:					
Gains/(losses) on pension scheme	19	317	-	317	34,139
Net movement in funds		(75,634)	5,013	(70,621)	185,322
Reconciliation of funds:					
Total funds brought forward		719,953	1,738	721,691	536,369
Net movement in funds		(75,634)	5,013	(70,621)	185,322
Total funds carried forward		644,319	6,751	651,070	721,691

The Consolidated Statement of Financial Activities includes all gains and losses recognised in the year. All income and expenditure derive from continuing activities.

The notes on pages 20 to 45 form part of these financial statements.

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)
REGISTERED NUMBER: 02685083

CONSOLIDATED BALANCE SHEET
AS AT 31 DECEMBER 2022

	Note	2022 £	2022 £	2021 £	2021 £
Fixed assets					
Intangible assets	14		1,836		8,832
Tangible assets	15		17,885		27,886
			<u>19,721</u>		<u>36,718</u>
Current assets					
Debtors: Amounts falling due within one year	17	65,445		159,515	
Cash at bank and in hand		687,108		649,260	
		<u>752,553</u>		<u>808,775</u>	
Creditors: Amounts falling due within one year	18	(116,940)		(115,028)	
Net current assets			<u>635,613</u>		<u>693,747</u>
Total assets less current liabilities			<u>655,334</u>		<u>730,465</u>
Creditors: Amounts falling due after more than one year	19		(4,264)		(8,774)
Total net assets			<u><u>651,070</u></u>		<u><u>721,691</u></u>
Group funds					
Restricted funds	20		6,751		1,738
Unrestricted funds	20		644,319		719,953
Total funds			<u><u>651,070</u></u>		<u><u>721,691</u></u>

The Charity was entitled to exemption from audit under section 477 of the Companies Act 2006.

The members have not required the company to obtain an audit for the year in question in accordance with section 476 of Companies Act 2006.

The Trustees acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to entities subject to the small companies regime.

The financial statements were approved and authorised for issue by the Trustees and signed on their behalf by:

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)
REGISTERED NUMBER: 02685083

CONSOLIDATED BALANCE SHEET (CONTINUED)
AS AT 31 DECEMBER 2022



.....
James Pitayanukul
Treasurer
Date: *7th September 2023*

The notes on pages 20 to 45 form part of these financial statements.

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)
REGISTERED NUMBER: 02685083

CHARITY BALANCE SHEET
AS AT 31 DECEMBER 2022

	Note	2022 £	2022 £	2021 £	2021 £
Fixed assets					
Intangible assets	14		1,836		8,832
Tangible assets	15		17,885		27,886
Investments	16		100		100
			<u>19,821</u>		<u>36,818</u>
Current assets					
Debtors: Amounts falling due within one year	17	132,652		211,072	
Cash at bank and in hand		647,526		624,435	
		<u>780,178</u>		<u>835,507</u>	
Creditors: Amounts falling due within one year	18	(115,140)		(113,228)	
Net current assets			<u>665,038</u>		<u>722,279</u>
Total assets less current liabilities			<u>684,859</u>		<u>759,097</u>
Creditors: Amounts falling due after more than one year	19		(4,264)		(8,774)
Total net assets			<u><u>680,595</u></u>		<u><u>750,323</u></u>
Charity funds					
Restricted funds	20		6,751		1,738
Unrestricted funds	20		673,844		748,585
Total funds			<u><u>680,595</u></u>		<u><u>750,323</u></u>

The Charity's net movement in funds for the year was £(69,728) (2021 - £188,521).

The Charity was entitled to exemption from audit under section 477 of the Companies Act 2006.

The members have not required the company to obtain an audit for the year in question in accordance with section 476 of Companies Act 2006.

The Trustees acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to entities subject to the small companies regime.

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)
REGISTERED NUMBER: 02685083

CHARITY BALANCE SHEET (CONTINUED)
AS AT 31 DECEMBER 2022

The financial statements were approved and authorised for issue by the Trustees and signed on their behalf by:



.....
James Pitayanukul
Treasurer
Date: 7th September 2023.

The notes on pages 20 to 45 form part of these financial statements.

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

CONSOLIDATED STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED 31 DECEMBER 2022

	Note	2022 £	2021 £
Cash flows from operating activities			
Net cash used in operating activities	22	36,416	52,795
Cash flows from investing activities			
Investment income	6	1,432	856
Purchase of tangible fixed assets	15	-	(2,146)
Net cash provided by/(used in) investing activities		1,432	(1,290)
Change in cash and cash equivalents in the year		37,848	51,505
Cash and cash equivalents at the beginning of the year		649,260	597,755
Cash and cash equivalents at the end of the year	23	687,108	649,260

The notes on pages 20 to 45 form part of these financial statements.

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2022

1. General information

National Eczema Society is a charitable company limited by guarantee and is registered with the Registrar of Companies (Company Registered Number: 02685083), the Charity Commission in England and Wales (Charity Registered Number: 1009671). The Charity deregistered from the Office of the Scottish Charity Regulator (OSCR) on 15th October 2021.

In the event of the Charity being wound up, the liability in respect of the guarantee is limited to £1 per Member of the Charity.

The address of the registered office is given in the Charity information on page 1 of these financial statements. The nature of the Charity's operations and principal activities are detailed in the Trustees' Report.

The significant accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all years presented unless otherwise stated.

2. Accounting policies

2.1 Basis of preparation of financial statements

The financial statements have been prepared in accordance with the Charities SORP (FRS 102) - Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

National Eczema Society meets the definition of a public benefit entity under FRS 102.

Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy.

The Consolidated Statement of Financial Activities (SOFA) and Consolidated Balance Sheet consolidate the financial statements of the Charity and its subsidiary undertaking. The results of the subsidiary are consolidated on a line by line basis.

The financial statements are prepared in sterling which is the functional and presentational currency of the Group and are rounded to the nearest pound.

2.2 Going concern

The Trustees have assessed the use of going concern and have considered possible events or conditions that might cast significant doubt on the ability of the Group to continue as a going concern. The Trustees have made this assessment for a period of at least one year from the date of the approval of these financial statements. The Trustees have concluded that there is a reasonable expectation that the Group has adequate resources to continue in operational existence for the foreseeable future, and that no material uncertainties exist. The Group therefore continues to adopt the going concern basis in preparing these financial statements.

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2022

2. Accounting policies (continued)

2.3 Income

All income is recognised once the Group has entitlement to the income, it is probable that the income will be received and the amount of income receivable can be measured reliably.

For donations and gift aid to be recognised the Group will have been notified of the amounts and the settlement date in writing. If there are conditions attached to the donation and this requires a level of performance before entitlement can be obtained then income is deferred until those conditions are fully met or the fulfilment of those conditions is within the control of the Group and it is probable that they will be fulfilled.

The recognition of income from legacies is dependent on establishing entitlement, the probability of receipt and the ability to estimate with sufficient accuracy the amount receivable. Evidence of entitlement to a legacy exists when the Group has sufficient evidence that a gift has been left to them (through knowledge of the existence of a valid will and the death of the benefactor) and the executor is satisfied that the property in question will not be required to satisfy claims in the estate. Receipt of a legacy must be recognised when it is probable that it will be received and the fair value of the amount receivable, which will generally be the expected cash amount to be distributed to the Group, can be reliably measured.

Subscription income is received in full and recognised evenly over the course of the subscription. The amount recognised in the Consolidated Statement of Financial Activities relates to the financial period in question.

Income from trading activities includes income earned from fundraising events and trading activities to raise funds for the Group. Income is received in exchange for supplying goods and services in order to raise funds and is recognised when entitlement has occurred.

2.4 Expenditure

All expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all costs related to the categories. Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Central staff costs are allocated on the basis of time spent, and depreciation charges allocated on the portion of the asset's use.

Expenditure on charitable activities is incurred on directly undertaking the activities which further the Group's objectives, as well as any associated support costs.

All expenditure is inclusive of irrecoverable VAT.

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2022

2. Accounting policies (continued)

2.5 Interest receivable

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the Group; this is normally upon notification of the interest paid or payable by the institution with whom the funds are deposited.

2.6 Taxation

The Charity is considered to pass the tests set out in Paragraph 1 Schedule 6 of the Finance Act 2010 and therefore it meets the definition of a charitable company for UK corporation tax purposes. Accordingly, the Charity is potentially exempt from taxation in respect of income or capital gains received within categories covered by Chapter 3 Part 11 of the Corporation Tax Act 2010 or Section 256 of the Taxation of Chargeable Gains Act 1992; to the extent that such income or gains are applied exclusively to charitable purposes.

2.7 Intangible assets and amortisation

Intangible assets costing £500 or more are capitalised and recognised when future economic benefits are probable and the cost or value of the asset can be measured reliably.

Intangible assets are initially recognised at cost. After recognition, under the cost model, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

Amortisation is provided on intangible assets at rates calculated to write off the cost of each asset on a straight-line basis over 3 years.

Assets under construction are not amortised until ready for use.

2.8 Tangible fixed assets and depreciation

Tangible fixed assets costing £500 or more are capitalised and recognised when future economic benefits are probable and the cost or value of the asset can be measured reliably.

Tangible fixed assets are initially recognised at cost. After recognition, under the cost model, tangible fixed assets are measured at cost less accumulated depreciation and any accumulated impairment losses. All costs incurred to bring a tangible fixed asset into its intended working condition should be included in the measurement of cost.

At each reporting date the Group assesses whether there is any indication of impairment. If such indication exists, the recoverable amount of the asset is determined to be the higher of its fair value less costs to sell and its value in use. An impairment loss is recognised where the carrying amount exceeds the recoverable amount.

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2022

2. Accounting policies (continued)

2.8 Tangible fixed assets and depreciation (continued)

Depreciation is charged so as to allocate the cost of tangible fixed assets less their residual value over their estimated useful lives, using the straight-line method.

Depreciation is provided on the following bases:

Leasehold improvements	- over 10 years
Furniture and fittings	- over 10 years
Office equipment	- over 10 years
Computer equipment	- over 3 years

2.9 Investments

The investment in the subsidiary company is valued at cost less provision for impairment.

2.10 Debtors

Trade and other debtors are recognised at the settlement amount after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

2.11 Cash at bank and in hand

Cash at bank and in hand includes cash and short-term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

2.12 Liabilities and provisions

Liabilities are recognised when there is an obligation at the Balance Sheet date as a result of a past event, it is probable that a transfer of economic benefit will be required in settlement, and the amount of the settlement can be estimated reliably.

Liabilities are recognised at the amount that the Group anticipates it will pay to settle the debt or the amount it has received as advanced payments for the goods or services it must provide.

Provisions are measured at the best estimate of the amounts required to settle the obligation. Where the effect of the time value of money is material, the provision is based on the present value of those amounts, discounted at the pre-tax discount rate that reflects the risks specific to the liability. The unwinding of the discount is recognised in the Consolidated Statement of Financial Activities as a finance cost.

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2022

2. Accounting policies (continued)

2.13 Financial instruments

The Group only holds basic Financial Instruments. The financial assets and financial liabilities of the Group are as follows:

Debtors – other debtors are basic financial instruments and are debt instruments measured at amortised cost as detailed in Note 17.

Cash at bank – is classified as a basic financial instrument and is measured at face value.

Liabilities – accruals are classified as financial instruments, and are measured at amortised cost as detailed in Notes 18 and 19.

2.14 Operating leases

Rentals paid under operating leases are charged to the Consolidated Statement of Financial Activities on a straight line basis over the lease term.

2.15 Pensions

Through its past participation, the Group has a liability to a pension scheme called the Series 3 Growth Plan, which closed in 2013. Since then, the Group has participated in a defined contribution pension scheme for employees, operated by workplace pension provider TPT.

The Group is part of the Series 3 Growth Plan which is a multi-employer pension Scheme which closed in 2013. The Scheme administrators have confirmed that it is not possible to separately identify the assets and liabilities of participating employers on a consistent and reasonable basis. The assets of the Scheme are co-mingled for investment purposes and benefits are paid from total Scheme assets. A deficit reduction plan has been agreed.

The Group accounts for its participation in this Plan as a defined contribution plan, as there is insufficient information available to account for this as a defined benefit plan, as the share of its assets and liabilities cannot be identified.

To avoid crystallizing an immediate payment of the apparent under-funding in the Series 3 Scheme, the Group is participating in the Series 3 Recovery Plan and the liability is included in Notes 18 and 19. The Group recognises its liability to make payments to fund the deficit relating to past service under an agreement to make those payments. It recognises the full liability for the present value of contributions payable that results from the agreement for funding the multi employer plan.

The Group also participates in a defined contribution pension scheme for its employees. The Group pays fixed contributions into a separate scheme. Once the defined contribution payments have been made, the Group has no further payment obligations in respect of this scheme. The contributions are recognised as an expense in the Consolidated Statement of Financial Activities as they fall due.

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2022

2. Accounting policies (continued)

2.16 Fund accounting

General funds are unrestricted funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the Group and which have not been designated for other purposes.

Designated funds comprise unrestricted funds that have been set aside by the Trustees for particular purposes. The aim and use of each designated fund is set out in the notes to the financial statements.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the Group for particular purposes. The costs of raising and administering such funds are charged against the specific fund. The aim and use of each restricted fund is set out in the notes to the financial statements.

Investment income, gains and losses are allocated to the appropriate fund.

3. Critical accounting estimates and areas of judgement

Estimates and judgements are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

Critical accounting estimates and assumptions:

The Group makes estimates and assumptions concerning the future. The resulting accounting estimates and assumptions will, by definition, seldom equal the related actual results. The estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are listed below.

- Allocation of support costs
- Legacy income recognition
- Depreciation rates for tangible fixed assets
- Useful economic lives of assets
- The discount rate used in valuing the year-end Pension Scheme deficit.

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2022

4. Income from donations and legacies

	Unrestricted funds 2022 £	Restricted funds 2022 £	Total funds 2022 £
Donations and similar income	132,853	5,013	137,866
Legacies	24,706	-	24,706
Subscriptions	143,952	-	143,952
Gift aid	20,551	-	20,551
Total 2022	322,062	5,013	327,075

	Unrestricted funds 2021 £	Total funds 2021 £
Donations and similar income	174,348	174,348
Legacies	181,302	181,302
Subscriptions	150,978	150,978
Gift aid	21,506	21,506
Total 2021	528,134	528,134

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2022

5. Income from other trading activities

Income from fundraising events

	Unrestricted funds 2022 £	Total funds 2022 £
Other corporate income	6,265	6,265
Other activities	3,940	3,940
Total 2022	<u><u>10,205</u></u>	<u><u>10,205</u></u>

	Unrestricted funds 2021 £	Total funds 2021 £
Other corporate income	1,607	1,607
Other activities	3,314	3,314
Total 2021	<u><u>4,921</u></u>	<u><u>4,921</u></u>

Income from non charitable trading activities

	Unrestricted funds 2022 £	Total funds 2022 £
Trading subsidiary	<u><u>4,109</u></u>	<u><u>4,109</u></u>

	Unrestricted funds 2021 £	Total funds 2021 £
Trading subsidiary	<u><u>1,801</u></u>	<u><u>1,801</u></u>

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2022

6. Income from investments

	Unrestricted funds 2022 £	Total funds 2022 £
Bank interest receivable	1,432	1,432

	Unrestricted funds 2021 £	Total funds 2021 £
Bank interest receivable	856	856

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2022

7. Expenditure on raising funds

	2022 £	2021 £
Fundraising costs		
Direct costs	59,330	27,431
Support costs	5,574	5,373
	<u>64,904</u>	<u>32,804</u>

Analysis of support costs - fundraising costs

	2022 £	2021 £
Staff costs	1,735	1,539
Depreciation	562	663
Premises costs	727	779
Carriage and postage	289	174
Professional fees	370	560
Bought-in services	33	30
Website, database and computing	583	541
Other costs	931	700
Governance costs	344	387
	<u>5,574</u>	<u>5,373</u>

	2022 £	2021 £
Trading costs		
Trading subsidiary - Direct costs	<u>2</u>	<u>-</u>

In both the current and previous financial years all Expenditure on raising funds was from Unrestricted funds.

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2022

8. Analysis of expenditure on charitable activities - by fund

	Unrestricted funds 2022 £	Total 2022 £
Helpline	100,310	100,310
Membership services	174,303	174,303
Information services	74,240	74,240
Total 2022	348,853	348,853

	Unrestricted funds 2021 £	Restricted funds 2021 £	Total 2021 £
Helpline	106,899	-	106,899
Membership services	160,938	-	160,938
Information services	73,138	10,750	83,888
Total 2021	340,975	10,750	351,725

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2022

9. Analysis of expenditure on charitable activities - by type

	Activities undertaken directly 2022 £	Support costs 2022 £	Total funds 2022 £
Helpline	56,071	44,239	100,310
Membership services	96,182	78,121	174,303
Information services	33,519	40,721	74,240
Total 2022	185,772	163,081	348,853

	Activities undertaken directly 2021 £	Support costs 2021 £	Total funds 2021 £
Helpline	64,245	42,654	106,899
Membership services	85,626	75,312	160,938
Information services	44,631	39,257	83,888
Total 2021	194,502	157,223	351,725

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2022

9. Analysis of expenditure on charitable activities - by type (continued)

Analysis of support costs

	Total funds 2022 £	Total funds 2021 £
Staff costs	50,750	49,310
Depreciation	16,435	18,645
Premises costs	21,266	21,884
Carriage and postage	8,468	4,888
Professional fees	10,838	15,743
Bought-in services	962	845
Website, database and computing	17,050	15,212
Other costs	27,236	19,819
Governance costs	10,076	10,877
	163,081	157,223

10. Governance costs

	2022 £	2021 £
Independent Examiner's remuneration	2,000	5,505
Rent & rates	-	(670)
Insurance	6,681	6,386
Recruitment	1,150	-
Room hire & Conference expenses	50	-
Trustees expenses	198	-
Travel, hotels & subsistence	245	-
General office expenses	96	43
	10,420	11,264

Total Governance costs above comprise £344 (2021 - £387) of Expenditure on raising funds and £10,076 (2021 - £10,877) of Expenditure on charitable activities.

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2022**

11. Auditors' and Independent examiner's remuneration

	2022 £	2021 £
Independent Examiner's remuneration - Examination of the financial statements	5,010	6,000
Independent Examiner's remuneration - prior year over-accrual	(3,010)	(495)
	<u> </u>	<u> </u>

12. Staff costs

	Group 2022 £	Group 2021 £	Charity 2022 £	Charity 2021 £
Wages and salaries	203,865	159,739	203,865	159,739
Social security costs	18,600	13,067	18,600	13,067
Pension costs	8,470	6,857	8,470	6,857
	<u>230,935</u>	<u>179,663</u>	<u>230,935</u>	<u>179,663</u>

The average number of persons employed by the Charity during the year was as follows:

	Group 2022 No.	Group 2021 No.
Direct charitable activities	3	2
Fundraising and communication	1	1
Support and governance	1	1
	<u>5</u>	<u>4</u>

The number of employees whose employee benefits (excluding employer pension costs) exceeded £60,000 was:

	Group 2022 No.	Group 2021 No.
In the band £60,001 - £70,000	1	1

The total amount of employee benefits, including employers national insurance and pension contributions, received by Key Management Personnel is £72,726 (2021 - £72,305). The Charity considers its Key Management Personnel comprise the Trustees and the Chief Executive Officer.

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2022

13. Trustees' remuneration and expenses

During the year, no Trustees received any remuneration or other benefits (2021 - £NIL).

During the year ended 31 December 2022, expenses totalling £198 were reimbursed or paid directly to 2 Trustees (2021 - £Nil) in relation to travel and conference costs.

14. Intangible assets

Group and Charity

	Website £
Cost	
At 1 January 2022	20,988
At 31 December 2022	20,988
Amortisation	
At 1 January 2022	12,156
Charge for the year	6,996
At 31 December 2022	19,152
Net book value	
At 31 December 2022	1,836
At 31 December 2021	8,832

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2022

15. Tangible fixed assets

Group and Charity

	Leasehold improvements £	Furniture and fixtures £	Office equipment £	Computer equipment £	Total £
Cost or valuation					
At 1 January 2022	41,470	2,493	3,873	24,189	72,025
At 31 December 2022	41,470	2,493	3,873	24,189	72,025
Depreciation					
At 1 January 2022	25,931	1,679	2,338	14,191	44,139
Charge for the year	4,147	250	355	5,249	10,001
At 31 December 2022	30,078	1,929	2,693	19,440	54,140
Net book value					
At 31 December 2022	11,392	564	1,180	4,749	17,885
At 31 December 2021	15,539	814	1,535	9,998	27,886

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2022

16. Fixed asset investments

	Investment in subsidiary company £
Charity	
Cost or valuation	
At 1 January 2022	100
At 31 December 2022	100

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2022**

16. Fixed asset investments (continued)

Principal subsidiaries

The following was a subsidiary undertaking of the Charity:

Name	Company number	Registered office or principal place of business	Holding	Included in consolidation
Eczema Trading Limited	06895048	11 Murray Street, London, NW1 9RE	100%	Yes

The financial results of the subsidiary for the year were:

Name	Income £	Expenditure £	Loss for the year £	Net liabilities £
Eczema Trading Limited	4,109	(5,002)	(893)	(29,425)

The results of Eczema Trading Limited are included in these consolidated accounts. Eczema Trading Limited did not meet the audit threshold and therefore did not require an audit for the year ended 31 December 2022. The reported deficit relates to intercompany management charges and minimal advertising and corporate membership revenue.

For the year ended 31 December 2022, the advertising revenue from our membership magazine, together with limited income from company supporters, is accounted for in Eczema Trading Limited. Going forward, the majority of income received from company supporters will be accounted for in Eczema Trading Limited.

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2022

17. Debtors

	Group 2022 £	Group 2021 £	Charity 2022 £	Charity 2021 £
Due within one year				
Trade debtors	26,160	24,500	-	24,500
Amounts owed by group undertakings	-	-	93,367	51,557
Other debtors	26,219	124,611	26,219	124,611
Prepayments and accrued income	13,066	10,404	13,066	10,404
	65,445	159,515	132,652	211,072

18. Creditors: Amounts falling due within one year

	Group 2022 £	Group 2021 £	Charity 2022 £	Charity 2021 £
Trade creditors	5,680	4,821	5,680	4,821
Other taxation and social security	12,616	12,761	12,616	12,761
Other creditors	6,995	7,770	6,995	7,770
Accruals and deferred income	91,649	89,676	89,849	87,876
	116,940	115,028	115,140	113,228
	Group 2022 £	Group 2021 £	Charity 2022 £	Charity 2021 £
Deferred income				
Deferred income at 1 January	75,422	103,016	73,622	103,016
Resources deferred during the year	78,080	75,422	78,080	73,622
Amounts released from previous periods	(73,622)	(103,016)	(73,622)	(103,016)
Deferred income at 31 December	79,880	75,422	78,080	73,622

Deferred income consists of membership income relating to future periods.

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2022

19. Creditors: Amounts falling due after more than one year

	Group 2022 £	Group 2021 £	Charity 2022 £	Charity 2021 £
Pension Scheme deficit	4,264	8,774	4,264	8,774

Through its past participation, the Group has a liability to a pension scheme called the Series 3 Growth Plan, which closed in 2013. Since then, the Group has participated in a defined contribution pension scheme for employees, operated by workplace pension provider TPT.

The Charity is participating in a recovery plan to eliminate its Series 3 scheme deficit over a ten year period. The Pensions Trust, the scheme administrator, has however advised that the amount of employer debt on the alternative of withdrawal from the Series 3 scheme has been estimated by actuaries to have been £200,161 as at 31 December 2016. As the Charity intends to continue participating in the recovery plan, no provision has been made for this potential withdrawal debt however, the Society accounted for the present value of all remaining contributions under the recovery plan in the 2017 accounts at their present value of £120,000, as advised by the scheme administrator. This liability has been adjusted annually to unwind the relevant discount applied.

In order to meet their share of the shortfall, the Charity has been asked to pay additional contributions to the scheme until 2025. A full actuarial valuation was carried out by the actuaries at 30 September 2017 and the funding shortfall calculated at that date gave rise to a remeasurement reduction of £15,624 in the deficit as at 31 December 2018. The deficit of the scheme is £8,587 (2021 - £15,879) at 31 December 2022. The payment by the Charity in the year was £7,105 (2021 - £15,333) with an interest payment of £130 (2021 - £155) and a revaluation gain of £317 (2021 - £(180)).

In addition, the Charity elected to switch, with effect from 1 October 2013, from Series 3 to Series 4, a defined contribution scheme. The pension cost in the accounts represents amounts payable by the charity as ordinary employer contributions to the Series 4 defined contribution fund.

During the year employer contributions of £8,470 (2021 - £6,857), interest of £130 (2021 - £155), actuarial (gains)/losses of £317 (2021 - £(180)) and remeasurements for amendments to the contribution schedule of £Nil (2021 - £(33,959)) have been charged to the Consolidated Statement of Financial Activities, along with scheme costs of £3,625 (2021: £Nil). There were no accrued contributions at 31 December 2022 (2021 - £NIL) but there is a liability of £8,587 (2021 - £15,879) for future contributions under the Series 3 Recovery Plan. Of this £4,323 (2021 - £7,105) is reported in Creditors: Amounts falling due within one year as part of Other creditors and £4,264 (2021 - £8,774) is reported in Creditors: Amounts falling due after more than one year.

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2022

20. Statement of funds

Statement of funds - current year

	Balance at 1 January 2022 £	Income £	Expenditure £	Transfers in/(out) £	Gains/ (Losses) £	Balance at 31 December 2022 £
Unrestricted funds						
Designated funds						
Fixed asset fund	36,718	-	(16,997)	-	-	19,721
Pension reserve	(15,879)	-	(3,755)	10,730	317	(8,587)
Research fund	-	-	-	110,000	-	110,000
	<u>20,839</u>	<u>-</u>	<u>(20,752)</u>	<u>120,730</u>	<u>317</u>	<u>121,134</u>
General funds						
General funds	699,114	337,808	(393,007)	(120,730)	-	523,185
Total Unrestricted funds	<u>719,953</u>	<u>337,808</u>	<u>(413,759)</u>	<u>-</u>	<u>317</u>	<u>644,319</u>
Restricted funds						
Research	1,738	5,013	-	-	-	6,751
Total of funds	<u>721,691</u>	<u>342,821</u>	<u>(413,759)</u>	<u>-</u>	<u>317</u>	<u>651,070</u>

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2022

20. Statement of funds (continued)

Statement of funds - prior year

	Balance at 1 January 2021 £	Income £	Expenditure £	Transfers in/out £	Gains/ (Losses) £	Balance at 31 December 2021 £
Unrestricted funds						
Designated funds						
Fixed asset fund	53,880	-	(19,308)	2,146	-	36,718
Pension reserve	(65,196)	-	(155)	15,333	34,139	(15,879)
	<u>(11,316)</u>	<u>-</u>	<u>(19,463)</u>	<u>17,479</u>	<u>34,139</u>	<u>20,839</u>
General funds						
General funds	<u>535,197</u>	<u>535,712</u>	<u>(354,316)</u>	<u>(17,479)</u>	<u>-</u>	<u>699,114</u>
Total Unrestricted funds	<u>523,881</u>	<u>535,712</u>	<u>(373,779)</u>	<u>-</u>	<u>34,139</u>	<u>719,953</u>
Restricted funds						
Research	<u>12,488</u>	<u>-</u>	<u>(10,750)</u>	<u>-</u>	<u>-</u>	<u>1,738</u>
Total of funds	<u><u>536,369</u></u>	<u><u>535,712</u></u>	<u><u>(384,529)</u></u>	<u><u>-</u></u>	<u><u>34,139</u></u>	<u><u>721,691</u></u>

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2022

20. Statement of funds (continued)

Designated funds

The Pension reserve has been established to show the future pension deficit payments in regards to a defined benefit pension scheme. This pension scheme is being treated as a defined contribution pension scheme as a reliable estimate cannot be made of the liability at the year end. The transfer of £10,730 was made to separate the deficit payments due as at 31 December 2022 from the Unrestricted general fund. Actuarial gains / (losses) are charged to this fund as they arise.

The Fixed asset fund has been established to reflect the funds tied up in Tangible and Intangible fixed assets and agrees back to the Net Book Value presented on the Consolidated Balance Sheet. Depreciation is charged to this fund as expenditure.

The Research fund has been established to designate funds for research into the causes and treatment of eczema, which is a key aim of the Society. The Society will provide grants to researchers on a periodic basis and it is necessary to designate sufficient reserves to fund the expected grant costs. The fund is expected to be utilised and grants awarded commencing in the financial year to 31 December 2024.

Unrestricted funds

General funds reflects funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the Charity and which have not been designated for other purposes.

Restricted funds

The Research fund exists to provide resources for research into the causes of eczema, with the aim of developing more effective treatments or a cure.

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2022

21. Analysis of net assets between funds

Analysis of net assets between funds - current year

	Unrestricted funds 2022 £	Restricted funds 2022 £	Total funds 2022 £
Tangible fixed assets	17,885	-	17,885
Intangible fixed assets	1,836	-	1,836
Current assets	745,802	6,751	752,553
Creditors due within one year	(114,456)	-	(114,456)
Creditors due in more than one year	(6,748)	-	(6,748)
Total	644,319	6,751	651,070

Analysis of net assets between funds - prior year

	Unrestricted funds 2021 £	Restricted funds 2021 £	Total funds 2021 £
Tangible fixed assets	27,886	-	27,886
Intangible fixed assets	8,832	-	8,832
Current assets	807,037	1,738	808,775
Creditors due within one year	(115,028)	-	(115,028)
Creditors due in more than one year	(8,774)	-	(8,774)
Total	719,953	1,738	721,691

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2022**

22. Reconciliation of net movement in funds to net cash flow from operating activities

		Group 2022 £	Group 2021 £
Net income/expenditure for the year (as per Statement of Financial Activities)		(70,938)	151,183
Adjustments for:			
Depreciation charges	15	10,001	12,312
Amortisation charges	14	6,996	6,996
Investment income	6	(1,432)	(856)
Decrease/(increase) in debtors	17	94,070	(114,754)
(Decrease)/increase in creditors	18	(2,598)	(2,086)
Actuarial Gains / (loss) on pension		317	-
Net cash provided by operating activities		36,416	52,795

23. Analysis of cash and cash equivalents

	Group 2022 £	Group 2021 £
Cash in hand	687,108	649,260
Total cash and cash equivalents	687,108	649,260

24. Analysis of changes in net debt

	At 1 January 2022 £	Cash flows £	At 31 December 2022 £
Cash at bank and in hand	649,260	37,848	687,108
	649,260	37,848	687,108

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2022

25. Operating lease commitments

At 31 December 2022 the Group and the Charity had commitments to make future minimum lease payments under non-cancellable operating leases as follows:

	Group 2022 £	Group 2021 £	Charity 2022 £	Charity 2021 £
Not later than 1 year	21,000	21,000	21,000	21,000
Later than 1 year and not later than 5 years	25,333	46,333	25,333	46,333
	46,333	67,333	46,333	67,333

The following lease payments have been recognised as an expense in the Statement of Financial Activities:

	Group 2022 £	Group 2021 £	Charity 2022 £	Charity 2021 £
Operating lease rentals	21,000	20,833	21,000	20,833

26. Related party transactions

In the year ended 31 December 2022, unrestricted donations of £1,158 (2021 - £1,200) were made by the Trustees of the Charity.


Accounts

Company Registered Number: 02685083
Charity Registered Number (England & Wales): 1009671

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

UNAUDITED

TRUSTEES' REPORT AND FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2021



NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

CONTENTS

	Page
Reference and Administrative Details of the Charity, its Trustees and Advisers	1
Trustees' Report	2 - 11
Statement of Trustees' Responsibilities	12
Independent Examiner's Report	13 - 14
Consolidated Statement of Financial Activities	15
Consolidated Balance Sheet	16 - 17
Charity Balance Sheet	18 - 19
Consolidated Statement of Cash Flows	20
Notes to the Financial Statements	21 - 46

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

**REFERENCE AND ADMINISTRATIVE DETAILS OF THE CHARITY, ITS TRUSTEES AND ADVISERS
FOR THE YEAR ENDED 31 DECEMBER 2021**

Trustees	Edward Davies QC, Chair (resigned 19 May 2022) Ellen Vincent, Vice Chair Stephen Pugh, Treasurer (appointed to Chair 19 May 2022, resigned as Treasurer 19 May 2022) Catherine Escott Myrtle Johnston Hannah Kunzlik (appointed 16 March 2022) Dr Simon Lovegrove (appointed 16 March 2022) Professor Celia Moss OBE Bharat Pandya (appointed 16 March 2022) James Pitayanukul (appointed to Treasurer 19 May 2022) Hedwig Vollers (appointed 16 March 2022) Suzanne Watson
Company registered number	02685083
Charity registered number	1009671
Registered office	11 Murray Street London NW1 9RE
Chief executive officer & Company secretary	Andrew Proctor
Independent Examiner	MHA MacIntyre Hudson Chartered Accountants 6th Floor 2 London Wall Place London EC2Y 5AU
Principal Bankers	CAF Bank Ltd National Westminster Bank plc Barclays Bank plc
Status and Governing Document	National Eczema Society is a charitable company, limited by guarantee. It was incorporated on 6 February 1992 and registered as a charity on 10 March 1992. It is governed by its Articles of Association.
Subsidiary Companies	Eczema Trading Limited

TRUSTEES' REPORT
FOR THE YEAR ENDED 31 DECEMBER 2021

The trustees present their annual report together with the financial statements of the Group and the Charity for the year 1 January 2021 to 31 December 2021. The trustees confirm that the Annual Report and financial statements of the company comply with the current statutory requirements, the requirements of the company's governing document and the provisions of the Statement of Recommended Practice (SORP), applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102). Since the Charity and the Group qualifies as small under section 383, the strategic report required of medium and large companies under The Companies Act 2006 (Strategic Report and Director's Report) Regulations 2013 is not required.

Purpose and aims

National Eczema Society was established in 1975 to support people with eczema and their families and to work on their behalf. We remain dedicated to these founding principles and today we continue to help people across the UK with evidence-based information and advice about eczema and its management. We deliver this in various ways through our website, webinars, instructional videos, social media channels, publications and nurse-supported Helpline. We also provide a collective voice for people with eczema, to inform research and influence health policy to improve eczema care, and raise greater awareness and understanding of the condition among people affected by eczema and the wider public.

The prevalence of eczema has increased over recent decades, and around one in five children and one in ten adults are now impacted by this life-challenging condition in the UK. While the reasons for the increase are not fully understood, it does mean the charity's services are needed more than ever. Our support has been especially valuable for many during the Coronavirus pandemic, when access to healthcare was more difficult for many. There is as yet no cure for eczema and, unless you have the condition, it can be hard to imagine the daily challenge of living with relentless itching and inflamed, painful skin. Many healthcare professionals have limited dermatology training and timely access to specialist dermatology healthcare for people with eczema can often be difficult. National Eczema Society aims to provide the information and support needed for people to self-manage their eczema effectively, to become experts in their own care, learn from the experiences of others, and provide the reassurance of knowing they are not on their own.

Ensuring our work delivers our charitable aims

We review our activities each year and monitor the impact of our work to ensure we continue to fulfil our purpose of supporting people affected by eczema. Among other ways, we assess the Society's performance and achievements through the number of people we have helped with information and advice, and the quality and consistency of the resources we provide.

We consider how planned activities will contribute to the aims and objectives we have set, and in doing this we have referred to the Charity Commission's general guidance on public benefit. We have had regard to the legislative and regulatory requirements for disclosing how our charitable objectives have provided such benefit, and complied with the duty set out in section 4 of the Charities Act 2011.

2021 Activity and achievements – delivering public benefit

All our charitable activities focus on supporting people affected by eczema and championing their needs, and further our charitable purposes for the public benefit. Here we present a summary of the Society's work over the year.

TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2021

Impact of Coronavirus pandemic

The Society's plans in 2021 reflected the ongoing impact of the Coronavirus pandemic and importance of effective remote working and service delivery. Once again, great credit and thanks are due to the staff team, trustees, volunteers and suppliers who worked so hard over the year to maintain the Society's services and operations in challenging circumstances.

The Society now operates a hybrid working model, first introduced at the start of the pandemic, and this will continue. Like many organisations, we moved to virtual meetings in response to the pandemic and held our second AGM, in September 2021, using the videoconferencing platform Zoom. Trustee Board meetings are now hybrid, with both in person and virtual attendance supported.

We took the difficult decision not to organise any face-to-face events again during 2021, reflecting the ongoing challenges of Covid restrictions. The Society's Helpline, website and social media communications continued operating as usual throughout the year. Coronavirus also affected some of our fundraising activity, notably challenge events and community fundraising. We are grateful to our members and supporters for being so generous with their donations during the year, at a time of continued uncertainty.

Delivering information and advice for people living with eczema

The Society continues to provide a wide range of high quality, evidence-based information and advice about eczema and its management for people living with the condition and their families.

Our eczema Helpline is at the heart of the Society's work, enabling the charity to provide the personalised independent advice and reassurance needed by people struggling to cope with eczema wherever they live in the UK. We receive around 1,600 telephone, email and message enquiries a year from parents of children with eczema and adults living with the condition. These cover a wide range of questions about eczema symptoms and treatments, from the latest biologic drugs to eczema-friendly clothing. We offer a dermatology nurse call-back service for people who have more complex enquiries, and around 40% of callers are helped by one of our experienced dermatology nurse advisers. Our Helpline is available free of charge to anyone affected by eczema in the UK who needs our support.

Alongside our Helpline, the Society produces a wide range of patient information booklets and factsheets about eczema management and treatment, available online and in print. We distribute printed copies at events the charity organises and attends, and we provided over 12,000 copies of our printed publications to healthcare professionals during the year, for onward distribution to patients in hospital dermatology clinics and other healthcare settings.

National Eczema Society factsheets and booklets are updated regularly on a rolling review cycle and checked by healthcare professionals to ensure the information is accurate and up-to-date. We updated and reprinted a number of publications over the year, including our Itching and Scratching booklet, Paste Bandages and Wet Wraps booklet and Childhood Atopic Eczema guide.

We continue to raise awareness of local volunteer-led patient support groups, by providing information and a presence for these groups on the Society's website. Unfortunately, because of ongoing Covid restrictions, the information talk planned by the Society's West Surrey and North-East Hampshire Support Group had to be postponed again, where Dr George Moncrieff was due to speak about the causes of eczema and latest thinking on eczema care.

TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2021

We publish all our eczema information on the Society's website, which received over 1.3 million visits during the year, and we promote health advice messages through our social media channels, media engagement and other external communications. This year we launched a series of popular webinars for people affected by eczema and their families, on various eczema management topics, and recordings of these are available to view on the Society's YouTube page.

NES membership scheme

National Eczema Society is a membership organisation and we are very grateful to our 2,300 members who support the Society through their annual membership fee and additional donations. Members receive our quarterly magazine Exchange, which features expert information and news about eczema. Members are also encouraged to attend the Society's Annual General Meeting and contribute their ideas on the running of the charity. As in previous years, support for our charity extends far beyond our membership and we remain grateful to all our donors, and to those members who continue to support us financially even though they no longer have any personal need of our help.

Representing patient views

As a national patient organisation for people with eczema, the Society plays a leading role in providing a collective voice to champion the needs of those affected by the condition. We seek to improve health outcomes for people with eczema by influencing health policy and participating in groups like the All Party Parliamentary Group on Skin (APPGS) and working with professional bodies like the British Association of Dermatologists. As a member of the steering group, we contributed to the major NHS England Dermatology Outpatient Transformation Programme, which developed a range of new guidance to help dermatology healthcare providers meet the challenges of responding to the disruption to services caused by Covid. This covered areas like teledermatology and waiting lists. We also worked to raise awareness of the need for better understanding and representation in dermatology for people with skin of colour.

Reflecting the growing patient interest and awareness of the side effects of topical steroid medication, and concerns about topical steroid withdrawal, the Society worked with the British Association of Dermatologists to develop a position statement on topical steroid withdrawal. Among other things, in the statement we sought to clarify the various terms used to describe topical steroid withdrawal and the different reactions people might experience when stopping using topical steroid treatments. Topical steroid withdrawal is complex and research into the causes, symptoms and treatments is limited. National Eczema Society wants to see more research in this area. One of the challenges is that the symptoms people experience when stopping using topical steroids can appear similar to those of poorly controlled eczema. These symptoms can be very painful and distressing. The Society is emphasising the importance of using topical steroid treatments safely and effectively, and among other things is calling for clearer labelling of topical steroids to show their potency/strength.

We continued to grow our organisational capacity to support patient involvement in shaping research. NES is approached regularly by researchers seeking patient views and to learn from patient experiences. It is so encouraging to see such a range of research underway and new treatments in the pipeline, following a long period when eczema was largely overlooked. The Society is actively supporting eczema research by participating in study steering groups, providing patient perspectives for research trials, and working with universities and companies that are assessing and developing new drug treatments. We do this to help ensure eczema research has the greatest chance of success in finding new treatments and ultimately a cure.

TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2021

We also provide a patient perspective to clinical guideline development, the assessment of new treatments, and policy consultations. We contributed to the assessment by the National Institute of Health and Care Excellence (NICE) and the Scottish Medicines consortium (SMC) of a new eczema drug called baricitinib, which was approved for use by the NHS in 2021. This is intended for adults with moderate to severe eczema. Baricitinib is a type of drug known as a Janus kinase (JAK) inhibitor and it works in a different way to other immunosuppressant and biologic drugs currently used to treat eczema. As eczema affects people in different ways, it is important that we have a range of treatment options to help ensure people can access a treatment that works effectively for them. During the year, we contributed a patient perspective and evidence to other NICE and SMC reviews, including assessment of several other new drugs for eczema, including a new biologic treatment called tralokinumab and two JAK-inhibitor drugs called upadacitinib and abrocitinib.

It is disappointing that efforts to press NHS England and NHS Improvement to clarify their prescribing guidance on emollients for people with eczema has not yet been fully realised. The current guidance is confusing and does not make it sufficiently clear that GPs can – and should – prescribe leave-on emollients for people with long-term inflammatory conditions, including eczema. We will continue working with other dermatology organisations, led by the Dermatology Council of England and British Association of Dermatologists, to press for the agreed clarification guidance to be issued to prescribers and commissioners.

In other influencing activity, the Society continues to work with the Medicines and Healthcare Products Regulatory Agency (MHRA) to support the Agency's communication programme to raise awareness of fire risks of emollients. Emollient packaging now comes with fire warning labels. Emollients are not flammable in themselves, or when they are on the skin. However, if bedding, clothing or dressings containing dried emollient residue catches fire (from a naked flame), they burn more quickly and intensely.

In October, the Society awarded a £10,000 grant for an important new research study, to investigate the impact of sleep disturbance on children with eczema and their families. It is the first time the charity has directly funded eczema research for some years and we are considering funding more studies in future. Many children experience disturbed sleep, especially when eczema is severe. Sleep disturbance causes tiredness, which in turn affects children's ability to concentrate, their mood and general well-being. The impact on parents caring for children with eczema can be profound too. The project is being led by Dr Connor Broderick and Professor Carsten Flohr, from St John's Institute of Dermatology at Guys and St Thomas' Hospital in London, working with colleagues at other universities and hospitals in the UK. The Society has collaborated with the UK Dermatology Clinical Trials Network to award this research grant.

Awareness raising, communications and campaigning

The charity undertakes a range of activities to raise awareness and understanding of eczema among the general public, and to promote the information and advice the Society provides for people living with eczema and their families.

The theme for National Eczema Week in September was 'My Eczema Story', when we called on people living with eczema to share their experiences of living with the condition. Eczema is different for every person who lives with this debilitating long-term condition. Through sharing experiences, ideas and top tips, we sought to help others feel they are not alone. The physical symptoms of eczema can be extremely difficult, including the relentless itching and having to cope with raw, inflamed and bleeding skin. The hidden cost of eczema is the profound impact it can have on people's emotional well-being.

TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2021

To support the campaign we produced a series of very personal, emotive and practical short videos of National Eczema Society members and eczema advocates, which we promoted across our social media channels. We are very grateful to everyone who took part, and special thanks are due to radio DJ Yasmin Evans for supporting the campaign

Alongside the campaign, we introduced a range of new information resources to help people manage eczema as effectively as possible. These 'My Eczema Toolkit' resources offer practical advice to support people with the many psychological and emotional challenges of living with eczema described so vividly by those sharing their eczema story during the campaign.

We achieved excellent campaign coverage, including several prominent articles on the BBC website, and stories in many regional and some national newspapers. Engagement on social media was excellent too. We are especially grateful to our courageous patient advocate Kymmene Dawson, who once again shared her challenging experiences of eczema in the media. The Society contributed to the media launch of Eli Lilly's #GOALS eczema management initiative and chief executive Andrew Proctor took part in several radio interviews related to this initiative during National Eczema Week.

We continued to grow our social media reach and activity during the year, reflecting how people increasingly seek and share information about eczema. The Society now has over 22,000 followers on Facebook, an increase of over 2000 over the year, and we grew our following on Twitter to over 8,000. We more than doubled the number of Instagram followers over the year, to reach 7,700 by the end of 2021.

Capacity constraints and competing priorities continued to impact on the media work we are able to undertake. The Society provided press comment on a number of eczema stories in the media over the year, and we again focussed our media engagement around National Eczema Week.

Growing income and building financial sustainability

In 2021, we continued to focus income generation to ensure we have the resources to achieve our charitable objectives and build future financial sustainability. We are immensely grateful to our thoughtful and generous supporters who choose to leave a gift to National Eczema Society in their Will. Our income from legacies in 2021 was once again higher than in some previous years, and this has been so important in building a stronger financial footing for the Society during a period of uncertainty.

We continue to develop partnerships with companies that share our values and are willing to support our work and engage in joint education and awareness-raising activity. During the year AbbVie, Eli Lilly, Johnson & Johnson, LEO Pharma, Sanofi and Thornton & Ross were all corporate members.

There were many fundraising highlights during the year and also challenges as a result of the impact of Covid. We were pleased to see the return of the London Marathon, staged in October, and we are grateful to NES runners Joe Jones and Dexy-Lea Palmer for taking on the race and raising much-needed funds for the Society.

The Society's West Surrey and North-East Hampshire Support Group was able to undertake local fundraising activity again, following the relaxation of Covid restrictions, and presented a cheque for £2,000 at the Annual General Meeting in September. The Society's members and donors generously supported our summer and Christmas fundraising appeals once again and we are grateful to everyone who supported the Society in different ways with their donations over what has been another challenging year with Covid.

TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2021

Organisational development

During the year, we reviewed our understanding and organisational approach to equality, diversity and inclusion, and are working towards better representing and serving all communities of people who are affected by eczema. We have a particular focus on recruitment, and we proactively encourage people to apply for staff and volunteer roles who contribute different perspectives and lived experience.

We successfully completed a major project to update our supporter database software, which also saw us move to a more secure cloud-based hosting solution.

We built our staff team and leadership capacity with the appointment in December of Samantha Skelding as Deputy Chief Executive.

Trustees agreed new vision and mission statements for the charity, which are:

Vision: Our vision is a world free of eczema.

Mission: We make life better for people with eczema and their families. We do this by providing the information, advice and emotional support needed to manage eczema well. We also create a healthier future by raising awareness and understanding of eczema, campaigning for improvements in care, and supporting research into new treatments and prevention.

2022 Plans and development priorities

Looking ahead, we aim to ensure National Eczema Society continues to achieve the greatest impact we can for members and others living with eczema. The charity's core charitable work will continue, as well as taking forward strategically important activity including building our digital capability, our fundraising, supporting research and strengthening our work to improve eczema care.

Development priorities for 2022 include:

Deliver information and advice

- Developing and launching an online forum on the Society's website to provide peer support for people affected by eczema.
- Scope and introduce a WhatsApp channel and an instant messaging option on the Society's website for advice enquiries.
- Work in partnership with St John's DermAcademy to co-produce and deliver eczema information webinars.

Patient voice

- Contribute patient perspectives to clinical guideline development and the assessment of new treatments and policy consultations, working with regulatory bodies including the MHRA, NICE and the SMC.
- Continue to be a campaigning voice for people with eczema, to challenge inequalities in health policy and practice.

TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2021

Communications and awareness raising

- Lead the annual national flagship awareness event, National Eczema Week in September.

Research and patient involvement

- Grow our organisational capacity to support patient and public involvement in shaping eczema research.

Organisation and governance

- Strengthen our work and approach to equality, diversity and inclusion.

Financial Results

We planned for a budget surplus in 2021, consistent with our strategic intention to achieve a balanced or surplus budget on an ongoing basis. We have actually achieved a more substantial surplus than budgeted, largely as a result of better than expected income from legacy gifts.

The outcome for the year was a surplus of £185,322. This compares with a surplus of £186,521 in the year ended 31 December 2020. At 31 December 2021, our reserves had increased to £721,691 (£536,369 at 31 December 2020).

We would like to thank the many people who, as in previous years, by joining or renewing their membership, supporting our appeals and fundraising in a variety of often innovative ways, have enabled us to continue our work. The efforts and contribution of supporters and volunteers is invaluable to the Society. We are grateful also to those who remembered the Society in their Wills, the charitable trusts and companies that have supported us during the year, and to all the healthcare professionals who have provided us with so much time, advice and support especially members of the Medical Advisory Board.

Reserves Policy

The trustees aim to maintain free reserves in unrestricted funds at a level which equates to approximately six months unrestricted charitable expenditure. The trustees consider that this level will provide sufficient funds to respond to unforeseen loss of income and give the charity time to build alternative sources of income, restructure activities or close or merge the charity. The trustees have reviewed the Reserves Policy in 2022 to ensure it remains appropriate and sufficient given the nature of the Society's income and historical trends, and have determined that it is often appropriate to hold a larger reserve as legacy income in particular can be significant in size and unpredictable in timing, and it does not match the more even flow of the Society's expenditure.

The balance held in unrestricted funds at 31 December 2021 was £719,953 of which £699,114 is regarded as free reserves, after allowing for funds tied up in tangible assets and those funds allocated for specific purposes. As budgeted six-month expenditure over January-June 2022 totals approximately £241,300, current reserves are now well ahead of the amount required in the Reserves Policy. Noting this surplus and normal sustainable levels of expenditure, the trustees intend to designate amounts beyond those needed to maintain the agreed minimum reserve, for the purposes of research. A particular focus of our research interest will be the poorly understood issue of topical steroid withdrawal.

TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2021

Risk Management

The trustees have taken steps to identify and address major risks facing the Society, including maintaining a risk register. The principal uncertainty in respect to the Society's future is the ability to maintain sufficient income to deliver the charity's services, and ensure the Society has adequate resources to comply with regulatory changes affecting the voluntary sector. Greater focus and investment are being directed to fundraising activities, to ensure the Society generates sufficient income each year to fund planned activities.

The principal risk of financial sustainability for the charity is closely monitored by the trustees on a regular basis, including reviewing management accounts at quarterly Board meetings. Attention also continues to focus on non-financial risks including health and safety, reputation, security, confidentiality and data protection, which are supported by appropriate policies and procedures as well as management updates as needed.

Investment Policy

All surplus funds are currently placed on deposit.

The Trustees and Organisation

The Society is a charitable company. Although called trustees, we are the directors of the company for the purposes of company law. The trustees who served during the year and up to the date of this report are given on page 1.

The Society's governance processes are set out in its Articles of Association. The Board of Trustees administers the Society, which meets routinely four times a year and additionally as circumstances demand. A chief executive is appointed by the trustees to manage the day-to-day operations of the Society within a framework agreed by the Board.

There must be a minimum of three trustees but there is no maximum number, and trustees must be elected by the members of the Society at its Annual General Meeting (AGM). Trustees may be co-opted onto the Board during the year and must then stand for election by the members at the next AGM. At least a third of trustees are required to retire from office each year but may, if they wish, offer themselves for re-election at the AGM. Trustees are recruited through the Society's membership, local support groups, other eczema community networks and open advertising. In seeking trustees, the Society has regard of the need to ensure that the Trustee Board has an appropriate range of professional skills and experience, reflects our commitment to diversity, and also that trustees are drawn from different areas of the UK.

Although not constitutionally binding, the Society wishes to work towards aligning with the Charity Governance Code, which recommends trustees serve fixed terms in office. The guidance recommends trustees serve an initial three-year term, with the possibility of being re-elected by members for a further three-year period. Trustees in particular roles (e.g. Chair, Treasurer) could serve a longer nine-year period, subject to formal review.

New trustees are provided with an introduction pack, which includes the Society's governing documents, copies of the past year's accounts, and a briefing on their duties and responsibilities and of the Society's governance processes. Prior to joining the Board, new trustees will usually attend at least one Board meeting in an observer capacity, which gives them the opportunity to meet the trustees and chief executive.

TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2021

During the year, the decision was taken to recruit several new trustees with the aim of refreshing and enhancing the collective professional skills of the Board, and strengthening the diversity of our governance. The trustee opportunity was promoted to the Society membership, other supporters and wider eczema community. We opted for an open, competitive recruitment process. Following shortlisting and interview by a sub-committee of trustees, it was decided to appoint four candidates as new trustees, namely Hannah Kunzlik, Dr Simon Lovegrove, Bharat Pandya and Hedwig Vollers. All four appointees attended the March 2022 Board meeting as observers, after which they were confirmed in post.

Trustees receive no remuneration and no trustee has a beneficial interest in any of the group companies.

In June 2021, the Society established a Medical Advisory Board (MAB) comprised of healthcare professionals who act in an advisory and ambassadorial capacity for the charity. Members volunteer their time and are all experienced healthcare professionals who work in the field of dermatology, and who have a particular professional interest in eczema management and research. The MAB is chaired by National Eczema Society Trustee, Professor Celia Moss OBE.

The trustees set the remuneration of the chief executive and approve the remuneration of other Society staff. Remuneration levels are based on research of similar roles and benchmark salary data.

Trustees took the decision to de-register with the Office of the Scottish Charity Regulator (OSCR) and the process was completed in October 2022. It is not a regulatory requirement for National Eczema Society to be registered in Scotland and de-registering helps reduce the Society's administrative and operating costs. Although no longer registered with OSCR, National Eczema Society continues to provide advice and support for the benefit of everyone affected by eczema in the UK.

Covid statement and response

National Eczema Society has been able to maintain its core services and other charitable activities during the Coronavirus pandemic period (as of June 2022), most of which are delivered remotely including our valued Eczema Helpline service. This has required changes in the way the charity operates, with staff now routinely working remotely at home. We have invested in our IT and cloud computing capability to support remote working and now have an effective hybrid working model. We have been cautious with planning to re-introduce face-to-face events, and have taken the decision not to organise such events again in 2022.

The Society benefits from a diverse range of income sources and is therefore more resilient to significant unexpected events like Covid. Rising inflation in 2022 will present challenges, in both managing costs and achieving income targets. Legacies are a significant element of the Society's overall income mix, and we expect legacy income to be lower in 2022 than previous years, although this is factored into our planning. Members, other individual donors and corporate partners have continued their support during the pandemic. We expect some traditional income sources to be stronger in 2022, including income from challenge events and we have factored this into our budgeting. Hence, while remaining vigilant to the changeable external environment, the trustees do not have reason to be concerned over the continued financial sustainability of the charity from the immediate and longer-term economic impact of Covid. As referenced earlier, the trustees are reviewing the Reserves Policy in 2022 to ensure it continues to meet current and known future requirements.

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2021

The Trustees Report has been prepared in accordance with the provisions applicable to entities subject to the small companies regime.

This report was approved by the Board of Trustees on
8 August 2022 and signed on their behalf by:



.....
Stephen Pugh
Chair

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

STATEMENT OF TRUSTEES' RESPONSIBILITIES
FOR THE YEAR ENDED 31 DECEMBER 2021

The Trustees (who are also the directors of the Charity for the purposes of company law) are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the Trustees to prepare financial statements for each financial year. Under company law, the Trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the Group and the Charity and of their incoming resources and application of resources, including their income and expenditure, for that period. In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles of the Charities SORP (FRS 102);
- make judgements and accounting estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards (FRS 102) have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Group will continue in business.

The Trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the Group and the Charity's transactions and disclose with reasonable accuracy at any time the financial position of the Group and the Charity and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the Group and the Charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Approved by order of the Members of the Board of Trustees and signed on its behalf by:



.....
Stephen Pugh
Chair
Date: 08/08/2022

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

INDEPENDENT EXAMINER'S REPORT
FOR THE YEAR ENDED 31 DECEMBER 2021

Independent Examiner's Report to the Trustees of National Eczema Society ('the Group')

I report to the Charity Trustees on my examination of the consolidated accounts of the Group, set out on pages 15 to 47, comprising the National Eczema Society ('the parent Charity') and its subsidiary undertakings for the year ended 31 December 2021.

Responsibilities and Basis of Report

As the Trustees of the parent Charity (and its Directors for the purposes of company law) you are responsible for the preparation of the consolidated accounts of the Group in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the consolidated accounts are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of the Group's accounts as carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

Independent Examiner's Statement

Since the Group's gross income exceeded £250,000 your examiner must be a member of a body listed in section 145 of the 2011 Act. I confirm that I am qualified to undertake the examination because I am a member of the Institute of Chartered Accountants in England and Wales, which is one of the listed bodies.


I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe in any material respect:

1. accounting records were not kept in respect of the parent Charity and its subsidiaries as required by section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a 'true and fair' view which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

INDEPENDENT EXAMINER'S REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2021

Signed: 

Dated: 15/08/2022

Stuart McKay BSc FCA DChA

MHA MacIntyre Hudson
Chartered Accountants
London, United Kingdom

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

CONSOLIDATED STATEMENT OF FINANCIAL ACTIVITIES (INCORPORATING INCOME AND EXPENDITURE ACCOUNT)
FOR THE YEAR ENDED 31 DECEMBER 2021

	Note	Unrestricted funds 2021 £	Restricted funds 2021 £	Total funds 2021 £	Total funds 2020 £
Income from:					
Donations and legacies	4	528,134	-	528,134	545,887
Other trading activities:	5				
Income from fundraising		4,921	-	4,921	1,321
Income from trading activities		1,801	-	1,801	1,809
Investments	6	856	-	856	2,143
Total income		535,712	-	535,712	551,160
Expenditure on:					
Raising funds:	7				
Fundraising costs		12,828	-	12,828	54,690
Trading costs		-	-	-	15
Other raising funds		19,976	-	19,976	-
Charitable activities	8,9	340,975	10,750	351,725	308,813
Total expenditure		373,779	10,750	384,529	363,518
Net movement in funds before other recognised gains		161,933	(10,750)	151,183	187,642
Other recognised gains/(losses):					
Gains/(losses) on pension scheme	19	34,139	-	34,139	(1,121)
Net movement in funds		196,072	(10,750)	185,322	186,521
Reconciliation of funds:					
Total funds brought forward		523,881	12,488	536,369	349,848
Net movement in funds		196,072	(10,750)	185,322	186,521
Total funds carried forward		719,953	1,738	721,691	536,369

The Consolidated Statement of Financial Activities includes all gains and losses recognised in the year. All income and expenditure derive from continuing activities.

The notes on pages 21 to 46 form part of these financial statements.

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)
REGISTERED NUMBER: 02685083

CONSOLIDATED BALANCE SHEET
AS AT 31 DECEMBER 2021

	Note	2021 £	2021 £	2020 £	2020 £
Fixed assets					
Intangible assets	14		8,832		15,828
Tangible assets	15		27,886		38,052
			36,718		53,880
Current assets					
Debtors: Amounts falling due within one year	17	159,515		90,598	
Cash at bank and in hand	23	649,260		597,755	
		808,775		688,353	
Creditors: Amounts falling due within one year	18	(115,028)		(156,001)	
Net current assets			693,747		532,352
Total assets less current liabilities			730,465		586,232
Creditors: Amounts falling due after more than one year	19		(8,774)		(49,863)
Total net assets			721,691		536,369
Group funds					
Restricted funds	20		1,738		12,488
Unrestricted funds	20		719,953		523,881
Total funds			721,691		536,369

The Charity was entitled to exemption from audit under section 477 of the Companies Act 2006.

The Members have not required the company to obtain an audit for the year in question in accordance with section 476 of Companies Act 2006.

The Trustees acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to entities subject to the small companies regime.

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)
REGISTERED NUMBER: 02685083

CONSOLIDATED BALANCE SHEET (CONTINUED)
AS AT 31 DECEMBER 2021

The financial statements were approved and authorised for issue by the Trustees and signed on their behalf by:



.....
Stephen Pugh
Chair
Date: 8 August 2022

The notes on pages 21 to 46 form part of these financial statements.

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)
REGISTERED NUMBER: 02685083

CHARITY BALANCE SHEET
AS AT 31 DECEMBER 2021

	Note	2021 £	2021 £	2020 £	2020 £
Fixed assets					
Intangible assets	14		8,832		15,828
Tangible assets	15		27,886		38,052
Investments	16		100		100
			36,818		53,980
Current assets					
Debtors: Amounts falling due within one year	17	211,072		136,435	
Cash at bank and in hand		624,435		577,251	
		835,507		713,686	
Creditors: Amounts falling due within one year	18	(113,228)		(156,001)	
Net current assets			722,279		557,685
Total assets less current liabilities			759,097		611,665
Creditors: Amounts falling due after more than one year	19		(8,774)		(49,863)
Net assets excluding pension asset			750,323		561,802
Total net assets			750,323		561,802
Charity funds					
Restricted funds	20		1,738		10,753
Unrestricted funds	20		748,585		551,049
Total funds			750,323		561,802

The Charity's net movement in funds for the year was £188,521 (2020 - £189,727).

The Charity was entitled to exemption from audit under section 477 of the Companies Act 2006.

The Members have not required the company to obtain an audit for the year in question in accordance with section 476 of Companies Act 2006.

The Trustees acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and preparation of financial statements.

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)
REGISTERED NUMBER: 02685083

CHARITY BALANCE SHEET (CONTINUED)
AS AT 31 DECEMBER 2021

The financial statements have been prepared in accordance with the provisions applicable to entities subject to the small companies regime.

The financial statements were approved and authorised for issue by the Trustees and signed on their behalf by:



.....
Stephen Pugh
Chair
Date: 8 August 2022

The notes on pages 21 to 46 form part of these financial statements.

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

CONSOLIDATED STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED 31 DECEMBER 2021

	Note	2021 £	2020 £
Cash flows from operating activities			
Net cash used in operating activities	22	52,795	180,039
Cash flows from investing activities			
Investment income	6	856	2,143
Purchase of intangible assets		-	(7,920)
Purchase of tangible fixed assets	15	(2,146)	(15,438)
Net cash used in investing activities		(1,290)	(21,215)
Change in cash and cash equivalents in the year		51,505	158,824
Cash and cash equivalents at the beginning of the year		597,755	438,931
Cash and cash equivalents at the end of the year	23	649,260	597,755

The notes on pages 21 to 46 form part of these financial statements.

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2021

1. General information

National Eczema Society is a charitable company limited by guarantee and is registered with the Registrar of Companies (Company Registered Number: 02685083), the Charity Commission in England and Wales (Charity Registered Number: 1009671). The Charity deregistered from the Office of the Scottish Charity Regulator (OSCR) on 15th October 2021.

In the event of the Charity being wound up, the liability in respect of the guarantee is limited to £1 per Member of the Charity.

The address of the registered office is given in the Charity information on page 1 of these financial statements. The nature of the Charity's operations and principal activities are detailed in the Trustees' Report.

The significant accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all years presented unless otherwise stated.

2. Accounting policies

2.1 Basis of preparation of financial statements

The financial statements have been prepared in accordance with the Charities SORP (FRS 102) - Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

National Eczema Society meets the definition of a public benefit entity under FRS 102.

Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy. The financial statements are prepared in sterling which is the functional and presentational currency of the Group and are rounded to the nearest pound.

The Consolidated Statement of Financial Activities (SOFA) and Consolidated Balance Sheet consolidate the financial statements of the Charity and its subsidiary undertaking. The results of the subsidiary are consolidated on a line by line basis.

2.2 Going concern

The Trustees have assessed the use of going concern and have considered possible events or conditions that might cast significant doubt on the ability of the Group to continue as a going concern. The Trustees have made this assessment for a period of at least one year from the date of the approval of these financial statements. The Trustees have concluded that there is a reasonable expectation that the Group has adequate resources to continue in operational existence for the foreseeable future, and that no material uncertainties exist. The Group therefore continues to adopt the going concern basis in preparing these financial statements.

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2021

2. Accounting policies (continued)

2.3 Income

All income is recognised once the Group has entitlement to the income, it is probable that the income will be received and the amount of income receivable can be measured reliably.

For donations and gift aid to be recognised the Group will have been notified of the amounts and the settlement date in writing. If there are conditions attached to the donation and this requires a level of performance before entitlement can be obtained then income is deferred until those conditions are fully met or the fulfilment of those conditions is within the control of the Group and it is probable that they will be fulfilled.

The recognition of income from legacies is dependent on establishing entitlement, the probability of receipt and the ability to estimate with sufficient accuracy the amount receivable. Evidence of entitlement to a legacy exists when the Group has sufficient evidence that a gift has been left to them (through knowledge of the existence of a valid will and the death of the benefactor) and the executor is satisfied that the property in question will not be required to satisfy claims in the estate. Receipt of a legacy must be recognised when it is probable that it will be received and the fair value of the amount receivable, which will generally be the expected cash amount to be distributed to the Group, can be reliably measured.

Subscription income is received in full and recognised evenly over the course of the subscription. The amount recognised in the Consolidated Statement of Financial Activities relates to the financial period in question.

Income from trading activities includes income earned from fundraising events and trading activities to raise funds for the Group. Income is received in exchange for supplying goods and services in order to raise funds and is recognised when entitlement has occurred.

2.4 Expenditure

All expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all costs related to the categories. Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Central staff costs are allocated on the basis of time spent, and depreciation charges allocated on the portion of the asset's use.

Expenditure on charitable activities is incurred on directly undertaking the activities which further the Group's objectives, as well as any associated support costs.

All expenditure is inclusive of irrecoverable VAT.

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2021

2. Accounting policies (continued)

2.5 Interest receivable

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the Group; this is normally upon notification of the interest paid or payable by the institution with whom the funds are deposited.

2.6 Taxation

The Charity is considered to pass the tests set out in Paragraph 1 Schedule 6 of the Finance Act 2010 and therefore it meets the definition of a charitable company for UK corporation tax purposes. Accordingly, the Charity is potentially exempt from taxation in respect of income or capital gains received within categories covered by Chapter 3 Part 11 of the Corporation Tax Act 2010 or Section 256 of the Taxation of Chargeable Gains Act 1992, to the extent that such income or gains are applied exclusively to charitable purposes.

2.7 Intangible assets and amortisation

Intangible assets costing £500 or more are capitalised and recognised when future economic benefits are probable and the cost or value of the asset can be measured reliably.

Intangible assets are initially recognised at cost. After recognition, under the cost model, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

Amortisation is provided on intangible assets at rates calculated to write off the cost of each asset on a straight-line basis over 3 years.

Assets under construction are not amortised until ready for use.

2.8 Tangible fixed assets and depreciation

Tangible fixed assets costing £500 or more are capitalised and recognised when future economic benefits are probable and the cost or value of the asset can be measured reliably.

Tangible fixed assets are initially recognised at cost. After recognition, under the cost model, tangible fixed assets are measured at cost less accumulated depreciation and any accumulated impairment losses. All costs incurred to bring a tangible fixed asset into its intended working condition should be included in the measurement of cost.

At each reporting date the Group assesses whether there is any indication of impairment. If such indication exists, the recoverable amount of the asset is determined to be the higher of its fair value less costs to sell and its value in use. An impairment loss is recognised where the carrying amount exceeds the recoverable amount.

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2021

2. Accounting policies (continued)

2.8 Tangible fixed assets and depreciation (continued)

Depreciation is charged so as to allocate the cost of tangible fixed assets less their residual value over their estimated useful lives, using the straight-line method.

Depreciation is provided on the following bases:

Leasehold improvements	- over 10 years
Furniture and fittings	- over 10 years
Office equipment	- over 10 years
Computer equipment	- over 3 years

2.9 Investments

The investment in the subsidiary company is valued at cost less provision for impairment.

2.10 Debtors

Trade and other debtors are recognised at the settlement amount after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

2.11 Cash at bank and in hand

Cash at bank and in hand includes cash and short-term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

2.12 Liabilities and provisions

Liabilities are recognised when there is an obligation at the Balance Sheet date as a result of a past event, it is probable that a transfer of economic benefit will be required in settlement, and the amount of the settlement can be estimated reliably.

Liabilities are recognised at the amount that the Group anticipates it will pay to settle the debt or the amount it has received as advanced payments for the goods or services it must provide.

Provisions are measured at the best estimate of the amounts required to settle the obligation. Where the effect of the time value of money is material, the provision is based on the present value of those amounts, discounted at the pre-tax discount rate that reflects the risks specific to the liability. The unwinding of the discount is recognised in the Consolidated Statement of Financial Activities as a finance cost.

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2021

2. Accounting policies (continued)

2.13 Financial instruments

The Group only holds basic Financial Instruments. The financial assets and financial liabilities of the Group are as follows:

Debtors – other debtors are basic financial instruments and are debt instruments measured at amortised cost as detailed in Note 17.

Cash at bank – is classified as a basic financial instrument and is measured at face value.

Liabilities – accruals are classified as financial instruments, and are measured at amortised cost as detailed in Notes 18 and 19.

2.14 Operating leases

Rentals paid under operating leases are charged to the Consolidated Statement of Financial Activities on a straight line basis over the lease term.

2.15 Pensions

The Group is part of the Series 3 Growth Plan which is a multi-employer pension Scheme which closed in 2013. The Scheme administrators have confirmed that it is not possible to separately identify the assets and liabilities of participating employers on a consistent and reasonable basis. The assets of the Scheme are co-mingled for investment purposes and benefits are paid from total Scheme assets. A deficit reduction plan has been agreed.

The Group accounts for its participation in this Plan as a defined contribution plan, as there is insufficient information available to account for this as a defined benefit plan, as the share of its assets and liabilities cannot be identified.

To avoid crystallizing an immediate payment of the apparent under-funding in the Series 3 Scheme, the Group is participating in the Series 3 Recovery Plan and the liability is included in Notes 17 and 18. The Group recognises its liability to make payments to fund the deficit relating to past service under an agreement to make those payments. It recognises the full liability for the present value of contributions payable that results from the agreement for funding the multi employer plan.

The Group also participates in a defined contribution pension scheme for its employees. The Group pays fixed contributions into a separate scheme. Once the defined contribution payments have been made, the Group has no further payment obligations in respect of this scheme. The contributions are recognised as an expense in the Consolidated Statement of Financial Activities as they fall due.

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2021

2. Accounting policies (continued)

2.16 Fund accounting

General funds are unrestricted funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the Group and which have not been designated for other purposes.

Designated funds comprise unrestricted funds that have been set aside by the Trustees for particular purposes. The aim and use of each designated fund is set out in the notes to the financial statements.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the Group for particular purposes. The costs of raising and administering such funds are charged against the specific fund. The aim and use of each restricted fund is set out in the notes to the financial statements.

Investment income, gains and losses are allocated to the appropriate fund.

3. Critical accounting estimates and areas of judgement

Estimates and judgements are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

Critical accounting estimates and assumptions:

The Group makes estimates and assumptions concerning the future. The resulting accounting estimates and assumptions will, by definition, seldom equal the related actual results. The estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are listed below.

- Allocation of support costs
- Depreciation rates for tangible fixed assets
- Useful economic lives of assets
- The discount rate used in valuing the year-end Pension Scheme deficit.

The Board do not consider the Covid-19 pandemic to have had a material impact on these accounting estimates and areas of judgement.

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2021

4. Income from donations and legacies

	Unrestricted funds 2021 £	Restricted funds 2021 £	Total funds 2021 £
Donations and similar income	174,348	-	174,348
Legacies	181,302	-	181,302
Subscriptions	150,978	-	150,978
Gift aid	21,506	-	21,506
Total 2021	528,134	-	528,134

	Unrestricted funds 2020 £	Restricted funds 2020 £	Total funds 2020 £
Donations and similar income	143,976	28,810	172,786
Legacies	199,306	-	199,306
Subscriptions	149,389	-	149,389
Gift aid	24,406	-	24,406
Total 2020	517,077	28,810	545,887

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2021

5. Income from other trading activities

Income from fundraising events

	Unrestricted funds 2021 £	Total funds 2021 £
Other corporate income	1,607	1,607
Other activities	3,314	3,314
Total 2021	<u><u>4,921</u></u>	<u><u>4,921</u></u>

	Unrestricted funds 2020 £	Total funds 2020 £
Other corporate income	587	587
Other activities	734	734
Total 2020	<u><u>1,321</u></u>	<u><u>1,321</u></u>

Income from trading activities

	Unrestricted funds 2021 £	Total funds 2021 £
Trading subsidiary	<u><u>1,801</u></u>	<u><u>1,801</u></u>

	Unrestricted funds 2020 £	Total funds 2020 £
Trading subsidiary	<u><u>1,809</u></u>	<u><u>1,809</u></u>

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2021

6. Income from investments

	Unrestricted funds 2021 £	Total funds 2021 £
Bank interest receivable	<u>856</u>	<u>856</u>

	Unrestricted funds 2020 £	Total funds 2020 £
Bank interest receivable	<u>2,143</u>	<u>2,143</u>

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2021

7. Expenditure on raising funds

	2021 £	2020 £
Fundraising costs		
Direct costs	27,431	28,685
Support costs	5,373	26,005
	<u>32,804</u>	<u>54,690</u>

Analysis of support costs - fundraising costs

	2021 £	2020 £
Staff costs	1,539	7,390
Depreciation	663	2,044
Premises costs	779	3,388
Carriage and postage	174	889
Professional fees	560	2,086
Bought-in services	30	498
Website, database and computing	541	3,082
Other costs	700	4,349
Governance costs	387	2,279
	<u>5,373</u>	<u>26,005</u>

	2021 £	2020 £
Trading costs		
Trading subsidiary - Direct costs	<u>-</u>	<u>15</u>

In both the current and previous financial years all Expenditure on raising funds was from Unrestricted funds.

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2021

8. Analysis of expenditure on charitable activities - by fund

	Unrestricted funds 2021 £	Restricted funds 2021 £	Total funds 2021 £
Helpline	106,899	-	106,899
Membership services	160,938	-	160,938
Information services	73,138	10,750	83,888
Total 2021	340,975	10,750	351,725

	Unrestricted funds 2020 £	Restricted funds 2020 £	Total funds 2020 £
Helpline	97,641	-	97,641
Membership services	120,172	-	120,172
Information services	73,925	17,075	91,000
Total 2020	291,738	17,075	308,813

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2021

9. Analysis of expenditure on charitable activities - by type

	Activities undertaken directly 2021 £	Support costs 2021 £	Total funds 2021 £
Helpline	64,245	42,654	106,899
Membership services	85,626	75,312	160,938
Information services	44,631	39,257	83,888
Total 2021	194,502	157,223	351,725

	Activities undertaken directly 2020 £	Support costs 2020 £	Total funds 2020 £
Helpline	50,806	46,835	97,641
Membership services	63,047	57,125	120,172
Information services	47,743	43,257	91,000
Total 2020	161,596	147,217	308,813

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2021

9. Analysis of expenditure on charitable activities - by type (continued)

Analysis of support costs

	Total funds 2021 £	Total funds 2020 £
Staff costs	49,310	41,608
Depreciation	18,645	11,506
Premises costs	21,884	19,077
Carriage and postage	4,888	5,003
Professional fees	15,743	11,746
Bought-in services	845	2,802
Website, database and computing	15,212	17,354
Other costs	19,819	25,290
Governance costs	10,877	12,831
	157,223	147,217

10. Governance costs

	2021 £	2020 £
Auditors' remuneration	-	9,000
Independent Examiner's remuneration	5,505	-
Rent & rates	(670)	(602)
Insurance	6,386	6,151
Trustees expenses	-	30
Legal & professional fees	-	504
General office expenses	43	27
	11,264	15,110

Total Governance costs above comprise £387 (2020 - £2,279) of Expenditure on raising funds and £10,877 (2020 - £12,831) of Expenditure on charitable activities.

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2021

11. Auditors' and Independent examiner's remuneration

	2021 £	2020 £
Auditors' remuneration - Audit of the Group and the Trading Subsidiary	-	9,540
Auditors' remuneration - Preparation of the statutory accounts for the Group and the Trading Subsidiary	-	2,100
Independent Examiner's remuneration - Examination of the financial statements	5,505	-
	<u><u>5,505</u></u>	<u><u>-</u></u>

12. Staff costs

	Group 2021 £	Group 2020 £	Charity 2021 £	Charity 2020 £
Wages and salaries	159,739	154,610	159,739	154,610
Social security costs	13,067	12,728	13,067	12,728
Pension costs	6,857	7,010	6,857	7,010
	<u><u>179,663</u></u>	<u><u>174,348</u></u>	<u><u>179,663</u></u>	<u><u>174,348</u></u>

The average number of persons employed by the Group during the year was as follows:

	Group 2021 No.	Group 2020 No.
Direct charitable activities	2	2
Fundraising and communication	1	1
Support and governance	1	1
	<u><u>4</u></u>	<u><u>4</u></u>

The number of employees whose employee benefits received (excluding employer pension costs) exceeded £60,000 was:

	Group 2021 No.	Group 2020 No.
In the band £60,001 - £70,000	1	1

The total amount of employee benefits, including employers national insurance and pension contributions, received by Key Management Personnel is £72,305 (2020 - £72,330). The Charity considers its Key Management Personnel comprise the Trustees and the Chief Executive Officer.

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2021

13. Trustees' remuneration and expenses

During the year, no Trustees received any remuneration or other benefits (2020 - £NIL).

During the year ended 31 December 2021, No expenses were reimbursed or paid directly to any Trustee (2020 - £30 to 2 Trustees).

14. Intangible assets

Group and Charity

	Website £
Cost	
At 1 January 2021	20,988
At 31 December 2021	<u>20,988</u>
Amortisation	
At 1 January 2021	5,160
Charge for the year	6,996
At 31 December 2021	<u>12,156</u>
Net book value	
At 31 December 2021	<u><u>8,832</u></u>
At 31 December 2020	<u><u>15,828</u></u>

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2021

15. Tangible fixed assets

Group and Charity

	Leasehold improvements £	Furniture and fixtures £	Office equipment £	Computer equipment £	Total £
Cost or valuation					
At 1 January 2021	41,470	2,493	3,873	22,043	69,879
Additions	-	-	-	2,146	2,146
At 31 December 2021	41,470	2,493	3,873	24,189	72,025
Depreciation					
At 1 January 2021	21,784	1,430	1,950	6,663	31,827
Charge for the year	4,147	249	388	7,528	12,312
At 31 December 2021	25,931	1,679	2,338	14,191	44,139
Net book value					
At 31 December 2021	15,539	814	1,535	9,998	27,886
At 31 December 2020	19,686	1,063	1,923	15,380	38,052

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2021

16. Fixed asset investments

Charity	Investment in subsidiary company £
Cost or valuation	
At 1 January 2021	100
At 31 December 2021	100

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2021

16. Fixed asset investments (continued)

Principal subsidiaries

The following was a subsidiary undertaking of the Charity:

Name	Company number	Registered office or principal place of business	Holding	Included in consolidation
Eczema Trading Limited	06895048	11 Murray Street, London, NW1 9RE	100%	Yes

The financial results of the subsidiary for the year were:

Name	Income £	Expenditure £	Loss for the year £	Net liabilities £
Eczema Trading Limited	1,801	(5,000)	(3,199)	(28,532)

The results of Eczema Trading Limited are included in these consolidated accounts. Eczema Trading Limited did not meet the audit threshold and therefore did not require an audit for the year ended 31 December 2021.

The deficit relates to intercompany management charges and minimal advertising revenue. Eczema Trading Limited was more active in the past when National Eczema Society had substantive trading operations, primarily selling Christmas cards. Currently, only the limited advertising revenue from our quarterly membership magazine is accounted for in Eczema Trading Limited. The Society keeps under review possible future activities that might constitute trading and so considers it appropriate to retain Eczema Trading Limited for the time being.

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2021

17. Debtors

	Group 2021 £	Group 2020 £	Charity 2021 £	Charity 2020 £
Due within one year				
Trade debtors	24,500	30,840	24,500	30,840
Amounts owed by group undertakings	-	-	51,557	45,837
Other debtors	124,611	48,047	124,611	48,047
Prepayments and accrued income	10,404	11,711	10,404	11,711
	159,515	90,598	211,072	136,435

18. Creditors: Amounts falling due within one year

	Group 2021 £	Group 2020 £	Charity 2021 £	Charity 2020 £
Trade creditors	4,821	6,004	4,821	6,004
Other taxation and social security	12,761	12,571	12,761	12,571
Other creditors	7,770	15,490	7,770	15,490
Accruals and deferred income	89,676	121,936	87,876	121,936
	115,028	156,001	113,228	156,001

	Group 2021 £	Group 2020 £	Charity 2021 £	Charity 2020 £
Deferred income				
Deferred income at 1 January	103,016	85,119	103,016	83,319
Resources deferred during the year	75,422	103,016	73,622	103,016
Amounts released from previous periods	(103,016)	(85,119)	(103,016)	(83,319)
Deferred income at 31 December	75,422	103,016	73,622	103,016

Deferred income consists of membership income relating to future periods.

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2021

19. Creditors: Amounts falling due after more than one year

	Group 2021	Group 2020	Charity 2021	Charity 2020
	£	£	£	£
Pension Scheme deficit	8,774	49,863	8,774	49,863

The Charity is participating in a recovery plan to eliminate its Series 3 scheme deficit over a ten year period. The Pensions Trust, the scheme administrator, has however advised that the amount of employer debt on the alternative of withdrawal from the Series 3 scheme has been estimated by actuaries to have been £200,161 as at 31 December 2016. As the Charity intends to continue participating in the recovery plan, no provision has been made for this potential withdrawal debt however, the Society accounted for the present value of all remaining contributions under the recovery plan in the 2017 accounts at their present value of £120,000, as advised by the scheme administrator. This liability has been adjusted annually to unwind the relevant discount applied.

In order to meet their share of the shortfall, the Charity has been asked to pay additional contributions to the scheme until 2025. A full actuarial valuation was carried out by the actuaries at 30 September 2017 and the funding shortfall calculated at that date gave rise to a remeasurement reduction of £15,624 in the deficit as at 31 December 2018. The deficit of the scheme is £15,879 (2020 - £65,196) at 31 December 2021. The payment by the Charity in the year was £15,333 (2020 - £14,887) with an interest payment of £155 (2020 - £794) and a remeasurement expense of (£180) (2020 - £1,121).

In addition, the Charity elected to switch, with effect from 1 October 2013, from Series 3 to Series 4, a defined contribution scheme. The pension cost in the accounts represents amounts payable by the charity as ordinary employer contributions to the Series 4 defined contribution fund.

During the year employer contributions of £6,858 (2020 - £7,010), interest of £155 (2020 - £794), actuarial (gains)/losses of (£180) (2020 - £1,121) and remeasurements for amendments to the contribution schedule of (£33,959) (2020 - £NIL) have been charged to the Consolidated Statement of Financial Activities. There were no accrued contributions at 31 December 2021 (2020 - £NIL) but there is a liability of £15,879 (2020 - £65,196) for future contributions under the Series 3 Recovery Plan. Of this £7,105 (2020 - £15,333) is reported in Creditors: Amounts falling due within one year as part of Other creditors and £8,774 (2020 - £49,863) is reported in Creditors: Amounts falling due after more then one year.

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2021

20. Statement of funds

Statement of funds - current year

	Balance at 1 January 2021 £	Income £	Expenditure £	Transfers in/out £	Gains/ (Losses) £	Balance at 31 December 2021 £
Unrestricted funds						
Designated funds						
Fixed asset fund	53,880	-	(19,308)	2,146	-	36,718
Pension reserve	(65,196)	-	(155)	15,333	34,139	(15,879)
	<u>(11,316)</u>	<u>-</u>	<u>(19,463)</u>	<u>17,479</u>	<u>34,139</u>	<u>20,839</u>
General funds						
General funds	<u>535,197</u>	<u>535,712</u>	<u>(354,316)</u>	<u>(17,479)</u>	<u>-</u>	<u>699,114</u>
Total Unrestricted funds	<u>523,881</u>	<u>535,712</u>	<u>(373,779)</u>	<u>-</u>	<u>34,139</u>	<u>719,953</u>
Restricted funds						
Research	<u>12,488</u>	<u>-</u>	<u>(10,750)</u>	<u>-</u>	<u>-</u>	<u>1,738</u>
Total of funds	<u><u>536,369</u></u>	<u><u>535,712</u></u>	<u><u>(384,529)</u></u>	<u><u>-</u></u>	<u><u>34,139</u></u>	<u><u>721,691</u></u>

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2021

20. Statement of funds (continued)

Statement of funds - prior year

	Balance at 1 January 2020 £	Income £	Expenditure £	Transfers in/out £	Gains/ (Losses) £	Balance at 31 December 2020 £
Unrestricted funds						
Designated funds						
Fixed asset fund	44,072	-	(13,550)	23,358	-	53,880
Pension reserve	(78,168)	-	(794)	14,887	(1,121)	(65,196)
	<u>(34,096)</u>	<u>-</u>	<u>(14,344)</u>	<u>38,245</u>	<u>(1,121)</u>	<u>(11,316)</u>
General funds						
General funds	<u>383,191</u>	<u>522,350</u>	<u>(332,099)</u>	<u>(38,245)</u>	<u>-</u>	<u>535,197</u>
Total Unrestricted funds	<u>349,095</u>	<u>522,350</u>	<u>(346,443)</u>	<u>-</u>	<u>(1,121)</u>	<u>523,881</u>
Restricted funds						
Research	753	11,735	-	-	-	12,488
ThankQ	-	13,800	(13,800)	-	-	-
Laptops	-	3,275	(3,275)	-	-	-
	<u>753</u>	<u>28,810</u>	<u>(17,075)</u>	<u>-</u>	<u>-</u>	<u>12,488</u>
Total of funds	<u>349,848</u>	<u>551,160</u>	<u>(363,518)</u>	<u>-</u>	<u>(1,121)</u>	<u>536,369</u>

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2021**

20. Statement of funds (continued)

Designated funds

The Pension reserve has been established to show the future pension deficit payments in regards to a defined benefit pension scheme. This pension scheme is being treated as a defined contribution pension scheme as a reliable estimate cannot be made of the liability at the year end. The transfer of £15,333 was made to separate the deficit payments due as at 31 December 2021 from the Unrestricted general fund. Actuarial gains / (losses) are charged to this fund as they arise.

The Fixed asset fund has been established to reflect the funds tied up in Tangible and Intangible fixed assets and agrees back to the Net Book Value presented on the Consolidated Balance Sheet. The transfer of £2,146 was made to represent capital additions during the year. Depreciation is charged to this fund as expenditure.

Unrestricted funds

General funds reflects funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the Charity and which have not been designated for other purposes.

Restricted funds

The Research fund exists to provide resources for research into the causes of Eczema, with the aim of developing more effective treatments or a cure.

The Society is grateful to two corporate members, Abbvie and Sanofi, which provided restricted funding to upgrade the Society's supporter database software, ThankQ, and implement cloud-based hosting. This work was essential in supporting more efficient remote working by the staff team, which was needed in response to the Covid-19 pandemic. The Society is grateful to the British Association of Dermatologists who provided funding for the software licence and hosting fees for the first year of use of the Society's upgraded supporter database.

The Society is grateful to the company Almirall, which provided restricted funding for new laptop computers and related costs, needed to facilitate home working by the staff team in response to the Covid-19 pandemic.

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2021

21. Analysis of net assets between funds

Analysis of net assets between funds - current year

	Unrestricted funds 2021 £	Restricted funds 2021 £	Total funds 2021 £
Tangible fixed assets	27,886	-	27,886
Intangible fixed assets	8,832	-	8,832
Current assets	807,037	1,738	808,775
Creditors due within one year	(115,028)	-	(115,028)
Creditors due in more than one year	(8,774)	-	(8,774)
Total	719,953	1,738	721,691

Analysis of net assets between funds - prior year

	Unrestricted funds 2020 £	Restricted funds 2020 £	Total funds 2020 £
Tangible fixed assets	38,052	-	38,052
Intangible fixed assets	15,828	-	15,828
Current assets	675,865	12,488	688,353
Creditors due within one year	(156,001)	-	(156,001)
Creditors due in more than one year	(49,863)	-	(49,863)
Total	523,881	12,488	536,369

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2021

22. Reconciliation of net movement in funds to net cash flow from operating activities

		Group 2021 £	Group 2020 £
Net income for the year (as per Statement of Financial Activities)		151,183	187,642
Adjustments for:			
Depreciation charges	15	12,312	8,390
Amortisation charges	14	6,996	5,160
Investment income	6	(856)	(2,143)
Increase in debtors	17	(114,754)	(26,950)
(Decrease)/increase in creditors	18	(2,086)	7,940
Net cash provided by operating activities		52,795	180,039

23. Analysis of cash and cash equivalents

	Group 2021 £	Group 2020 £
Cash in hand	649,260	597,755
Total cash and cash equivalents	649,260	597,755

24. Analysis of changes in net debt

	At 1 January 2021 £	Cash flows £	At 31 December 2021 £
Cash at bank and in hand	597,755	51,505	649,260
	597,755	51,505	649,260

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2021

25. Operating lease commitments

At 31 December 2021 the Group and the Charity had commitments to make future minimum lease payments under non-cancellable operating leases as follows:

	Group 2021 £	Group 2020 £	Charity 2021 £	Charity 2020 £
Not later than 1 year	21,000	20,833	21,000	20,833
Later than 1 year and not later than 5 years	46,333	66,500	46,333	66,500
	67,333	87,333	67,333	87,333

The following lease payments have been recognised as an expense in the Consolidated Statement of Financial Activities:

	Group 2021 £	Group 2020 £	Charity 2021 £	Charity 2020 £
Operating lease rentals	20,833	20,000	20,833	20,000

26. Related party transactions

In the year ended 31 December 2021, donations of £1,200 (2020 - £NIL) were made by 1 Trustee (2020 - None) to the Charity.

Accounts

Company Registered Number: 02685083
Charity Registered Numbers (England & Wales and Scotland): 1009671 & SCO43669

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

TRUSTEES' REPORT AND FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2020



NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

CONTENTS

	Page
Reference and Administrative Details of the Charity, its Trustees and Advisers	1
Trustees' Report	2 - 11
Statement of Trustees' Responsibilities	12
Independent Auditors' Report on the Financial Statements	13 - 16
Consolidated Statement of Financial Activities	17
Charity Statement of Financial Activities	18
Consolidated Balance Sheet	19
Charity Balance Sheet	20
Consolidated Statement of Cash Flows	21
Notes to the Financial Statements	22 - 48

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

**REFERENCE AND ADMINISTRATIVE DETAILS OF THE CHARITY, ITS TRUSTEES AND ADVISERS
FOR THE YEAR ENDED 31 DECEMBER 2020**

Trustees	Edward Davies, Chair Ellen Vincent, Vice Chair Stephen Pugh, Treasurer Alexis Brooke (resigned 17 June 2020) Myrtle Johnston Suzanne Watson Catherine Escott Dr Celia Moss James Pitayanukul (appointed 18 March 2020)
Company registered number	02685083
Charity registered numbers	1009671 and SCO43669
Registered office	11 Murray Street London NW1 9RE
Chief executive officer & Company secretary	Andrew Proctor
Independent auditors	MHA MacIntyre Hudson Chartered Accountants Statutory Auditor 6th Floor 2 London Wall Place London EC2Y 5AU
Principal Bankers	CAF Bank Ltd National Westminster Bank plc Barclays Bank plc
Status and Governing Document	National Eczema Society is a charitable company, limited by guarantee. It was incorporated on 6 February 1992 and registered as a charity on 10 March 1992. It is governed by its Articles of Association.
Subsidiary Companies	Eczema Trading Limited

TRUSTEES' REPORT
FOR THE YEAR ENDED 31 DECEMBER 2020

The Trustees present their Annual Report together with the financial statements of the Group and the Charity for the year 1 January 2020 to 31 December 2020. The Trustees confirm that the Annual Report and financial statements of the company comply with the current statutory requirements, the requirements of the company's governing document and the provisions of the Statement of Recommended Practice (SORP), applicable to Charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102). Since the Charity and the Group qualifies as small under section 383, the strategic report required of medium and large companies under The Companies Act 2006 (Strategic Report and Director's Report) Regulations 2013 is not required.

Purpose and aims

National Eczema Society was established in 1975 to support people with eczema and their families and to work on their behalf. We remain dedicated to these founding principles and today we continue to help people across the UK with evidence-based information and advice about eczema and its management. We deliver this in various ways through our website, social media channels, publications and nurse-supported Helpline. We also provide a collective voice for people with eczema, to inform research and influence health policy to improve care and raise greater awareness and understanding of the condition among people affected by eczema and the wider public.

The prevalence of eczema has increased over recent decades, and around one in five children and one in ten adults are now impacted by this life-challenging condition in the UK. While the reasons for the increase are not fully understood, it does mean the Charity's services are needed more than ever. Our support has been especially valuable for many during the Coronavirus pandemic, when access to healthcare was more difficult for many. There is as yet no cure for eczema and, unless you have the condition, it can be hard to imagine the daily challenge of living with relentless itching and inflamed, painful skin. Many healthcare professionals have limited dermatology training and timely access to specialist dermatology healthcare for people with eczema can sometimes be difficult. National Eczema Society aims to provide the information and support needed for people to self-manage their eczema effectively, to become experts in their own care, and provide the reassurance of knowing they are not on their own.

Ensuring our work delivers our charitable aims

We review our activities each year and monitor the impact of our work to ensure we continue to fulfil our purpose of supporting people affected by eczema. Among other ways, we assess the Society's performance and achievements through the number of people we have helped with information and advice, and the quality and consistency of the resources we provide.

We consider how planned activities will contribute to the aims and objectives we have set, and in doing this we have referred to the Charity Commission's general guidance on public benefit. We have had regard to the legislative and regulatory requirements for disclosing how our charitable objectives have provided such benefit, and complied with the duty set out in section 4 of the Charities Act 2011 and that set out by the Office of the Scottish Charity Regulator in the Trustee Investment (Scotland) Act 2005.

2020 Activity and achievements – delivering public benefit

All our charitable activities focus on supporting people affected by eczema and championing their needs, and further our charitable purposes for the public benefit. Here we present a summary of the Society's work over the year.

TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2020

Impact of Coronavirus pandemic

The Society's plans for 2020 were impacted significantly by the Coronavirus pandemic and we needed to quickly readjust to meet the challenges of implementing remote working and service delivery. Great credit and thanks are due to the staff team, Trustees, volunteers and suppliers who went the extra mile to maintain the Society's services and operations in difficult circumstances. We are also grateful to our members for their patience when we needed more time than usual to manage membership enquiries and renewals.

Routine home-working for staff was introduced in March and this more flexible working approach was successful and will be continued after Covid restrictions are lifted. Like many organisations, we moved to virtual meetings in response to the pandemic and held our 2020 AGM using the videoconferencing platform Zoom. We also invested in our IT and systems to support effective remote working. The Society is grateful to two corporate members, Abbvie and Sanofi, and the British Association of Dermatologists, for providing financial support to allow us to upgrade our database software and implement cloud hosting. Another corporate partner, Almirall, provided support for the Society to purchase laptops for staff.

We took the difficult decision to postpone or cancel face-to-face events during 2020, or reconfigure to deliver virtually, in order to comply with Government advice on travel and gatherings. Although disappointing, it was the right thing to do to stay safe. The Society's Helpline, website and social media communications continued operating as usual throughout the lockdowns. Helpline enquiries increased significantly in March-June and a greater proportion of questions were more complex in nature. As might be expected, we also received many routine coronavirus-related questions around hand washing and hand care, as well as more searching questions about shielding and risk. The Society worked with a number of professional bodies including the National Institute of Health and Care Excellence (NICE) to provide information for medical guidance on eczema and Covid.

Coronavirus also affected some of our fundraising activity, notably challenge events and community fundraising. Sponsorship income from supporters taking part in the virtual London Marathon was lower than usual, and many other mass participation events during the year were cancelled. We are grateful to our members and supporters for being so generous with their donations during the year, at a time of uncertainty for many over jobs and livelihoods.

Delivering information and advice for people living with eczema

The Society continues to provide a wide range of high quality, evidence-based information and advice about eczema and its management for people living with the condition and their families.

Our eczema Helpline is at the heart of the Society's work, enabling the Charity to provide the independent advice and reassurance needed by people struggling to cope with eczema wherever they live in the UK. We receive around 1,600 telephone, email and message enquiries a year from parents of children with eczema and adults living with the condition. These cover a wide range of questions about eczema symptoms and treatments, from the latest biologic drugs to eczema-friendly clothing. We offer a dermatology nurse call-back service for people who have more complex enquiries, and around 40% of callers are helped by one of our experienced dermatology nurse advisers. Our Helpline is available free of charge to anyone affected by eczema in the UK who needs our support.

TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2020

Alongside our Helpline, the Society produces a wide range of patient information booklets and factsheets about eczema management and treatment, available online and in print. We distribute printed copies at events the Charity organises and attends, and we provide healthcare professionals with free-of-charge bulk copies of our printed publications, for onward distribution to patients in hospital dermatology clinics and other healthcare settings.

National Eczema Society factsheets and booklets are updated regularly on a rolling review cycle and checked by healthcare professionals to ensure the information is accurate and up-to-date. We updated and reprinted a number of our publications over the year, including our Living with Eczema guide for adults. We continue to raise awareness of local volunteer-led patient support groups, by providing information and a presence for these groups on the Society's website. Unfortunately, because of Covid restrictions, the information talk planned by the Society's West Surrey and North-East Hampshire Support Group had to be postponed, where Dr George Moncrieff was due to speak about the causes of eczema and latest thinking on eczema care.

We publish all our eczema information on the Society's website, which attracted nearly 500,000 users in the first year since its launch, and we promote health advice messages through our social media channels, media engagement and other external communications.

NES membership scheme

National Eczema Society is a membership organisation and we are very grateful to our 2,400 members who support the Society through their annual membership fee and additional donations. Members receive our quarterly magazine Exchange, which features expert information and news about eczema. Members are also encouraged to attend the Society's Annual General Meeting and contribute their ideas on the running of the Charity. As in previous years, support for our Charity extends far beyond our membership and we remain grateful to all our donors, and to those members who continue to support us financially even though they no longer have any personal need of our help.

Following a long period of no change, in February we increased the annual membership fee for individuals from £20 to £25 per annum. It is reassuring that members have been understanding of the need for the fee increase.

Representing patient views

As the national patient organisation for people with eczema, the Society plays a leading role in providing a collective voice to champion the needs of those affected by the condition. We seek to improve health outcomes for people with eczema by influencing health policy and participating in groups like the All Party Parliamentary Group on Skin (APPGS) and working with professional bodies like the British Association of Dermatologists. Policy influencing opportunities were limited during the year due to Covid, but where possible we used our campaigning voice to challenge health inequalities including the lack of mental health services for people with skin conditions.

We continued to grow our organisational capacity to support patient involvement in shaping research. NES is approached regularly by researchers seeking patient views and to learn from patient experiences. It is so encouraging to see such a range of research underway and new treatments in the pipeline, following a long period when eczema was largely overlooked. The Society is actively supporting eczema research by participating in study steering groups, providing patient perspectives on research trials, and working with universities and companies that are assessing and developing new drug treatments. We do this to help ensure eczema research has the greatest chance of success in finding new treatments and ultimately a cure.

TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2020

We also contribute a patient perspective to clinical guideline development, the assessment of new treatments, and policy consultations. During the year, we contributed a patient perspective and evidence to the National Institute of Health and Care Excellence (NICE) for its assessment of several new drugs for eczema, including a new type of JAK-inhibitor drug called Baricitinib to treat people with moderate-to-severe eczema.

National Eczema Society has been working hard behind the scenes to continue pressing NHS England and NHS Improvement to clarify their prescribing guidance on emollients. Emollients are essential for managing eczema as reflected in clinical guidelines. We have been working on this initiative alongside other dermatology organisations, led by the Dermatology Council of England and British Association of Dermatologists.

The current guidance is confusing and does not make it sufficiently clear that GPs can – and should – prescribe leave-on emollients for people with long-term inflammatory conditions, including eczema. Some local health commissioners in England have interpreted the guidance incorrectly, making it harder for GPs to prescribe emollients for eczema. This has caused real hardship for people who have been unable to get emollients on prescription or in the quantities they need.

We are therefore delighted that NHS England has agreed to issue new clarification guidance making clear that leave-on emollients should be offered on NHS prescription for people with eczema. Discussions have taken much longer than we wanted, but we believe the new clarification guidance will be very helpful for patients when advocating with their GPs for the emollients they need to manage their eczema. This guidance also makes clear that GPs can prescribe bath and shower preparations when medically appropriate.

The Society was pleased to contribute to a major new report on mental health and skin disease, published in September 2020 by the All Party Parliamentary Group on Skin (APPGS). The report includes several powerful quotes from people with eczema, including the Society's patient ambassador Shal Henry-Treloar. The report reinforced many of the findings of the Society's Eczema Unmasked campaign, which showed the profound impact of eczema on people's mental health.

In other influencing activity, the Society worked with the Medicines and Healthcare Products Regulatory Agency (MHRA) to support the launch of fire warning labels on emollient packaging. Emollients are not flammable in themselves, or when they are on the skin. However, if bedding, clothing or dressings containing dried emollient residue catches fire (from a naked flame), they burn more quickly and intensely.

There is much we still do not know about eczema, what causes it and how best to manage it. More research is needed to provide the answers, which is why the Society took the decision in 2020 to start funding research. This was the theme of our Christmas fundraising appeal. We are working with the UK Dermatology Clinical Trials Network, a group of leading dermatologists, dermatology nurses and health services researchers, which has an established research programme. The Society will support the most promising research ideas for improving eczema care for children by providing a £10,000 grant to fund a pilot or feasibility study. We expect to make the award in late 2021. The British Society of Paediatric Dermatology is also supporting this joint research call and is providing a separate funding award.

TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2020

Awareness raising, communications and campaigning

The Charity undertakes a range of activities to raise awareness and understanding of eczema among the general public, and to promote the information and advice the Society provides for people living with eczema and their families.

Our hard-hitting Eczema Unmasked campaign hit the national headlines during National Eczema Week in September 2020. We wanted to raise awareness of what it is truly like to live with eczema and dispel the myth that eczema is only a minor skin complaint. Using data from a large patient survey, we showed that eczema can profoundly affect people's physical and mental health, quality of life and even their life chances. We wanted the campaign to encourage people to start talking more about how they are affected by eczema and help break down the isolation that can come from the daily grind of living with a painful long-term condition.

We achieved excellent campaign coverage, including a spot on BBC Breakfast TV, several articles on the BBC website, and stories in many regional and some national newspapers. Engagement on social media was excellent too. We are grateful to dermatologist Professor Andrew Wright, who lent his support to the campaign, and to our courageous patient advocates Anna, Kymmene, Suzanne and Nicola who shared their experiences of eczema in the media. Due to Coronavirus restrictions, we did not encourage eczema awareness activity in hospital dermatology clinics this year, or organise face-to-face eczema information events.

We continued to increase our social media reach and activity during the year, reflecting how people increasingly seek and share information about eczema. The Society has over 20,000 followers on Facebook, an increase of 1571 over the year, and grew our support on Twitter. We also began posting on Instagram in February and the Society had attracted over 3000 Instagram followers by the end of 2020.

Capacity constraints and competing priorities continued to impact on the media work we are able to undertake. The Society provided press comment on a number of eczema stories in the media over the year, and focussed our media engagement around National Eczema Week. We secured excellent media coverage for the Eczema Unmasked campaign at a time when it was hard to get attention for non-Covid health stories.

Following many months of planning and preparation, we launched the Society's new website in March, just before the first of the Covid lockdowns were implemented. The website is a core digital capability, on which to build the Society's reach and impact. We worked with digital agency Bluestone365 to design the site.

Growing income and building financial sustainability

In 2020 we continued to focus on growing our income to ensure we have the resources to achieve our charitable objectives and to build future financial sustainability.

We are immensely grateful to our thoughtful and generous supporters who choose to leave a gift to National Eczema Society in their Will. Our income from legacies in 2020 was once again considerably higher than in many previous years, and this has been so important in building a stronger financial footing for the Society during a period of change.

TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2020

We continue to develop partnerships with companies that share our aims and are willing to support our work and engage in joint education and awareness-raising activity. During the year AbbVie, Dermal Laboratories, Eli Lilly, Johnson & Johnson, LEO Pharma, Reckitt Benckiser (E45), Sanofi and Thornton & Ross were all corporate members. Among other initiatives, we were delighted to support Dermal Laboratories eczema information resources and work with LEO Pharma on the Eczema Unmasked survey and report.

There were many fundraising highlights during the year and also challenges as a result of the impact of Covid. One of our mainstay fundraising events, the London Marathon, was postponed until October because of Coronavirus concerns, and then was changed to a virtual event as it was considered too risky for so many people to gather around the iconic London route. We are grateful to NES runners Lucy Ellis and Karen Stephen for taking on the virtual challenge to raise much-needed funds for the Society. Many other events, like the Great North Run, were cancelled in 2020.

We were delighted to be awarded a grant of £60,000 from the Coronavirus Community Support Fund, to help finance our Helpline service during the pandemic. Our Helpline was busier than ever supporting people with the additional challenges and worries of managing their eczema during the pandemic. The Coronavirus Community Support Fund, distributed by The National Lottery Community Fund, was created to help third-sector organisations continue to deliver much-needed information and support during the crisis. We are grateful to the Government for making this possible.

The Society's West Surrey and North-East Hampshire Support Group had to cancel most of their local fundraising activity because of Covid concerns, but were still able to present a cheque for £2,500 at the Annual General Meeting in September. The Society's members and donors generously supported our summer and Christmas fundraising appeals once again and we are grateful to everyone who supported the Society in different ways with their donations over what has been a challenging year for all with Covid.

2021 Plans and development priorities

Looking ahead, we aim to ensure National Eczema Society continues to achieve the greatest impact we can for members and others living with eczema. Our operating plan provides a strong platform to deliver our charitable programme, while retaining an appropriate level of reserves in accordance with the Society's reserves policy. The Charity's core charitable work will continue, along with strategically important activity including building our digital capability, our fundraising, supporting research and strengthening our patient voice.

Development priorities for 2021 include:

Information and advice

- Introduce a series of webinars for people affected by eczema covering different aspects of eczema care
- Develop plans for an online forum on the NES website to provide peer support for people affected by eczema
- Publish past editions of Exchange magazine on the Society's website, so content is available to help everyone affected by eczema.

TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2020

Patient voice

- Contribute with patient perspectives to clinical guideline development and the assessment of new treatments and policy consultations, working with regulatory bodies including the MHRA and NICE
- Continue to be a campaigning voice for people with eczema, to challenge inequalities in health policy and practice.

Communications and awareness-raising

- Lead the annual national flagship awareness event, National Eczema Week in September, with a focus on achieving strong media and social media coverage
- Introduce a monthly email newsletter for people with eczema, to provide regular information updates and highlight opportunities to support the Charity.

Research and patient involvement

- Grow our organisational capacity to support patient and public involvement in shaping eczema research, by building a panel of people with eczema who are willing to share their experience and views with researchers
- Provide funding for a £10,000 award for childhood eczema research, in association with the UK Dermatology Clinical Trials Network.

Income and commercial partnerships

- Prioritise fundraising development on securing grants from charitable trusts and foundations
- Develop and service partnerships with companies that share our values and are willing to support our work and engage in joint awareness-raising and educational activity.

Organisation and governance

- Undertake a strategy review to set priorities for the future direction of the Society
- Establish a multidisciplinary Medical Advisory Board to support and steer the Charity's work
- Review our approach and policy to support the Society's work towards greater equality, diversity and inclusion
- Complete the upgrade of our supporter database software.

Financial Results

We planned for a modest budget surplus in 2020, consistent with our strategic intention to move towards achieving a balanced or surplus budget on an ongoing basis. We have actually achieved a substantial surplus for the year, largely as a result of better than expected income from legacy gifts.

The outcome for the year for the Group was a surplus of £186,521. This compares with a modest surplus of £3,420 in the year ended 31 December 2019. At 31 December 2020 our reserves had increased to £536,369 (£349,848 at 31 December 2019).

The outcome for the year for the trading subsidiary was a net deficit of £3,206 (£2,448 at 31 December 2019). At 31 December 2020 the trading subsidiary had net liabilities of £25,333 (£22,127 at 31 December 2019).

TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2020

We would like to thank the many people who, as in previous years, by joining or renewing their membership, supporting our appeals and fundraising in a variety of often innovative ways, have enabled us to continue our work. The efforts and contribution of supporters and volunteers is invaluable to the Society. We are grateful also to those who remembered the Society in their Wills, the charitable trusts and companies that have supported us during the year, and to all the healthcare professionals who have provided us with so much time, advice and support.

Reserves Policy

The Trustees aim to maintain free reserves in unrestricted funds at a level, which equates to approximately six months unrestricted charitable expenditure. The Trustees consider that this level will provide sufficient funds to respond to unforeseen loss of income and give the Charity time to build alternative sources of income, restructure activities or close or merge the Charity. The Trustees consider that this level of six months is appropriate and sufficient given the recurring nature of the Society's core income and historical trends.

The balance held in unrestricted funds at 31 December 2020 was £523,881, of which £470,001 is regarded as free reserves, after allowing for funds tied up in tangible assets and those funds allocated for specific purposes. Budgeted six-month expenditure over January-June 2021 totals approximately £227,352. The current level of reserves exceeds the amount needed, and the Society's plans and budget for 2021 and beyond reflect the opportunity to draw on reserves for in-year expenditure if required.

Risk Management

The Trustees have taken steps to identify and address major risks facing the Society. The principal uncertainty in respect to the Society's future is the ability to maintain sufficient income to deliver the Charity's services, and ensure the Society has adequate resources to comply with regulatory changes affecting the voluntary sector. Greater focus and investment are being directed to fundraising activities, to ensure the Society generates sufficient income each year to fund planned activities.

The principal risk of financial sustainability for the Charity is closely monitored by the Trustees on a regular basis, including reviewing management accounts at quarterly Board meetings. Attention also continues to focus on non-financial risks including health and safety, reputation, security, confidentiality and data protection, which are supported by appropriate policies and procedures as well as management updates as needed.

The Trustees and Organisation

The Society is a charitable company. Although called Trustees, members of our governing body are the Directors of the company for the purposes of company law. The Trustees who served during the year and up to the date of this report are given on page 1.

The Society's governance processes are set out in its Articles of Association. The Board of Trustees administers the Society, which meets routinely four times a year and additionally as circumstances demand. A chief executive is appointed by the Trustees to manage the day-to-day operations of the Society within a framework agreed by the Board.

TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2020

There must be a minimum of three Trustees but there is no maximum number, and Trustees must be elected by the members of the Society at its Annual General Meeting (AGM). Trustees may be co-opted onto the Board during the year and must then stand for election by the members at the next AGM. At least a third of Trustees are required to retire from office each year but may, if they wish, offer themselves for re-election at the AGM. Trustees are recruited through the Society's members' magazine, Exchange, local support groups and other supporter networks. In seeking Trustees, the Society has regard to the need to ensure that the Trustee Board has an appropriate range of professional skills and experience, reflects equality and diversity, and also that Trustees are drawn from different areas of the UK.

New Trustees are provided with an introduction pack, which includes the Society's governing documents, copies of past year's accounts, and a briefing on their duties and responsibilities and of the Society's governance processes. Prior to joining the Board, new Trustees will usually attend at least one Board meeting in an observer capacity, which gives them the opportunity to meet the Trustees and chief executive.

Ongoing training opportunities on Charity governance topics are available to Trustees, along with briefing updates from professional bodies and sector regulators including the Charity Commission.

Trustees receive no remuneration and no Trustee has a beneficial interest in any of the group companies.

The Trustees set the remuneration of the chief executive and approve the remuneration of other Society staff. Remuneration levels are based on research of similar roles and benchmark salary data.

Covid statement and response

National Eczema Society has been able to maintain its core services and other charitable activities during the Coronavirus crisis (as of June 2021), most of which are delivered remotely including our valued Eczema Helpline service. Demand has been higher as we strived to support people impacted most from Coronavirus. This has required changes in the way the Charity operates, with staff routinely now working remotely at home. We have invested in our IT and cloud computing capability to support remote working and now have an effective hybrid working model. We have been cautious with planning to re-introduce face-to-face events, and have taken the decision not to organise such events in 2021. We are now accelerating plans to develop new, remote ways of supporting people in response to the challenge of Covid. This reflects our core strategic objective of reaching and supporting many more people affected by eczema through digital channels.

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2020

The Society benefits from a diverse range of income sources and is therefore more resilient to significant unexpected events like Covid. Our legacy income will be significant again in 2021 from known bequests, and corporate partners have continued their support during the pandemic. We expect some traditional income sources to be lower again in 2021, including income from challenge events and donations from individuals, and we have factored this into our budget planning. Hence, while remaining vigilant to the volatile external environment, the Trustees do not have reason to be concerned over the continued financial sustainability of the Charity from the immediate and longer-term economic impact of Covid. Reflecting the expected financial position, the Trustees also do not consider it necessary at this time to amend the reserves policy or designate funds for a future Covid response.

This report was approved by the Board of Trustees on
signed on their behalf by:

and


.....
Stephen Pugh
Treasurer

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

STATEMENT OF TRUSTEES' RESPONSIBILITIES
FOR THE YEAR ENDED 31 DECEMBER 2020

The Trustees (who are also the Directors of the Charity for the purposes of company law) are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the Trustees to prepare financial statements for each financial year. Under company law, the Trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the Group and the Charity and of their incoming resources and application of resources, including their income and expenditure, for that period. In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles of the Charities SORP (FRS 102);
- make judgements and accounting estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards (FRS 102) have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Group will continue in business.

The Trustees are responsible for keeping adequate accounting records that disclose with reasonable accuracy at any time the financial position of the Group and enable them to ensure that the financial statements comply with the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 and the Charities Accounts (Scotland) Regulations 2006 (as amended). They are also responsible for safeguarding the assets of the Group and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

In so far as the Trustees are aware:

- there is no relevant audit information of which the Group's auditor is unaware; and
- the Trustees have taken all steps that they ought to have taken to make themselves aware of any relevant audit information and to establish that the auditor is aware of that information.

Approved by order of the Members of the Board of Trustees and signed on its behalf by:


.....
Stephen Pugh
Treasurer

Date: 16th June 2021

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF NATIONAL ECZEMA SOCIETY

Opinion

We have audited the financial statements of National Eczema Society (the 'parent charitable company') and its subsidiaries (the 'Group') for the year ended 31 December 2020 which comprise the Consolidated Statement of Financial Activities, the Consolidated Income and Expenditure Account, the Consolidated Balance Sheet, the Charity Balance Sheet, the Consolidated Statement of Cash Flows and the related notes, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the Group's and of the parent charitable company's affairs as at 31 December 2020 and of the Group's incoming resources and application of resources, including its income and expenditure for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006, Charities Act 2011, the Charities and Trustee Investment (Scotland) Act 2005 and regulations 6 and 8 of the Charities Accounts (Scotland) Regulations 2006.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the Group in accordance with the ethical requirements that are relevant to our audit of the financial statements in the United Kingdom, including the Financial Reporting Council's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the Trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the Group's or the parent charitable company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the Trustees with respect to going concern are described in the relevant sections of this report.

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF NATIONAL ECZEMA SOCIETY
(CONTINUED)

Other information

The Trustees are responsible for the other information. The other information comprises the information included in the Annual Report, other than the financial statements and our Auditors' Report thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Opinion on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the Trustees' Report for the financial year for which the financial statements are prepared is consistent with the financial statements.
- the Trustees' Report has been prepared in accordance with applicable legal requirements.

Matters on which we are required to report by exception

In the light of our knowledge and understanding of the Group and parent charitable company and its environment obtained in the course of the audit, we have not identified material misstatements in the Trustees' Report.

We have nothing to report in respect of the following matters in relation to which Companies Act 2006 and the Charities Accounts (Scotland) Regulations 2006 (as amended) require us to report to you if, in our opinion:

- the Group and parent charitable company has not kept adequate and sufficient accounting records, or returns adequate for our audit have not been received from branches not visited by us; or
- the Group and parent charitable company financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of Trustees' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit.

Responsibilities of Trustees

As explained more fully in the Statement of Trustees' Responsibilities, the Trustees (who are also the Directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the Trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF NATIONAL ECZEMA SOCIETY
(CONTINUED)

In preparing the financial statements, the Trustees are responsible for assessing the Group's and the parent charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Trustees either intend to liquidate the Group or the parent charitable company or to cease operations, or have no realistic alternative but to do so.

Auditors' responsibilities for the audit of the financial statements

We have been appointed as auditor under section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005 and under the Companies Act 2006 and report in accordance with the Act and relevant regulations made or having effect thereunder.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an Auditors' Report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists.

Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

- Enquiry of management and those charged with governance around actual and potential litigation and claims;
- Enquiry of staff in tax and compliance functions to identify any instances of non-compliance with laws and regulations;
- Performing audit work over the risk of management override of controls, including testing of journal entries and other adjustments for appropriateness, evaluating the business rationale of significant transactions outside the normal course of business and reviewing accounting estimates for bias;
- Reviewing minutes of meetings of those charged with governance; and
- Reviewing financial statement disclosures and testing to supporting documentation to assess compliance with applicable laws and regulations.

Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of non-compliance. The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission or misrepresentation.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our Auditors' Report.

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF NATIONAL ECZEMA SOCIETY
(CONTINUED)

Use of our report

This report is made solely to the charitable company's Members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006, and to the charitable company's Trustees, as a body, Part 4 of the Charities (Accounts and Reports) Regulations 2008 and regulation 10 of the Charities Accounts (Scotland) Regulations 2006. Our audit work has been undertaken so that we might state to the charitable company's Members those matters we are required to state to them in an Auditors' Report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and its Members, as a body, for our audit work, for this report, or for the opinions we have formed.



Stuart McKay BSc FCA DChA (Senior Statutory Auditor)

for and on behalf of

MHA MacIntyre Hudson

Chartered Accountants

Statutory Auditor

6th Floor

2 London Wall Place

London

EC2Y 5AU

Date: 19/08/2021

MHA MacIntyre Hudson are eligible to act as auditors in terms of section 1212 of the Companies Act 2006.

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

CONSOLIDATED STATEMENT OF FINANCIAL ACTIVITIES
FOR THE YEAR ENDED 31 DECEMBER 2020

	Note	Unrestricted funds 2020 £	Restricted funds 2020 £	Total funds 2020 £	Total funds 2019 £
Income from:					
Donations and legacies	4	517,077	28,810	545,887	415,656
Charitable activities	5	-	-	-	(60)
Other trading activities:	6				
Income from fundraising		1,321	-	1,321	10,196
Income from trading activities		1,809	-	1,809	3,612
Investments	7	2,143	-	2,143	1,323
Total income		522,350	28,810	551,160	430,727
Expenditure on:					
Raising funds:	8				
Fundraising costs		54,690	-	54,690	26,189
Trading costs		15	-	15	1,060
Charitable activities	9,10	291,738	17,075	308,813	398,857
Total expenditure		346,443	17,075	363,518	426,106
Net movement in funds before other recognised gains		175,907	11,735	187,642	4,621
Other recognised gains/(losses):					
Losses on pension scheme	20	(1,121)	-	(1,121)	(1,201)
Net movement in funds		174,786	11,735	186,521	3,420
Reconciliation of funds:					
Total funds brought forward		349,095	753	349,848	346,428
Net movement in funds		174,786	11,735	186,521	3,420
Total funds carried forward		523,881	12,488	536,369	349,848

The Consolidated Statement of Financial Activities includes all gains and losses recognised in the year. All income and expenditure derive from continuing activities.

The notes on pages 22 to 48 form part of these financial statements.

NATIONAL ECZEMA SOCIETY

(A Company Limited by Guarantee)

**CHARITY STATEMENT OF FINANCIAL ACTIVITIES (INCORPORATING INCOME AND EXPENDITURE ACCOUNT)
FOR THE YEAR ENDED 31 DECEMBER 2020**

	Unrestricted funds 2020 £	Restricted funds 2020 £	Total funds 2020 £	Total funds 2019 £
Income from:				
Donations and legacies	517,077	28,810	545,887	415,656
Charitable activities	-	-	-	(60)
Income from fundraising	6,321	-	6,321	15,196
Investments	2,143	-	2,143	1,323
Total income	525,541	28,810	554,351	432,115
Expenditure on:				
Fundraising costs	54,690	-	54,690	26,189
Charitable activities	291,738	17,075	308,813	398,857
Total expenditure	346,428	17,075	363,503	425,046
Net movement in funds before other recognised gains	179,113	11,735	190,848	7,069
Other recognised gains/(losses):				
Losses on pension scheme	(1,121)	-	(1,121)	(1,201)
Net movement in funds	177,992	11,735	189,727	5,868
Reconciliation of funds:				
Total funds brought forward	371,322	753	372,075	366,207
Net movement in funds	177,992	11,735	189,727	5,868
Total funds carried forward	549,314	12,488	561,802	372,075

The Charity Statement of Financial Activities includes all gains and losses recognised in the year. All income and expenditure derives from continuing activities.

The notes on pages 22 to 48 form part of these financial statements.

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)
REGISTERED NUMBER: 02685083

CONSOLIDATED BALANCE SHEET
AS AT 31 DECEMBER 2020

	Note	2020 £	2020 £	2019 £	2019 £
Fixed assets					
Intangible assets	15		15,828		13,068
Tangible assets	16		38,052		31,004
			<u>53,880</u>		<u>44,072</u>
Current assets					
Debtors	18	90,598		63,648	
Cash at bank and in hand	24	597,755		438,931	
		<u>688,353</u>		<u>502,579</u>	
Creditors: amounts falling due within one year	19	(156,001)		(133,522)	
Net current assets			<u>532,352</u>		<u>369,057</u>
Total assets less current liabilities			<u>586,232</u>		<u>413,129</u>
Creditors: amounts falling due after more than one year	20		(49,863)		(63,281)
Total net assets			<u><u>536,369</u></u>		<u><u>349,848</u></u>
Group funds					
Restricted funds	21		12,488		753
Unrestricted funds	21		523,881		349,095
Total funds			<u><u>536,369</u></u>		<u><u>349,848</u></u>

The Trustees acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to entities subject to the small companies regime.

The financial statements were approved and authorised for issue by the Trustees and signed on their behalf by:


Stephen Pugh

Treasurer

Date: 16 June 2021

The notes on pages 22 to 48 form part of these financial statements.

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)
REGISTERED NUMBER: 02685083


CHARITY BALANCE SHEET
AS AT 31 DECEMBER 2020

	Note	2020 £	2020 £	2019 £	2019 £
Fixed assets					
Intangible assets	15		15,828		13,068
Tangible assets	16		38,052		31,004
Investments	17		100		100
			<u>53,980</u>		<u>44,172</u>
Current assets					
Debtors	18	136,435		99,713	
Cash at bank and in hand	24	577,251		420,581	
		<u>713,686</u>		<u>520,294</u>	
Creditors: amounts falling due within one year	19	(156,001)		(129,110)	
Net current assets			<u>557,685</u>		<u>391,184</u>
Total assets less current liabilities			<u>611,665</u>		<u>435,356</u>
Creditors: amounts falling due after more than one year	20		(49,863)		(63,281)
Total net assets			<u><u>561,802</u></u>		<u><u>372,075</u></u>
Charity funds					
Restricted funds	21		10,753		753
Unrestricted funds	21		551,049		371,322
Total funds			<u><u>561,802</u></u>		<u><u>372,075</u></u>

The Trustees acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to entities subject to the small companies regime.

The financial statements were approved and authorised for issue by the Trustees and signed on their behalf by:


.....
Stephen Pugh, Treasurer

Date: 16th June 2021

The notes on pages 22 to 48 form part of these financial statements.

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

CONSOLIDATED STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED 31 DECEMBER 2020

	Note	2020 £	2019 £
Cash flows from operating activities			
Net cash used in operating activities	23	180,039	22,935
Cash flows from investing activities			
Investment income	7	2,143	1,323
Purchase of intangible assets	15	(7,920)	(13,068)
Purchase of tangible fixed assets	16	(15,438)	(4,804)
Net cash used in investing activities		(21,215)	(16,549)
Change in cash and cash equivalents in the year		158,824	6,386
Cash and cash equivalents at the beginning of the year		438,931	432,545
Cash and cash equivalents at the end of the year	24	597,755	438,931

The notes on pages 22 to 48 form part of these financial statements.

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2020

1. General information

National Eczema Society is a charitable company limited by guarantee and is registered with the Registrar of Companies (Company Registered Number: 02685083), the Charity Commission in England and Wales (Charity Registered Number: 1009671) and the Scottish Charity Regulator (Charity Registered Number: SCO43669).

In the event of the Charity being wound up, the liability in respect of the guarantee is limited to £1 per Member of the Charity.

The address of the registered office is given in the Charity information on page 1 of these financial statements. The nature of the Charity's operations and principal activities are detailed in the Trustees' Report.

The significant accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all years presented unless otherwise stated.

2. Accounting policies

2.1 Basis of preparation of financial statements

The financial statements have been prepared in accordance with the Charities SORP (FRS 102) - Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102), the Charities and Trustee Investment (Scotland) Act 2005, the Charities Accounts (Scotland) Regulations 2006 and the Companies Act 2006.

National Eczema Society meets the definition of a public benefit entity under FRS 102.

Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy. The financial statements are prepared in sterling which is the functional and presentational currency of the Group and are rounded to the nearest pound.

The Consolidated Statement of Financial Activities (SOFA) and Consolidated Balance Sheet consolidate the financial statements of the Charity and its subsidiary undertaking. The results of the subsidiary are consolidated on a line by line basis.

The Income and Expenditure Account for the year dealt with in the accounts of the Charity showed a surplus of £189,727 (2019: surplus of £5,868).

2.2 Going concern

The Trustees have assessed the use of going concern and have considered possible events or conditions that might cast significant doubt on the ability of the Group to continue as a going concern including the impact of COVID-19. The Trustees have made this assessment for a period of at least one year from the date of the approval of these financial statements. The Trustees have concluded that there is a reasonable expectation that the Group has adequate resources to continue in operational existence for the foreseeable future, and that no material uncertainties exist. The Group therefore continues to adopt the going concern basis in preparing these financial statements.

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2020

2. Accounting policies (continued)

2.3 Income

All income is recognised once the Group has entitlement to the income, it is probable that the income will be received and the amount of income receivable can be measured reliably.

For donations and gift aid to be recognised the Group will have been notified of the amounts and the settlement date in writing. If there are conditions attached to the donation and this requires a level of performance before entitlement can be obtained then income is deferred until those conditions are fully met or the fulfilment of those conditions is within the control of the Group and it is probable that they will be fulfilled.

The recognition of income from legacies is dependent on establishing entitlement, the probability of receipt and the ability to estimate with sufficient accuracy the amount receivable. Evidence of entitlement to a legacy exists when the Group has sufficient evidence that a gift has been left to them (through knowledge of the existence of a valid will and the death of the benefactor) and the executor is satisfied that the property in question will not be required to satisfy claims in the estate. Receipt of a legacy must be recognised when it is probable that it will be received and the fair value of the amount receivable, which will generally be the expected cash amount to be distributed to the Group, can be reliably measured.

Subscription income is received in full and recognised evenly over the course of the subscription. The amount recognised in the Consolidated Statement of Financial Activities relates to the financial period in question.

Income from trading activities includes income earned from fundraising events and trading activities to raise funds for the Group. Income is received in exchange for supplying goods and services in order to raise funds and is recognised when entitlement has occurred.

2.4 Expenditure

All expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all costs related to the categories. Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Central staff costs are allocated on the basis of time spent, and depreciation charges allocated on the portion of the asset's use.

Expenditure on raising funds includes all expenditure incurred by the Group to raise funds for its charitable purposes and includes costs of all fundraising activities events and non-charitable trading.

Expenditure on charitable activities is incurred on directly undertaking the activities which further the Group's objectives, as well as any associated support costs.

All expenditure is inclusive of irrecoverable VAT.

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2020

2. Accounting policies (continued)

2.5 Interest receivable

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the Group; this is normally upon notification of the interest paid or payable by the institution with whom the funds are deposited.

2.6 Taxation

The Charity is considered to pass the tests set out in Paragraph 1 Schedule 6 of the Finance Act 2010 and therefore it meets the definition of a charitable company for UK corporation tax purposes. Accordingly, the Charity is potentially exempt from taxation in respect of income or capital gains received within categories covered by Chapter 3 Part 11 of the Corporation Tax Act 2010 or Section 256 of the Taxation of Chargeable Gains Act 1992, to the extent that such income or gains are applied exclusively to charitable purposes.

2.7 Intangible assets and amortisation

Intangible assets costing £500 or more are capitalised and recognised when future economic benefits are probable and the cost or value of the asset can be measured reliably.

Intangible assets are initially recognised at cost. After recognition, under the cost model, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

Amortisation is provided on intangible assets at rates calculated to write off the cost of each asset on a straight-line basis over its expected useful life.

Assets under construction are not amortised until ready for use.

2.8 Tangible fixed assets and depreciation

Tangible fixed assets costing £500 or more are capitalised and recognised when future economic benefits are probable and the cost or value of the asset can be measured reliably.

Tangible fixed assets are initially recognised at cost. After recognition, under the cost model, tangible fixed assets are measured at cost less accumulated depreciation and any accumulated impairment losses. All costs incurred to bring a tangible fixed asset into its intended working condition should be included in the measurement of cost.

At each reporting date the Group assesses whether there is any indication of impairment. If such indication exists, the recoverable amount of the asset is determined to be the higher of its fair value less costs to sell and its value in use. An impairment loss is recognised where the carrying amount exceeds the recoverable amount.

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2020

2. Accounting policies (continued)

2.8 Tangible fixed assets and depreciation (continued)

Depreciation is charged so as to allocate the cost of tangible fixed assets less their residual value over their estimated useful lives, using the straight-line method.

Depreciation is provided on the following bases:

Leasehold improvements	- over 10 years
Furniture and fittings	- over 10 years
Office equipment	- over 10 years
Computer equipment	- over 3 years

2.9 Investments

The investment in the subsidiary company is valued at cost less provision for impairment.

2.10 Debtors

Trade and other debtors are recognised at the settlement amount after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

2.11 Cash at bank and in hand

Cash at bank and in hand includes cash and short-term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

2.12 Liabilities and provisions

Liabilities are recognised when there is an obligation at the Balance Sheet date as a result of a past event, it is probable that a transfer of economic benefit will be required in settlement, and the amount of the settlement can be estimated reliably.

Liabilities are recognised at the amount that the Group anticipates it will pay to settle the debt or the amount it has received as advanced payments for the goods or services it must provide.

Provisions are measured at the best estimate of the amounts required to settle the obligation. Where the effect of the time value of money is material, the provision is based on the present value of those amounts, discounted at the pre-tax discount rate that reflects the risks specific to the liability. The unwinding of the discount is recognised in the Consolidated Statement of Financial Activities as a finance cost.

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2020

2. Accounting policies (continued)

2.13 Financial instruments

The Group only holds basic Financial Instruments. The financial assets and financial liabilities of the Group are as follows:

Debtors – other debtors are basic financial instruments and are debt instruments measured at amortised cost as detailed in Note 18.

Cash at bank – is classified as a basic financial instrument and is measured at face value.

Liabilities – accruals are classified as financial instruments, and are measured at amortised cost as detailed in Notes 19 and 20.

2.14 Operating leases

Rentals paid under operating leases are charged to the Consolidated Statement of Financial Activities on a straight line basis over the lease term.

2.15 Pensions

The Group is part of the Series 3 Growth Plan which is a multi-employer pension Scheme which closed in 2013. The Scheme administrators have confirmed that it is not possible to separately identify the assets and liabilities of participating employers on a consistent and reasonable basis. The assets of the Scheme are co-mingled for investment purposes and benefits are paid from total Scheme assets. A deficit reduction plan has been agreed.

The Group accounts for its participation in this Plan as a defined contribution plan, as there is insufficient information available to account for this as a defined benefit plan, as the share of its assets and liabilities cannot be identified.

To avoid crystallizing an immediate payment of the apparent under-funding in the Series 3 Scheme, the Group is participating in the Series 3 Recovery Plan and the liability is included in Notes 17 and 18. The Group recognises its liability to make payments to fund the deficit relating to past service under an agreement to make those payments. It recognises the full liability for the present value of contributions payable that results from the agreement for funding the multi employer plan.

The Group also participates in a defined contribution pension scheme for its employees. The Group pays fixed contributions into a separate scheme. Once the defined contribution payments have been made, the Group has no further payment obligations in respect of this scheme. The contributions are recognised as an expense in the Consolidated Statement of Financial Activities as they fall due.

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2020

2. Accounting policies (continued)

2.16 Fund accounting

General funds are unrestricted funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the Group and which have not been designated for other purposes.

Designated funds comprise unrestricted funds that have been set aside by the Trustees for particular purposes. The aim and use of each designated fund is set out in the notes to the financial statements.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the Group for particular purposes. The costs of raising and administering such funds are charged against the specific fund. The aim and use of each restricted fund is set out in the notes to the financial statements.

Investment income, gains and losses are allocated to the appropriate fund.

3. Critical accounting estimates and areas of judgement

Estimates and judgements are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

Critical accounting estimates and assumptions:

The Group makes estimates and assumptions concerning the future. The resulting accounting estimates and assumptions will, by definition, seldom equal the related actual results. The estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are listed below.

- Allocation of support costs
- Depreciation rates for tangible fixed assets
- Useful economic lives of assets
- The discount rate used in valuing the year-end Pension Scheme deficit.

The Board do not consider the Covid-19 pandemic to have had a material impact on these accounting estimates and areas of judgement.

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2020

4. Income from donations and legacies

	Unrestricted funds 2020 £	Restricted funds 2020 £	Total funds 2020 £
Donations and similar income	143,976	28,810	172,786
Legacies	199,306	-	199,306
Subscriptions	149,389	-	149,389
Gift aid	24,406	-	24,406
Total 2020	517,077	28,810	545,887

	Unrestricted funds 2019 £	Total funds 2019 £
Donations and similar income	148,050	148,050
Legacies	140,897	140,897
Subscriptions	106,225	106,225
Gift aid	20,484	20,484
Total 2019	415,656	415,656

5. Income from charitable activities

		Total funds 2020 £
Membership services		-
	Unrestricted funds 2019 £	Total funds 2019 £
Membership services	(60)	(60)

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2020

6. Income from other trading activities

Income from fundraising events

	Unrestricted funds 2020 £	Total funds 2020 £
Other corporate income	587	587
Other activities	734	734
Total 2020	1,321	1,321

	Unrestricted funds 2019 £	Total funds 2019 £
Other corporate income	9,037	9,037
Other activities	1,159	1,159
Total 2019	10,196	10,196

Income from trading activities

	Unrestricted funds 2020 £	Total funds 2020 £
Trading subsidiary	1,809	1,809

	Unrestricted funds 2019 £	Total funds 2019 £
Trading subsidiary	3,612	3,612

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2020

7. Income from investments

	Unrestricted funds 2020 £	Total funds 2020 £
Bank interest receivable	<u>2,143</u>	<u>2,143</u>

	<i>Unrestricted funds 2019 £</i>	<i>Total funds 2019 £</i>
Bank interest receivable	<u>1,323</u>	<u>1,323</u>

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2020**

8. Expenditure on raising funds

	2020 £	2019 £
Fundraising costs		
Direct costs	28,685	5,499
Support costs	26,005	20,690
	<u>54,690</u>	<u>26,189</u>

Analysis of support costs - fundraising costs

	2020 £	2019 £
Staff costs	7,390	12,547
Depreciation	2,044	421
Premises costs	3,388	1,286
Carriage and postage	889	429
Design and print	-	198
Professional fees	2,086	1,361
Bought-in services	498	1,167
Website, database and computing	3,082	820
Other costs	4,349	1,826
Governance costs	2,279	635
	<u>26,005</u>	<u>20,690</u>

	2020 £	2019 £
Trading costs		
Trading subsidiary - Direct costs	<u>15</u>	<u>1,060</u>

In both the current and previous financial years all Expenditure on raising funds was from Unrestricted funds.

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2020

9. Analysis of expenditure on charitable activities - by fund

	Unrestricted funds 2020 £	Restricted funds 2020 £	Total funds 2020 £
Helpline	97,641	-	97,641
Membership services	120,172	-	120,172
Information services	73,925	17,075	91,000
Total 2020	291,738	17,075	308,813

	<i>Unrestricted funds 2019 £</i>	<i>Total funds 2019 £</i>
Helpline	145,330	145,330
Membership services	180,415	180,415
Information services	73,112	73,112
<i>Total 2019</i>	<i>398,857</i>	<i>398,857</i>

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2020

10. Analysis of expenditure on charitable activities - by type

	Activities undertaken directly 2020 £	Support costs 2020 £	Total funds 2020 £
Helpline	50,806	46,835	97,641
Membership services	63,047	57,125	120,172
Information services	47,743	43,257	91,000
Total 2020	161,596	147,217	308,813

	Activities undertaken directly 2019 £	Support costs 2019 £	Total funds 2019 £
Helpline	29,777	115,553	145,330
Membership services	37,884	142,531	180,415
Information services	15,352	57,760	73,112
Total 2019	83,013	315,844	398,857

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2020

10. Analysis of expenditure on charitable activities - by type (continued)

Analysis of support costs

	Total funds 2020 £	Total funds 2019 £
Staff costs	41,608	190,656
Depreciation	11,506	6,396
Premises costs	19,077	19,544
Carriage and postage	5,003	6,515
Design and print	-	3,004
Professional fees	11,746	20,678
Bought-in services	2,802	17,740
Website, database and computing	17,354	12,465
Other costs	25,290	29,193
Governance costs	12,831	9,653
	147,217	315,844

11. Governance costs

	2020 £	2019 £
Auditors' remuneration	9,000	-
Independent Examiner's remuneration	-	3,680
Rent & rates	(602)	-
Insurance	6,151	6,609
Trustees expenses	30	-
Legal fees	504	-
General office expenses	27	-
	15,110	10,289

Total Governance costs above comprise £2,279 (2019 - £635) of Expenditure on raising funds and £12,831 (2019 - £9,653) of Expenditure on charitable activities.

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2020

12. Auditors' remuneration

	2020 £	2019 £
Auditors' remuneration - Audit of the Group and the Trading Subsidiary	9,540	-
Auditors' remuneration - Preparation of the statutory accounts for the Group and the Trading Subsidiary	2,100	-
Independent Examiner's remuneration - Examination of the financial statements	-	2,580
Independent Examiner's remuneration - Taxation services	-	1,100
	<u> </u>	<u> </u>

13. Staff costs

	Group 2020 £	Group 2019 £	Charity 2020 £	Charity 2019 £
Wages and salaries	154,610	181,583	154,610	181,583
Social security costs	12,728	14,636	12,728	14,636
Pension costs	7,010	6,984	7,010	6,984
	<u>174,348</u>	<u>203,203</u>	<u>174,348</u>	<u>203,203</u>

Included in Wages and salaries above are redundancy costs of £NIL (2019: £32,027). Of this amount, £NIL (2019: £17,098) relates to statutory redundancy, £NIL (2019: £13,473) relates to voluntary redundancy and £NIL (2019: £1,456) relates to compulsory redundancy.

The average number of persons employed by the Group during the year was as follows:

	Group 2020 No.	Group 2019 No.
Direct charitable activities	2	5
Fundraising and communication	1	1
Support and governance	1	1
	<u>4</u>	<u>7</u>

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2020

13. Staff costs (continued)

The number of employees whose employee benefits received (excluding employer pension costs) exceeded £60,000 was:

	Group 2020 No.	Group 2019 No.
In the band £60,001 - £70,000	1	1

The total amount of employee benefits, including employers national insurance and pension contributions, received by Key Management Personnel is £72,330 (2019: £71,284). The Charity considers its Key Management Personnel comprise the Trustees and the Chief Executive Officer.

14. Trustees' remuneration and expenses

During the year, no Trustees received any remuneration or other benefits (2019 - £NIL).

During the year ended 31 December 2020, expenses totalling £30 were reimbursed or paid directly to 2 Trustees (2019 - £1,086 to 4 Trustees). The expenditure was to cover travel costs.

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2020

15. Intangible assets

Group and Charity

	Assets under construction £	Website £	Total £
Cost			
At 1 January 2020	13,068	-	13,068
Additions	-	7,920	7,920
Transfer between classes	(13,068)	13,068	-
At 31 December 2020	-	20,988	20,988
Amortisation			
Charge for the year	-	5,160	5,160
At 31 December 2020	-	5,160	5,160
Net book value			
At 31 December 2020	-	15,828	15,828
At 31 December 2019	13,068	-	13,068

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2020

16. Tangible fixed assets

Group and Charity

	Leasehold improvements £	Furniture and fixtures £	Office equipment £	Computer equipment £	Total £
Cost or valuation					
At 1 January 2020	41,470	2,493	4,140	12,149	60,252
Additions	-	-	-	15,438	15,438
Disposals	-	-	(267)	(5,544)	(5,811)
At 31 December 2020	41,470	2,493	3,873	22,043	69,879
Depreciation					
At 1 January 2020	17,637	1,181	1,830	8,600	29,248
Charge for the year	4,147	249	387	3,607	8,390
On disposals	-	-	(267)	(5,544)	(5,811)
At 31 December 2020	21,784	1,430	1,950	6,663	31,827
Net book value					
At 31 December 2020	19,686	1,063	1,923	15,380	38,052
At 31 December 2019	23,833	1,312	2,310	3,549	31,004

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2020

17. Fixed asset investments

Charity	Investment in subsidiary company £
Cost or valuation	
At 1 January 2020	100
At 31 December 2020	<u>100</u>

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2020

17. Fixed asset investments (continued)

Principal subsidiaries

The following was a subsidiary undertaking of the Charity:

Name	Company number	Registered office or principal place of business	Holding	Included in consolidation
Eczema Trading Limited	06895048	11 Murray Street, London, NW1 9RE	100%	Yes

The financial results of the subsidiary for the year were:

Name	Income £	Expenditure £	Loss for the year £	Net liabilities £
Eczema Trading Limited	1,809	(5,015)	(3,206)	(25,333)

The results of Eczema Trading Limited are included in these consolidated accounts. Eczema Trading Limited did not meet the audit threshold and therefore did not require an audit for the year ended 31 December 2020.

The deficit relates to intercompany management charges and minimal advertising revenue. Eczema Trading Limited was more active in the past when National Eczema Society had substantive trading operations, primarily selling Christmas cards. Currently, only the limited advertising revenue from our quarterly membership magazine is accounted for in Eczema Trading Limited. Going forward, the Society is looking to introduce a 'kite mark' type of endorsement scheme for products more suited to people with eczema. Should this scheme go ahead, it will be accounted for in Eczema Trading Limited hence the reason for retaining the company for the time-being.

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2020**

18. Debtors

	Group 2020 £	Group 2019 £	Charity 2020 £	Charity 2019 £
Due within one year				
Trade debtors	30,840	39,300	30,840	37,500
Amounts owed by group undertakings	-	-	45,837	37,865
Other debtors	48,047	13,550	48,047	13,550
Prepayments and accrued income	11,711	10,798	11,711	10,798
	90,598	63,648	136,435	99,713

19. Creditors: Amounts falling due within one year

	Group 2020 £	Group 2019 £	Charity 2020 £	Charity 2019 £
Trade creditors	6,004	12,520	6,004	12,520
Other taxation and social security	12,571	8,764	12,571	8,764
Other creditors	15,490	14,956	15,490	14,956
Accruals and deferred income	121,936	97,282	121,936	92,870
	156,001	133,522	156,001	129,110

	Group 2020 £	Group 2019 £	Charity 2020 £	Charity 2019 £
Deferred income				
Deferred income at 1 January	85,119	66,463	83,319	63,263
Resources deferred during the year	103,016	85,119	103,016	83,319
Amounts released from previous periods	(85,119)	(66,463)	(83,319)	(63,263)
Deferred income at 31 December	103,016	85,119	103,016	83,319

Deferred income consists of membership income relating to future periods.

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2020

20. Creditors: Amounts falling due after more than one year

	Group 2020 £	Group 2019 £	Charity 2020 £	Charity 2019 £
Pension Scheme deficit	49,863	63,281	49,863	63,281

The Charity is participating in a recovery plan to eliminate its Series 3 scheme deficit over a ten year period. The Pensions Trust, the scheme administrator, has however, advised that the amount of employer debt on the alternative of withdrawal from the Series 3 scheme has been estimated by actuaries to have been £200,161 as at 31 December 2016. As the Charity intends to continue participating in the recovery plan, no provision has been made for this potential withdrawal debt however, the Society accounted for the present value of all remaining contributions under the recovery plan in the 2017 accounts at their present value of £120,000, as advised by the scheme administrator. This liability has been adjusted annually to unwind the relevant discount applied.

In order to meet their share of the shortfall, the Charity has been asked to pay additional contributions to the scheme until 2025. A full actuarial valuation was carried out by the actuaries at 30 September 2017 and the funding shortfall calculated at that date gave rise to a remeasurement reduction of £15,624 in the deficit as at 31 December 2018. The deficit of the scheme is £65,196 (2019: £78,168) at 31 December 2020. The payment by the Charity in the year was £14,887 (2019: £14,636) with an interest payment of £794 (2019: £1,438) and a remeasurement expense of £1,121 (2019: £1,201).

In addition, the Charity elected to switch, with effect from 1 October 2013, from Series 3 to Series 4, a defined contribution scheme. The pension cost in the accounts represents amounts payable by the charity as ordinary employer contributions to the Series 4 defined contribution fund.

During the year employer contributions of £7,010 (2019: £6,983), interest of £794 (2019: £1,438) and actuarial losses of £1,121 (2019: £1,201) have been charged to the Consolidated Statement of Financial Activities. There were no accrued contributions at 31 December 2020 (2019: £NIL) but there is a liability of £65,196 (2019: £78,168) for future contributions under the Series 3 Recovery Plan. Of this £15,333 (2019: £14,887) is reported in Creditors: Amounts falling due within one year as part of Other creditors and £49,863 (2019: £63,281) is reported in Creditors: Amounts falling due after more than one year.

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2020

21. Statement of funds

Statement of funds - current year

	Balance at 1 January 2020 £	Income £	Expenditure £	Transfers in/out £	Gains/ (Losses) £	Balance at 31 December 2020 £
Unrestricted funds						
Designated funds						
Fixed asset fund	44,072	-	(13,550)	23,358	-	53,880
Pension reserve	(78,168)	-	(794)	14,887	(1,121)	(65,196)
	<u>(34,096)</u>	<u>-</u>	<u>(14,344)</u>	<u>38,245</u>	<u>(1,121)</u>	<u>(11,316)</u>
General funds						
General funds	<u>383,191</u>	<u>522,350</u>	<u>(332,099)</u>	<u>(38,245)</u>	<u>-</u>	<u>535,197</u>
Total Unrestricted funds	<u>349,095</u>	<u>522,350</u>	<u>(346,443)</u>	<u>-</u>	<u>(1,121)</u>	<u>523,881</u>
Restricted funds						
Research	753	11,735	-	-	-	12,488
ThankQ	-	13,800	(13,800)	-	-	-
Laptops	-	3,275	(3,275)	-	-	-
	<u>753</u>	<u>28,810</u>	<u>(17,075)</u>	<u>-</u>	<u>-</u>	<u>12,488</u>
Total of funds	<u>349,848</u>	<u>551,160</u>	<u>(363,518)</u>	<u>-</u>	<u>(1,121)</u>	<u>536,369</u>

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2020

21. Statement of funds (continued)

Statement of funds - prior year

	<i>Balance at 1 January 2019 £</i>	<i>Income £</i>	<i>Expenditure £</i>	<i>Transfers in/out £</i>	<i>Gains/ (Losses) £</i>	<i>Balance at 31 December 2019 £</i>
Unrestricted funds						
Designated funds						
Fixed asset fund	33,019	-	(6,819)	17,872	-	44,072
Pension reserve	(90,165)	-	(1,438)	14,636	(1,201)	(78,168)
	<u>(57,146)</u>	<u>-</u>	<u>(8,257)</u>	<u>32,508</u>	<u>(1,201)</u>	<u>(34,096)</u>
General funds						
General funds	<u>402,821</u>	<u>430,727</u>	<u>(417,849)</u>	<u>(32,508)</u>	<u>-</u>	<u>383,191</u>
Total Unrestricted funds	<u>345,675</u>	<u>430,727</u>	<u>(426,106)</u>	<u>-</u>	<u>(1,201)</u>	<u>349,095</u>
Restricted funds						
Research	<u>753</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>753</u>
Total of funds	<u><u>346,428</u></u>	<u><u>430,727</u></u>	<u><u>(426,106)</u></u>	<u><u>-</u></u>	<u><u>(1,201)</u></u>	<u><u>349,848</u></u>

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2020

21. Statement of funds (continued)

Designated funds

The Pension reserve has been established to show the future pension deficit payments in regards to a defined benefit pension scheme. This pension scheme is being treated as a defined contribution pension scheme as a reliable estimate cannot be made of the liability at the year end. The transfer of £14,887 was made to separate the deficit payments due as at 31 December 2020 from the Unrestricted general fund. Actuarial gains / (losses) are charged to this fund as they arise.

The Fixed asset fund has been established to reflect the funds tied up in Tangible and Intangible fixed assets and agrees back to the Net Book Value presented on the Consolidated Balance Sheet. The transfer of £23,358 was made to represent the net of capital additions and disposals during the year. Depreciation is charged to this fund as expenditure.

Unrestricted funds

General funds reflects funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the Charity and which have not been designated for other purposes.

Restricted funds

The Research fund exists to provide resources for research into the causes of Eczema, with the aim of developing more effective treatments or a cure.

The Society is grateful to two corporate members, Abbvie and Sanofi, which provided restricted funding to upgrade the Society's supporter database software, ThankQ, and implement cloud-based hosting. This work was essential in supporting more efficient remote working by the staff team, which was needed in response to the Covid-19 pandemic. The Society is grateful to the British Association of Dermatologists who provided funding for the software licence and hosting fees for the first year of use of the Society's upgraded supporter database.

The Society is grateful to the company Almirall, which provided restricted funding for new laptop computers and related costs, needed to facilitate home working by the staff team in response to the Covid-19 pandemic.

The Society's 2020 Christmas fundraising was for donations to take forward the Charity's plans to start funding research into eczema. Donations made to this specific fundraising appeal are restricted for the purpose of funding research.

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2020

22. Analysis of net assets between funds

Analysis of net assets between funds - current year

	Unrestricted funds 2020 £	Restricted funds 2020 £	Total funds 2020 £
Tangible fixed assets	38,052	-	38,052
Intangible fixed assets	15,828	-	15,828
Current assets	675,865	12,488	688,353
Creditors due within one year	(156,001)	-	(156,001)
Creditors due in more than one year	(49,863)	-	(49,863)
Total	523,881	12,488	536,369

Analysis of net assets between funds - prior year

	<i>Unrestricted funds 2019 £</i>	<i>Restricted funds 2019 £</i>	<i>Total funds 2019 £</i>
Tangible fixed assets	31,004	-	31,004
Intangible fixed assets	13,068	-	13,068
Current assets	501,826	753	502,579
Creditors due within one year	(133,522)	-	(133,522)
Creditors due in more than one year	(63,281)	-	(63,281)
Total	349,095	753	349,848

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2020

23. Reconciliation of net movement in funds to net cash flow from operating activities

		Group 2020 £	Group 2019 £
Net income for the period (as per Statement of Financial Activities)		187,642	4,621
Adjustments for:			
Depreciation charges	16	8,390	6,819
Amortisation charges	15	5,160	-
Investment income	7	(2,143)	(1,323)
Increase in debtors	18	(26,950)	(892)
Increase in creditors	19	7,940	13,710
Net cash provided by operating activities		180,039	22,935

24. Analysis of cash and cash equivalents

	Group 2020 £	Group 2019 £
Cash in hand	597,755	438,931
Total cash and cash equivalents	597,755	438,931

25. Analysis of changes in net debt

	At 1 January 2020 £	Cash flows £	At 31 December 2020 £
Cash at bank and in hand	438,931	158,824	597,755
	438,931	158,824	597,755

NATIONAL ECZEMA SOCIETY
(A Company Limited by Guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2020**

26. Capital commitments

	Group 2020 £	Group 2019 £	Charity 2020 £	Charity 2019 £
Contracted for but not provided in these financial statements				
Acquisition of intangible assets	-	6,534	-	6,534

27. Operating lease commitments

At 31 December 2020 the Group and the Charity had commitments to make future minimum lease payments under non-cancellable operating leases as follows:

	Group 2020 £	Group 2019 £	Charity 2020 £	Charity 2019 £
Not later than 1 year	20,833	20,000	20,833	20,000
Later than 1 year and not later than 5 years	66,500	80,000	66,500	80,000
Later than 5 years	-	3,333	-	3,333
	87,333	103,333	87,333	103,333

The following lease payments have been recognised as an expense in the Consolidated Statement of Financial Activities:

	Group 2020 £	Group 2019 £	Charity 2020 £	Charity 2019 £
Operating lease rentals	20,000	20,000	20,000	20,000

28. Related party transactions

In the year ended 31 December 2020 there were no related party transactions other than the Trustee and Key Management Personnel transactions detailed in Notes 13 and 14 (2019: None).